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Angiogenesis is a key physiological process by which new blood vessels are dynamically 
formed in Endothelial cell (EC) driven processes. The identification of new potential genes of 
interest in ECs can help to further understand the underlying mechanisms of angiogenesis 
and help develop new therapeutic strategies for cardiovascular disease. One such gene 
identified in the Caporali lab is Anillin (ANLN) an F-actin binding protein with functions in 
cytokinesis, asymmetric cell division and potential roles in migration and proliferation in 
multiple cell types.  
We identified that ANLN was highly upregulated in the ECs of a mouse model of hind limb 
ischaemia. In vitro modulation of ANLN expression with siRNA and ANLN-EGFP lentivirus in 
HUVECs identified an effect of ANLN expression on multiple aspects of EC function including, 
migration wound healing and barrier function. A correlation between ANLN expression and 
tubulogenesis assay performance was observed associating ANLN with an early model of 
sprouting angiogenesis. A potential regulatory mechanism of ANLN by ZFP36 RNA binding 
proteins was identified in vascular inflammation and ischaemia in vivo and in vitro. Based on 
in vitro observations, ANLN expression was investigated in the ECs of the developing 
vasculature, and in a model of vascular injury using the anln:anln-eGFP x flk:mcherry reporter 
zebrafish. ANLN was not associated with the 24 hpf developing vasculature in the trunk, CNS 
or tail of the fish however there was a strong band of Anln+ve cells near the developing trunk 
vasculature and caudal artery plexus. A micro point laser injury of the caudal artery was 
developed; with injuries being recoverable 24 hours post injury and causing association of 
neutrophils with injury sites. Anln was not observed in ECs of the caudal artery after laser 
injury, however, increased Anln+ve cells are observed in mechanical injury of the tail fin 
identifying Anln expression in a response to injury. Hypomorphic modulation of anln 
expression by morpholino injection of flk:gfp embryos did not alter the vascular morphology 
of the 2-3 dpf zebrafish vasculature. 
This data for the first time associates ANLN with the EC response to the angiogenic response 
in ischaemia. Although our zebrafish study was mostly negative a new method for inducing 
vascular injury in zebrafish was developed and there was a novel application of an anln:anln-
eGFP zebrafish  for the investigation of ANLN in vascular regeneration. Our vascular injury 
model for the investigation of ANLN can be improved by utilising a mechanical method of 
vessel injury for further studies. Application of vascular specific CRISPR/CAS9 mutation of 
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ANLN expression may improve identification of a vascular phenotype in zebrafish, which was 
not observed with morpholino injection. Further in vitro experiments should focus on ANLN-

























Cardiovascular disease is the leading cause of death world-wide, this is caused by the 
blockage of blood vessels, leading to heart attacks and poor blood flow in the legs. Both of 
these conditions can cause life changing health effects and death. In response to these 
diseases, the body needs to grow new blood vessels from existing vessels to supply tissues 
that are not receiving enough blood flow. This process is referred to as “angiogenesis” (new 
blood vessel formation) and is guided by a specialist cell called the endothelial cell.  
In my PhD I investigated the effect of a protein called Anillin on endothelial cell function in 
angiogenesis. It was found that altering levels of Anillin altered the movement and general 
function of endothelial cells in cell based experiments that mimic angiogenesis.  
Zebrafish embryos were used to identify Anillin expression in a live model of angiogenesis 
and blood vessel injury. The zebrafish embryos used had fluorescent blood vessels and a 
modified fluorescent version of Anillin, this allowed identification of Anillin’s location in 
individual endothelial cells. There was no association of fluorescent Anillin with the 
developing blood vessels in the embryos. A new method for investigating blood vessel injury 
was created, using a laser to damage a large blood vessel in the embryo and observing it 
recover. There was no association of fluorescent Anillin with the recovering injured vessels, 
but this may be due to the weak detectable Anillin fluorescence.  
In conclusion further research can be used to identify ANLNs role in endothelial cells in 
angiogenesis. We could further investigate potential interactions of ANLN with other 
proteins to identify how it functions in angiogenesis to try and develop new therapies for 
cardiovascular disease. The new zebrafish vessel injury can be used to investigate how blood 
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1.1 The function and structure of the cardiovascular system: 
The cardiovascular system is a key collection of tissues and organs that evolved in 
response  to the limitations of diffusion in the supply of oxygen and the removal of 
the waste products of respiration (Siddall 2004). Vertebrate species possess a 
collection of large and small blood vessels supplying the organs with oxygenated 
blood and removing deoxygenated blood (Monahan-Earley et al. 2013). 
Blood vessels carry blood flow from the heart and are made up mainly of four cells 
types, endothelial cells (ECs), vascular smooth muscle (VSMC), pericyte and, 
occasionally neuronal cells. These cells are organised into 4 vessel categories. Arteries 
and arterioles carry oxygenated blood whereas veins and venules carry 
deoxygenated blood (Lake 1985). The arterioles are adapted for carrying high 
pressure blood and feature a thick external tunica adventitia consisting of connective 
tissues and a thick medial layer of concentric smooth muscle cells, that maintain an 
elastic quality (Lake 1985). They lead into a large network of capillaries consist of 
endothelial cells with only a sparse covering of pericytes. The capillaries maintain the 
homeostasis of tissues by allowing the passive transport of metabolites into the 
tissues and waste products of respiration away for excretion (Lake 1985). Veins and 
venules are adapted to carry low pressure blood and are similarly structured to the 
arteries, except that they contain valves that protrude into the lumen to prevent 
backflow.  The integrity of these vascular structures is a key component of 











1.2 Cardiovascular disease: 
Currently the second leading cause of death globally, cardiovascular disease is 
associated with many contributing factors including obesity, old age, and diabetes 
(Hennekens & Gaziano 1993). Cardiovascular disease begins with atherosclerosis, 
where lipid plaques develop in the vessels. Atherosclerotic plaque number and size 
increase with age and are used as an overall indicator of cardiovascular health (Ross 
1999; Lang & Insull 1970). These plaques arise from an initial insult to the endothelial 
cell (EC) layer and the deposition of lipids between the intimal and medial layers of 
the vessel, referred to as atherosis (Steinbrecher et al. 1984). This results in a raised 
plaque which increases in size exhibiting a dense lipid core. Neutrophil accumulation 
induces a focal point of inflammation, an external sclerosis is formed by vascular 
smooth muscle cell (VSMC) proliferation (Newby & Zaltsman 1999). VSMC 
proliferation generates a fibrous cap covering the lipid core which partially occludes 
the vessel. Inflammation and cell death can lead to rupture of the fibrous cap, 
allowing exposure of the lipid core to circulating platelets, and eventually resulting in 
thrombus formation (Falk 1992). Thrombi can induce the complete occlusion of a 
vessel and result in a critical loss of blood flow defined as Ischaemia, causing damage 
to the supplied tissue (Figure 1.1).  
Ischaemic heart disease is caused by atherosclerotic plaque formation in the 
descending coronary arteries (Vlodaver & Edwards 1971). Plaque rupture results in 
acute ischaemia of the heart muscle causing myocardial infarction (Fuster et al. 
1992). There is rapid damage to the cardiomyocytes induced by hypoxia, reactive 
oxygen species and inflammation resulting in death of the ischaemic portion of the 
heart muscle. Due to the low regenerative capacity of the heart, dead cells are 
replaced by fibroblasts resulting in a reduction of its contractility and pathological 
muscle remodelling (Fuster et al. 1992). This results in the progression to eventual 
heart failure as the heart becomes unable to maintain normal cardiac output 
resulting in disability and death (Cohn 1996). Peripheral artery disease (PAD) is major 
symptom of systemic atherosclerosis with 12% of the adult population suffering from 
this condition (Caporali et al. 2018). PAD initially results in acute pain caused by 
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transient ischaemia in the lower limb and this can progress to critical limb ischaemia. 
Critical limb ischaemia is the acute loss of blood flow to the lower limbs resulting in 
insufficient perfusion of skeletal muscle (Ouriel 2001). This results in EC dysfunction, 
chronic inflammation and tissue necrosis, eventually requiring the amputation of 
affected limbs. 
Typical care consists of initial anti-thrombotic treatment to remove thrombi and vein 
grafting or stent insertion to stabilise unstable atherosclerotic plaques (Hlatky et al. 
2004). Vein grafting uses a non-diseased vein typically from the lower limb, grafted 
onto the diseased artery to bypass the occluded vessel. While this treatment is very 
effective in the short-term, the procedure can have catastrophic failure within one 
year of surgery giving it a limited long term life span (De Vries et al. 2016). Stenting is 
the insertion of a cylindrical drug eluting metal construct into the affected arteries to 
forcibly open the artery and prevent further atherosclerosis and reduce thrombus 
formation (Mattichak et al. 2008). These approaches whilst effective as immediate 
treatments to stabilise ischaemic disease, don’t improve overall cardiovascular 
health or aid the formation of new blood vessels. There is therefore a clinical need 
for new therapeutic approaches that improve the body’s natural process for blood 

























Figure 1.1:  The progression of Atherosclerosis leads to common ischaemic diseases 
(A) Cardiovascular disease caused by increasing atheroma formation in the arteries reducing 
blood flow and creating chronic ischaemia. (B) Plaque ruptures result in critical ischaemia in 




1.3. Cardiovascular Development: 
The blood vessels form early on in embryonic development, and this process is 
referred to as vasculogenesis. During gastrulation of the embryo, at E6.5-7 
haemangioblasts arise from the mesoderm in the blood islands of the yolk sac (Drake 
& Fleming 2000). These cells differentiate into the early haematopoietic stem cells 
and angioblasts, the angioblasts form tube like structures and differentiate into the 
early ECs. The ECs coalesce to form a primitive vascular plexus, a primitive lumen, and 
they begin to secrete an extracellular matrix. This early vascular plexus connects to 
the pre-contractile heart tube (Patel-Hett & D’Amore 2011). The differentiation of 
these primitive vessels into a more complicated network containing arteries and 
veins is controlled by multiple signalling mechanisms and this has been described in 











1.4 The Angiogenesis process: 
The sprouting of new vessels from mature vascular networks is defined as 
angiogenesis (Folkman 1971) (Figure 1.2). At rest, blood vessels are quiescent, 
forming a confluent barrier of ECs. EC junctions consist of VE-cadherin (VCAD) and 
adherens junctions that maintain vascular homeostasis and promote resistance to 
secreted factors that alter vascular structures (table 1) (Ehling et al. 2013; Giannotta 
et al. 2013). 
Table 1 Key angiogenic factors: 
Factor  nomenclature Function reference 
Vascular endothelial 
growth factor  
VEGF A-E  Guides EC migration, 
promotes proliferation 







FGF, FGF Promotes capillary 





Tumour necrosis factor 
α 
TNF-α Stimulates inflammatory 
response and growth factor 







TGFβ 1-3 Promotes mural cell 
attachment and extra 
cellular matrix degradation. 
(Pardali et 
al. 2010) 
Angiopoietins ANG-1,2  Alters vessel stability by 
regulating permeability and 




Platelet derived growth 
factor B 
PDGF-B Promotes vessel 
maturation by influencing 





After ischaemic insult or wound repair, the ECs become activated by hypoxia or 
inflammatory mediators released by the surrounding tissues. Secretion of matrix 
metalloproteinases (MMP), including MMP1/2, allows for digestion of the 
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extracellular matrix (ECM) followed by ANG-2 stimulation and detachment VSMCs 
and pericytes (Blasi & Carmeliet 2002; Eble & Niland 2009; Augustin et al. 2009). 
Growth factors stored in the ECM are liberated during ECM degradation and affect 
the initial increase in EC motility (Arroyo & Iruela-Arispe 2010).  
VEGF is the most important growth factor in angiogenesis (table 2). VEGF is secreted 
by the surrounding tissue and acts on the exposed ECs to promote sprouting 
angiogenesis, this is driven by a VEGF concentration gradient in the tissue (Gerhardt 
et al. 2003). ECs located at the highest concentration of VEGF become tip cells that 
migrate along the VEGF gradient (Gerhardt et al. 2003). Neighbouring ECs at lower 
VEGF concentrations become proliferating stalk cells that make the body of the new 
vessel. The differences in tip and stalk cell behaviour is affected by different VEGF 
signalling. VEGFR2 mediates the majority of VEGF signalling by receptor tyrosine 
kinase activation in combination with its co receptor NRP-1/2 (Takahashi & Shibuya 
2005). VEGFR1, expressed mainly by the stalk cell acts as an antagonist of VEGF 
activity, alternatively spliced soluble VEGFR1 is secreted by stalk cells to sequester 
free VEGF (Kendall & Thomas 1993; Chappell et al. 2009; Roberts et al. 2004). 
Tip/stalk cell designation is referred to as dorsal lateral inhibition, a process where 












Table 2 Key VEGF signalling components in angiogenesis: 
Signalling 
component 
Role  References 
Vascular endothelial 
growth factor (VEGF) 
Soluble ligand of VEGF receptors, 
present in multiple isoforms (VEGF-A-
E) and splice variants with VEGF-A 
mediating most of its effects in 
angiogenesis. 
(Tischer et al. 1991) 
Vascular endothelial 
growth factor 
receptor 2 (VEGFR2) 
Receptor of VEGF and the main 
mediator of angiogenic signalling 







Acts a co-receptor with VEGFR1 and 
VEGFR2 to enhance VEGF signal 
transduction. 
(Soker et al. 1998) 
Vascular endothelial 
growth factor 
receptor 1 (VEGFR1) 
High affinity receptor for VEGF-A but 
with low receptor tyrosine kinase 
activity, acts as a sink for VEGF to 






There is a significant interplay between Notch and VEGF signalling in controlling 
dorsal lateral inhibition as shown in figure 1.2. Notch signalling is a highly conserved 
intercellular contact mediated receptor ligand interaction that is involved in cell fate 
and tissue development (Karsan 2005). In dorsal lateral inhibition VEGFR2 receptor 
signalling upregulates Dll4 notch ligand in the newly defined tip cells (Lobov et al. 
2007). Dll4 interacts with the Notch receptor on stalk cells and suppresses VEGFR2 
and NRP1/2 expression while upregulating VEGFR1 (Eilken & Adams 2010). 
Expression of the Notch ligand JAGGED on stalk cells antagonises Dll4 activation of 
Notch on the tip cell, thus, enhancing VEGFR2 expression and suppressing VEGFR1 
expression (Kofler & Simons 2015). This dynamic interaction between VEGF and 
Notch signalling helps to maintain the tip/stalk cell behaviour and allows orderly 
angiogenesis. Leading edge tip ECs form extensive filopodia driven by VEGFR2 
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activation of CDC42 driving migration towards the chemoattractant VEGF (De Smet 
et al. 2009). Stalk cells supported by FGF2 expression proliferate forming intercellular 
connections and begin to generate the ECM to provide structural support to the new 




















Figure 1.2 Dorsal lateral inhibition by VEGF and Notch signalling drives EC migration and 
proliferation: 
VEGF secreted by surrounding tissues acts on VEGFR2 on ECs closest to the highest VEGF 
concentration. Activation of VEGFR2 and its co-receptor activate downstream signalling 
pathways to generate the migratory tip cell phenotype which is the leading migrating EC. 
High VEGFR2 signalling increases Dll4 Notch ligand integration in to the membrane which 
activates the Notch receptor on neighbouring proliferative stalk cells. This suppresses 
VEGFR2 expression in the stalk cell and promotes VEGFR1 and soluble VEGFR1 expression, 
VEGFR1 sequesters VEGF from the surrounding cells maintaining a polarising VEGF gradient. 
Simultaneously JAGGED1 Notch ligand antagonises Dll4 Notch signalling in the tip cell 
suppressing Notch mediated expression of VEGFR1. This paradigm maintains the distinct 
migratory tip cell and the proliferative stalk cell to allow for organised angiogenesis. Adapted 
from  (Blanco & Gerhardt 2013) 
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As new networks are formed, tip cell filopodia interact to form branching vessels and 
the two vessels anastamose by forming VE-cadherin rich connections (Fantin et al. 
2010). Lumenisation of the new vessel occurs through apical-basal polarisation of 
ECs, wherein, parallel stalk cells connected by apical VE-cadherin junctions integrate 
negatively charged glycoproteins into the apical EC membrane (Strilić et al. 2009). 
The negatively charged apical membrane gives a repulsive signal which encourages 
lumenisation of the new vessel with EC architecture modulated by VEGF activation of 
Rho kinase (ROCK) (Zeeb et al. 2010). Secretion of tissue inhibitors of 
metalloproteinases (TIMPs) allows for regeneration of the ECM and establishment of 
EC junctional integrity (Stetler-Stevenson & Seo 2005). Vessel quiescence is 
encouraged by VSMC and pericyte recruitment supported by the secretion of ANG-1, 
PDGF-B, S1P and TGF-β by ECs (Krump-Konvalinkova et al. 2005; Allende & Proia 
2002; Lindblom et al. 2003). After stabilisation of the new vessel, blood flow begins 
to the ischaemic or injured area (figure 1.3).  
In ischaemia and inflammation, neutrophils and macrophages of the immune system 
have key roles in angiogenesis (Campbell 2015). Factors like VEGF and TNF-α are 
released by macrophages and neutrophils in ischaemia, impacting on EC migration  
(Stark et al. 2013; Gong & Koh 2010). Neutrophil secretion of MMPs assists in 
basement matrix degradation promoting increased EC motility, in ischaemia and 
inflammation the loss of neutrophil presence is a hallmark of new vessel quiescence 
(Ardi et al. 2007). Tip cell fusion events at sites of anastomosis are mediated in part 
by macrophages which associate with the junction between two new vessels. This 
improves cell to cell communication before VE-cadherin mediated filopodia 
interaction and vessel fusion (Liu et al. 2016; Fantin et al. 2010).  
The transcription factor hypoxia induced factor 1 (HIF-1α) is a key regulator of 
angiogenesis. HIF-1α controls a number of key genes in the EC response to O2 
deprivation by binding to hypoxia response elements in target genes (Semenza 2012). 
MMP-2 and associated metalloproteinases are direct targets of HIF-1α leading to an 
initial increase in EC motility in early angiogenesis (Shweiki et al. 1992; Krock et al. 
2011). Other important targets include VEGF-A, VEGFR1, PDGF-B, ANG-1, and, ANG-
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2 with further control of genes involved in autophagy and PH regulation (Semenza 
2012). Partial knockout of HIF-1α in mice results in an impaired angiogenesis in hind 










Figure 1.3: Haemodynamic forces and ischaemia induces sprouting angiogenesis: 
Quiescent vessels exhibit very little proliferation and cell migration but upon ischaemic 
challenge or haemodynamic stresses sprouting begins. Vessel dilation followed by tip cell 
selection allows for sprouting of a new vessel with dorsal-lateral inhibition by VEGF/Notch 
signalling maintaining tip and stalk cell heterogeneity. After fusion with another sprouting 
vessel lumenisation occurs and vessel quiescence is supported by mural cell attachment and 




1.5 The failure of endogenous angiogenesis in cardiovascular disease: 
Failure of endogenous angiogenesis to provide an adequate response in 
cardiovascular disease is a key area of interest to develop therapies to improve the 
clinical outcome in ischaemic conditions (Dragneva et al. 2013).  
In critical PAD, limb loss is attributed to a failure of vessel collateralisation of the 
ischaemic limb for a number of reasons (Scholz et al. 2002; Ziegler et al. 2010). 
Atherosclerotic plaques form throughout the vessels of the lower limb leading to a 
gradual decrease in blood pressure and increased hypoxia (Dragneva et al. 2013). This 
condition leads to maximal vasodilation of arterioles and EC resistance to 
vasodilatory stimuli. Increased reactive oxygen species and inflammation leads to EC 
dysfunction in capillaries (Coats & Wadsworth 2005). EC dysfunction in the micro 
vessels leads to small thromboses and the gradual accumulation of oedema, 
promoting fibrosis of tissue and gradual necrosis. The resulting ischaemic condition 
worsens and due to encroaching irreparable necrosis removal of the affected limb is 
required (Dragneva et al. 2013).  
The lack of appropriate angiogenesis in coronary artery disease is observable 
clinically through the prevalence of angina (Ischaemic pain in the heart) and heart 
failure in cardiovascular disease patients (Henry et al. 2014; Henry et al. 2013). 
Although there is an angiogenic response to ischaemia in the heart, continued 
insufficient reperfusion can lead to pathological ventricular remodelling resulting in 
reduced cardiac output increasing the chance of death (Taggart 2012; Kobayashi et 
al. 2017). Therefore there is an insufficiency of endogenous angiogenesis in 
conjunction with regular therapies to sufficiently perfuse myocardial infarction 
(Taggart 2013; Taggart et al. 2006) 
Metabolic disease, particularly diabetes, can exacerbate EC dysfunction and produce 
unique challenges in treating ischaemic disease as well as producing new 
complications like diabetic retinopathy (Rosberger 2013). EC dysfunction induced by 
diabetes mainly affects the architecture and function of the micro vessels, by causing 
a loss of control of the numerous growth factors controlling angiogenesis induced by 
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hyperglycaemia (J. Wang et al. 2010). Long term diabetic conditions result in 
increased expression of VEGF and VEGFR2. Simultaneously a reduction in VEGF 
sensing is observed through a reduced activation of VEGFR1 (Waltenberger et al. 
2000; Sasso et al. 2005). Altered expression of VEGF and VEGF receptors results in 
signalling imbalances, impairing new vessel formation (Sasso et al. 2005). Excess 
systemic VEGF causes an increase in vascular permeability by disrupting EC junctional 
integrity,  resulting in tissue oedema (Adamis et al. 1999; Weis & Cheresh 2005). 
Vascular dysfunction is worsened by chronic inflammation associated with diabetes 
and the expression of inflammatory cytokines (Ziyadeh et al. 2000).  
1.6 Therapeutic angiogenesis 
The main outcome intended from angiogenic therapy is to promote the formation of 
new blood vessels to ischaemic tissue to treat the aforementioned ischaemic 
conditions mentioned in section 1.2 (Folkman 1971). Approaches using the growth 
factors FGF-2, VEGF, IGF, ANG-1 and EGF to modulate angiogenesis in ischaemic 
conditions have had limited success (Lazarous et al. 1997; Ferrara & Alitalo 1999). 
Due to the complex nature of angiogenesis, applying one growth factor to stimulate 
vessel growth or repair is unlikely to provide lasting treatment (Chu & Wang 2012). 
In PAD, improving micro vessel density of skeletal muscle by VEGF treatment has had 
no effect on the overall perfusion of the limb due to a continued lack of large vessel 
collateralisation (Scholz et al. 2002). Pre-clinical studies in PAD animal models have 
shown an improvement of vascularisation after growth factor treatments (table 3). 
However human clinical trials have not produced a significant improvement in post 
ischaemic angiogenesis (table 4). Furthermore, treatment of diabetic patients with 
VEGF or EGF could complicate diabetic retinopathy and nephropathy by enhancing 






Table 3: Post-ischaemic angiogenesis is improved in animal models of ischaemia 
(Caporali et al. 2018). 
Growth factors  Animal model Effect Reference 
VEGF PIG MI Increased neo angiogenesis and 
improved myocardial function. 
(Choi et al. 2006) 
FGF2 PIG MI Enhanced arteriogenesis within 
the ischaemic area 
(Horvath et al. 
2002) 
HGF Rabbit HLI Increased blood flow and 
arteriogenesis 
(Taniyama et al. 
2001) 
ANG-1 Mouse MI Increase in capillary density, 
reduction in infarct size, and 
increased heart performance 
(Takahashi et al. 
2003) 
IGF-1 Mouse MI Increased capillary density  (Dobrucki et al. 
2010) 
 
Table 4: Growth factor treatment in humans does not improve clinical outcomes of 





Primary outcome Trial 
reference 
PAD/60 FGF-2/SeV Walking performance NCT02276
937  
PAD/500 HGF/PI Time to major amputation NCT02144
610 
MI/41  HGF Time 1mm ST depression during 














1.7 Anillin - a new target in angiogenesis? 
In order to improve current treatments of cardiovascular disease there is a 
requirement for the identification of novel genes that regulate regenerative 
angiogenesis in the response to ischaemia. Previous studies by Andrea Caporali have 
identified numerous genes that may have key roles in early regenerative 
angiogenesis. Analysis of microarray data from hind limb ischaemic adductor muscle 
and ECs overexpressing the P75 neurotrophin receptor 2, a negative regulator of 
angiogenesis, identified actin cytoskeletal reorganisation and cytokinesis as key gene 
clusters affected by ischaemia (GSE34675+GSE9910). ECs undergo major structural 
changes in early sprouting and lumenisation of the newly formed vessel with 
cytoskeletal remodelling being required for this process. Among the listed genes, the 
F-actin binding protein Anillin (ANLN) was highlighted in all the considered datasets. 
Therefore, we have further explored the role of ANLN in ischaemia-induced 
angiogenesis.  
Human ANLN is an 1124 amino acid protein that is highly conserved across multiple 
species. Found in all cell types, ANLN is heavily associated with the cell cycle and in 
particular the completion of cytokinesis (Rogers et al. 2003). ANLN was first identified 
in 1989 by Miller et al in D.melanogaster by actin filament affinity chromatography 
as a unique actin binding protein and cloned by Field et al (Field & Alberts 1995; Miller 
et al. 1989). The general structure of ANLN consists of a large protein ~1100-1200 
amino acids in length with an N-terminal region consisting of myosin and actin 
binding domains with a nuclear localisation site (Piekny & Glotzer 2008). The C-
terminal domain referred to as the Anillin homology region (AHR) contains a 
Pleckstrin homology (PH) domain (Piekny & Glotzer 2008). ANLN has been shown to 
have multiple binding partners in the formation of the contractile ring at the cleavage 
furrow in cytokinesis (table 5). These associated binding partners include key 
regulators of actomyosin contractility in the cleavage furrow as shown in figure 1.4. 
These include Rho GTPases, particularly RhoA, which when bound to GTP in its active 
state at the central spindle acts through downstream signalling effectors to mediate 
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actin bundling. ECT2 a Guanine nucleotide exchange factor (GEF) activates RhoA 
during cleavage furrow ingression by increasing the concentration of GTP bound 
RhoA (Miller 2011). Actin filament formation and depolymerisation is mediated by 
septins and formins. RhoA activates Rho kinase (Rock) which phosphorylates non 
muscle myosin light chain 2, initiating contraction of the contractile ring. The activity 
of RhoA in contractile ring formation and contraction is moreover regulated by 
GTPase activating proteins (GAPS), with p190RhoGAPA thought to regulate RhoA 




















Table 5: Known ANLN binding partners 
Protein  species Role  Reference 
APCcdh15/cyclosome H. Sapiens Degrade ANLN after the cell 
cycle  
(Zhao & Fang 
2005) 
Importin α/β D. 
Melanogaster 
H. Sapiens 
Maintains ANLN localization in 
the nucleus through a RAN 
dependent mechanism 
(Chen et al. 2015; 
Silverman-Gavrila 
et al. 2008) 
mDia2 H. Sapiens Actin crosslink regulator in 
cytokinesis 
(Watanabe et al. 
2010) 
CD2AP D.Melanogaster 
H. Sapiens  
Intercellular bridge stability 
Stabilisation of podocyte foot 
processes 
(Haglund et al. 
2010) 
(Hall et al. 2018) 
Non-muscle myosin 
light chain 2 
X. Laevis 
 
Contraction at the equatorial 
plane  of cell division  
Contractile ring formation in 
epithelial cell junctions  
(Reyes et al. 
2014) 
F-actin  L. Xenopus Crosslinking F-actin in the 
cleavage furrow 
Contractile ring formation in 
Epithelial junctions 




Crosslink the central spindle to 
the contractile ring 
(D’Avino 2009) 
P-190RhoGAPA H. Sapiens  Inactivates RhoA in the 
contractile ring 
(Manukyan et al. 
2015) 
RhoA H. Sapiens Stabilising RhoA to F-actin and 
myosin to the contractile ring 
(Piekny & Glotzer 
2008) 
RhoG C.Elegans Actin polymerisation in 
filopodia extension in neurite 
outgrowth 
(Tian et al. 2015) 
ECT2 (GEF) H. Sapiens Activates RhoA in the 
contractile ring 
(Mikawa et al. 
2008) 
Septins (peanut, 
sep 2 +5) 




Link F-actin and septins for 
cleavage furrow stabilisation 
(D’Avino 2009; 
Liu, Gregory D 






















Figure 1.4: Contractile ring formation and contraction requires RhoA initiated 
assembly: 
In contractile ring formation and contraction RhoA is regulated at the cleavage furrow 
by GAPs and GEFs. RhoA-GTP mediates actin filament bundling through formins and 
stimulates actin contraction through ROCK-mediated phosphorylation of MLC2. 




Initial investigations of ANLN in D.melanogaster identified a unique role for ANLN in 
controlling the contractile ring in cytokinesis and embryogenesis. Several ANLN 
mutants, so-called scraps mutants, have been shown in Drosophila to cause maternal 
sterility that can be rescued by ANLN cDNA injection (Schüpbach & Wieschaus 1991; 
Field et al. 2005). Mutations of the ANLN sequence in the AHR resulted in embryonic 
lethality due to a failure of cellularisation and gastrulation of the embryo (Field et al. 
2005). This was attributed to a failure of localisation of ANLN with F-actin, myosin-2 
and septins, reducing the stability of intracellular bridges. Altered cleavage furrow 
ingression caused by contractile ring failure destabilised new plasma formation 
during cellularisation of the embryo (Straight et al. 2005). 
Further investigations of ANLN in human cell lines have identified further functions 
of the AHR in contractile ring stabilisation during cytokinesis. There is an enrichment 
of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) in the plasma membrane at the 
cleavage furrow, which is preferentially bound by the ANLN PH domain (Liu, Gregory 
D Fairn, et al. 2012). Mutation of the PI(4,5)P2 binding site in the PH domain results 
in loss of ANLN from the cleavage furrow, causing destabilisation of the contractile 
ring and a loss of symmetric cell division (Liu, Gregory D Fairn, et al. 2012). Fusion of 
ANLN with other PI(4,5)P2 targeting PH domains restores ANLN localisation to the 
cleavage furrow, however, cytokinetic defects remain. This is attributed to the loss of 
ANLN mediated stabilisation of septins 2, 9 and 11 at the cleavage furrow (Liu, 
Gregory D Fairn, et al. 2012) . Therefore the AHR is required not only for ANLN 
localisation to the cleavage furrow and the stabilisation of F-actin, but also for septin 
localisation to the cleavage furrow (Liu, Gregory D Fairn, et al. 2012).  
A simplified schematic for ANLN expression and localisation dynamics in mammalian 
cytokinesis is shown in figure 1.5A. ANLN expression increases during G1-G2 phases 
of the cell cycle, accumulating in the nucleus by a Ran dependent mechanism 
mediated by importin-β2 (Chen et al. 2015; Beaudet et al. 2017). Here importin-β2 
binds to ANLNs nuclear localisation sites (NLS) and transports it through the nuclear 
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pore into the nucleus, the small GTPase Ran then binds importin-β2 dissociating 
ANLN (Cavazza & Vernos 2016). ANLN is sequestered in the nucleus during interphase 
to prevent adverse interactions of ANLN with the cytoskeleton (Chen et al. 2015). 
After the dissolution of the nuclear membrane ANLN is localised to peripheral cortical 
stress fibres of the cell (Kinoshita et al. 2002). In anaphase, ANLN localises to the 
cleavage furrow for contractile ring formation, with association of its PH domain with 
PI(4,5)P2 resulting in improved actin accumulation and the formation of the 
contractile ring. Association of ANLN allows for the interaction of F-actin, MLC2 and 
active RhoA regulated by ECT2 and P-190RhoGAPA activity (Mikawa et al. 2008). 
ANLN remains at the cleavage furrow until cytokinesis has been completed and only 
then transported back to the nucleus. Degradation is mediated the anaphase 
promoting complex (APCcdh1), APCchd1 is responsible for the degradation of multiple 































Figure 1.5: ANLN function and localisation during the cell cycle and cleavage 
furrow ingression: 
(A) ANLN expression increases and is localised to the nucleus during G1-G2 
phases, dissolution of the nuclear membrane encourages ANLN localisation to 
the cell cortex. In metaphase gradually restricting to the equator to regulate 
contractile ring formation in anaphase restricting till the completion of 
cytokinesis where in interphase ANLN is rapidly. The ANLN actin-myosin complex 
functions by allowing the interaction of ANLN, F-actin, RhoA and numerous 
septins facilitated by ANLN with localisation maintained by interaction of ANLNs 
PH domain with PIP2 in the cell membrane (Piekny & Glotzer 2008). (B) Schematic 
of the cell cycle showing the individual cell cycle stages and associated cyclins. 




Outside of its role in cytokinesis, ANLN has been associated with multiple cell 
phenotypes that may help with identifying a potential role of ANLN in ECs during 
angiogenesis. ANLN homologues in C. elegans have been shown to perform vital roles 
in neuronal cell development (Tian et al. 2015; Fotopoulos et al. 2013). ANLN is 
present in three isoforms, Ani-1-3 in C. elegans, all of which have been identified as 
having individual functions, unlike in vertebrates. Ani-1 silencing causes a range of 
cytokinetic defects, key of which is a misalignment of neuroblast cell division resulting 
in serious embryonic phenotypes (Fotopoulos et al. 2013). Further in development 
ANLN has been associated with neurite outgrowth and migration of Q-cell 
neuroblasts, here ani-1 localises to the leading edges of migrating Q-cell neuroblasts. 
The proposed mechanism was a myosin independent stabilisation of leading edge 
lamella protrusions by an interaction between Ani-1 and RhoG for the regulation of 
actin filament assembly (Tian et al. 2015). Ani-2 has a role in antagonising the effect 
of Ani-1, Ani-2 lacks the n-terminal actin/myosin domain, and has been suggested to 
compete with Ani-1 to regulate the contractile ring (Chartier et al. 2011; Pacquelet et 
al. 2015). C.Elegans ani-1-2 lack the NLS site, so they may have different cellular 
functions and distribution to vertebrate ANLN (Maddox et al. 2005).  
In cancer cells, ANLN expression can be upregulated 2-6 fold in multiple human 
tumours which is associated with an increase of tumour migration and metastasis 
(Hall et al. 2005). In ovarian cancer, high ANLN expression was associated with a 
decrease in survival amongst patients compared to groups with low ANLN expressing 
tumours (Suzuki et al. 2005). Silencing of ANLN with shRNA has been shown to 
markedly reduce the proliferative and migration capacity of breast cancer cell lines 
in vitro (Zhou et al. 2015). This was due to a dysregulation of the cell cycle, ANLN 
silenced cells expressed less cyclin D1 and had an increase in cdc2 phosphorylation 
(see figure 1.5B). This caused the arrest of the cell cycle and accumulation in the 
G2/M stage (Zhou et al. 2015). Similarly, ANLN silencing in human non-small cell lung 
cancer cell lines has been shown to impair cell migration and proliferation whereas 
overexpression increases these factors (Suzuki et al. 2005). Interestingly an 
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association between PI3K-activity and the nuclear localisation of ANLN showing a 
potential nuclear effect of ANLN in cancer invasiveness (Suzuki et al. 2005).  
ANLN has also been associated with cell-cell junction integrity in epithelial cell lines 
which may be relevant to EC junctions. ANLN silencing in Xenopus oocyte epithelial 
cell layers has been shown to reduce integrity of cell-cell junctions. Silencing of ANLN 
strongly disrupts claudin 5 distribution and β-catenin localisation at the cell to cell 
junction (Reyes et al. 2014). Rho activity is also disturbed resulting in an increased 
number of shorter, more intense bursts at the cell-cell junction. Interestingly, ANLN 
overexpression causes a severe contractile phenotype resulting in an increased 
localisation of P-MLC2 at the cell-cell junctions and the formation of aberrant 
contractile rings (Reyes et al. 2014). Investigations in human epithelial cell lines have 
demonstrated similar functional phenotypes. In human epithelial cells, ANLN 
exclusively localises to the nucleus during interphase. ANLN silencing resulting in an 
overall severe general cellular phenotype characterised by cell-cell junctional 
disorganisation without loss of expression of common junctional proteins despite 
there being no association of ANLN at the cell-cell junction (Wang et al. 2015).  
Unique interactors with ANLN have been investigated in renal familial focal 
segmental glomerulosclerosis (FSGS). FSGS is the gradual damage to individual 
glomeruli resulting in renal failure, usually manifesting between 35 and 75 years of 
age. A missense mutation located at R431C in ANLN was identified using genome 
wide association and exome sequencing in families with the inherited disorder. One 
particular kindred that had a high prevalence of the disorder carried the R431C 
mutation of ANLN (Gbadegesin et al. 2014). ANLN was upregulated in FSGS patient 
biopsies and overexpression of R431C mutant ANLN increases the migration and 
motility of immortalised podocytes. Further investigation identified the mutant as 
the interaction site ANLN with CD2AP, a key component of the structural foot 
processes of podocytes (Gbadegesin et al. 2014). The mutant form of ANLN results in 
the uncoupling of ANLN from CD2AP causing hyper activation of the PI3K/AKT/mTOR 
signalling pathway (Hall et al. 2018). This signalling pathway controls aspects of the 
cell cycle, proliferation and survival. Overexpression of mutant R431C mutant ANLN 
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results in endoplasmic reticulum stress and apoptosis in cultured immortalised 
podocytes (Hall et al. 2018). Inhibition of mTOR with rapamycin reduced pro 
migratory phenotypes and ER-stress induced apoptosis in podocytes (Hall et al. 
2018). 
The relevance of ANLN to the regenerative response in cardiovascular disease has 
been explored in myocardial infarction (Livet et al. 2007). Hesse et al produced a CAG-
ANLN-EGFP reporter mouse for the investigation of ANLN in the cell cycle dynamics 
of mouse embryonic development which reported a nuclear localisation of ANLN-
eGFP in cells in S/G2 phase (Hesse et al. 2012). ANLN was moreover found to act as a 
mitotic marker in pluripotent stem cells and importantly marked endoreduplication 
in myocardial injury. Transmural myocardial injury of the CAG-ANLN-eGFP mouse 
identified ANLN positive cells in the border zone of myocardial injury. Analysis of 
cardiomyocytes via flow cytometry showed that ANLN-eGFP positive cardiomyocytes 
had an increased DNA content compared to ANLN negative cells (Hesse et al. 2012). 
Supporting this, ANLN one of the top 5 upregulated genes in RNA sequencing of 













1.8 RNA binding proteins a potential regulatory mechanism of ANLN in CV disease? 
Post transcriptional regulation is the process of regulating gene expression at the 
mRNA transcript level and is mediated by multiple biological mechanisms. A key post 
transcriptional regulatory mechanism is RNA binding protein modulation of mRNA 




Figure 1.6: RNA binding proteins regulate the translation of protein from mRNA;  
RBPs expressed in the cytoplasm are activated/deactivated by phosphorylation through 
numerous signalling pathways. When active RBPs can bind to the 3’UTR of multiple 
target genes to mediate mRNA stability and the translational efficiency of proteins in 
target pathways. (Sanduja et al. 2012) 
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RNA binding proteins (RBPs) are a diverse group of proteins which have been 
observed to suppress and facilitate the expression of target genes in cardiovascular 
cell types. RBPs attach to adenylate uridylate rich elements (ARE) in the 3’UTR of 
mRNA transcripts and induce either degradation or stabilisation of the mRNA 
transcript. The ANLN 3’UTR contains multiple ARE sequences in its 3’UTR making it a 
potential target of RBPs as shown in figure 1.7. Multiple RNA binding protein families 
have been identified to function in cardiovascular cell types. RBPs which induce 
degradation of mRNA include AUF1, ZFP36, QKR1 and KSRP, mRNA stabilising RBPs 
include HuR, PAIP2 and AUF1. These RBPs control the expression of multiple genes in 
embryogenesis, inflammation and cell growth in multiple cell types.  
RBPs are known to play key roles in cardiovascular development and EC function in 
health and disease. In the maintenance of normal EC cell junction behaviour VE-
Cadherin and β-catenin mRNAs are stabilised by the binding of QKR1 RBP to the 3’UTR 
enhancing mRNA translation (De Bruin et al. 2016). QKR1 is highly expressed in the 
endothelium and the loss of QKR1 results in an overall increase in vascular 
permeability and a reduction of EC barrier function. In the EC response to ischaemia 
the transcription factor hypoxia inducible factor 1α and VEGF are controlled by 
multiple RBPs; HUR and PTB have been shown to improve the translation of these 
key genes in angiogenesis (Galbán et al. 2008). Conversely, the degradation of these 
factors is mediated by ZFP36 family RBPS during angiogenesis and this assists in 
regulating the EC response to growth factor stimulation. The interplay between RNA 
Figure 1.7: The ANLN 3’UTR contains multiple ATTTA sites for regulation by RNA binding proteins: 
Screening of the ANLN 3’UTR contains using AREsite identified ANLN as having multiple ATTTA 
ARE elements for targeting by RNA binding proteins. (Fallmann et al. 2016) 
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binding protein regulation of target genes in disease can be affected inflammatory 
status. For example in ECs ZFP36 regulation of VEGF stability is suppressed by TNF-α 
leading to increased HUR and PTB translational enhancement of VEGF (Dean et al. 
2001). 
1.9 ZFP36 family RNA binding proteins: 
The ZFP36 RBP family consisting of ZFP36, ZFP36L1 and ZFP36L2 are key regulators of 
angiogenesis (Bell et al. 2006). This family has overlapping targets and functions at 
similar time points in development and in the response to cytokines and chemokine 
expression in inflammation and cell growth. There are three main constituents of the 
ZFP36 RBPs family in humans, each have a highly conserved core RNA binding domain 
featuring a tandem zinc finger domain figure 1.8 (Lai et al. 2014).  These domains 
function to bind the highly conserved  ARE elements in the 3’UTR of target genes (Lai 
et al. 2014). 
 
Although the different members of the family exhibit a highly conserved structure 
they respond differently to growth factor stimuli to regulate multiple genes (Hacker, 
Valchanova, Adams & Munz 2010; Lai et al. 2014; Hudson et al. 2004; Blackshear et 
al. 2005). ZFP36 was first identified as an inducible protein by sequencing of cDNA 
from insulin stimulated mouse fibroblasts (Blackshear et al. 2005). Shortly thereafter 
the human ZFP36 sequence was described and found to be a potent regulator of TNF-
α mRNA stability (Taylor et al. 1996). ZFP36L1 and ZFP36L2, the second and third 
Figure 1.8: Representation of the homologous protein structure of the three members of 
the human ZFP36 family showing the N terminal domain (NTD) and C terminal domain 
(CTD) which function as activators of the zinc finger (ZF) RNA binding as well as inhibited 
mRNA deadenylation and decay.  
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members of the family were identified after their cDNA sequence was cloned from 
TPA treated fibroblasts (Varnum et al. 1991). The sequence and structural similarity 
of these proteins with ZFP36 were noted particularly the 67 amino acid RNA binding 
domains (Varnum et al. 1991; Bustin et al. 1994). Screening for the optimum binding 
sites of ZFP36 RBPs found the ideal ARE UUAUUUAUU sequence, although partially 
complete binding sites can allow binding of ZFP36 family RBPs (Blackshear et al. 
2003). ZFP36 mRNA mediation of decay each zinc finger domains binds to a UAUU 
subsite in the binding site (Hudson et al. 2004). The ZFP36 RBPs function through the 
binding to the 3’UTR of target transcripts and remove the polyA tail as shown in figure 
1.9 by promoting association of the deadenylase complex leading to destabilisation 
of the mRNA transcript  (Blackshear 2002; Sandler et al. 2011). Following mRNA 
destabilisation the RBP mRNA complex is transported into organelles for processing. 
ZFP36 mRNA complexes in exosomes undergo 3’ 5’ degradation by endonuclease 
digestion (Garneau et al. 2007).  ZFP36 mRNA complexes in P-bodies undergo rapid 
decapping of the 5’ 7- methyl guanosine cap by DCP-1 resulting in 5’ to 3’ degradation 












Figure 1.9: ZFP36 regulates mRNA transcripts through ARE mediated decay 
Processed mRNA transcripts are exported from the nucleus where ZFP36 family RBPs 
bind to ARE elements in the 3’UTR. Recruitment of the deadenylase complex (DA) 
removes the polyA tail to destabilise the mRNA transcript. ZFP36 bound transcripts 
are then localised to exosomes where the transcript is degraded by 3’ to 5’ nucleases. 
In P-bodies the 5’ end is decapped followed by 3’ to 5’ degradation of the transcript. 
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Normal regulation of ZFP36 RBP mediated mRNA decay is maintained by the 
phosphorylation of several residues of ZFP36 family RBPs controlled by multiple cell 
signalling pathways. This process is well described in macrophages, where ZFP36 
regulation of inflammatory gene expression is associated with an increased activation 
of MKP-1 following a peak of p38-MAPK activity a key regulator of inflammatory 
signalling mRNA stability (Cao et al. 2006). The overlap of gene expression from P38-
MAPK, activation expression and targets of ZFP36 shows a significant regulatory role 
of ZFP36 in controlling inflammation. Phosphorylation controls binding of the RBP to 
RNA transcripts by multiple mechanisms, downstream of p38-MAPK MK2 
phosphorylates ZFP36 at Ser52 and Ser178 (Chrestensen et al. 2004). 
Phosphorylation results in association of ZFP36 with the 14-3-3 complex greatly 
reducing the RNA binding efficiency of ZFP36 (Chrestensen et al. 2004). Subcellular 
localisation is altered by association with 14-3-3 resulting in exclusion of ZFP36 from 
P bodies and stress granules further improving mRNA stability. To stop the 
inflammatory response PP2A dephosphorylates ZFP36 at Ser52 and Ser178 resulting 
in a loss of 14-3-3 interaction and recovery of RNA binding efficiency and the 
suppression of inflammation through mRNA degradation (Sun et al. 2007). There is 
presence of an auto-regulatory loop by which ZFP36 regulates the DUSP-1 3UTR the 
phosphatase responsible for dephosphorylating and inactivating p38 MAPK. 
Therefore suppression of ZFP36 activity leads to an increased deactivation of 
p38MAPK in a negative feedback loop mechanism.  
Similar mechanisms are present in other members of the ZFP36 family of RBPs, 
ZFP36L1 is phosphorylated heavily by AKT/PKB a constituent of the PI3K pathway. 
Phosphorylation of Ser92 and Ser203 results in the protection from degradation by 
improving association with the 14-3-3 complex and preventing mRNA degradation 
(Benjamin et al. 2006). Enhancement of ZFP36L1 RNA binding efficiency can be 
initiated by the cAMP signalling pathway. Phosphorylation of Ser54 and Ser334 by 
PKA increases the half-life of ZFP36L1 and improves the binding and degradation of 
ZFP3l61 target mRNA (Rataj et al. 2016). ZFP36L2 doesn’t currently have any reported 
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phosphoserine residues that regulate its function although it is presumed there are 
several present on its structure.  
ZFP36 knockout mice exhibit a moderate phenotype having a 2-5 fold reduction in 
weight than controls and exhibit overall poor health. This is associated with an 
increase in inflammation causing an enlarged spleen, lymph nodes and atrophied 
thymus. ZFP36L1 knockout mouse embryos exhibit embryonic lethality at E9.5 due to 
cardiac outflow tract and multiple vascular abnormalities. These phenotypes 
produced were attributed to high VEGF-A production from embryonic fibroblasts 
causing overall vascular disorganisation (Bell et al. 2006; Stumpo et al. 2004).  Tissue 
specific knockouts of ZFP36L1 and ZFP36L2 identified ZFP36L1 as a regulator of key 
transcription factors controlling the cell survival, maturation and migration of B cells 
in a ZFP36L1 Cre-Lox mouse (Newman et al. 2017).  
ZFP36 and ZFP36L1 have been shown to regulate the differentiation of quiescent 
stem cell populations in development and regeneration (McClelland et al. 2017). In 
the response to injury of skeletal muscle, populations of quiescent satellite stem cells 
differentiate to replace damaged or injured myofibers (Hausburg, Doles, Clement, 
Cadwallader, Hall, Blackshear, Lykke-andersen, et al. 2015). MAPK inactivation of 
ZFP36 and stabilisation of the target mRNA myoD, allows for the differentiation and 
cell fusion into the myofibers (Hausburg, Doles, Clement, Cadwallader, Hall, 
Blackshear, Lykke-andersen, et al. 2015; Busse et al. 2008).  
ZFP36 and ZFP36L1 are key mediators of multiple angiogenic genes and control 
targets such as HIF1-α and VEGF expression in ECs (Hacker et al. 2010). ZFP36L1 
appears to have a more important vascular phenotype than ZFP36 in knockout mouse 
lines. VEGF is a target of both ZFP36 and ZFP36L1 which means dysregulation of VEGF 
is not the main cause of vascular malformation. Dll4, the notch ligand responsible for 
tip stalk cell designation and controlling blood vessel branching and density, has been 
shown to be strong target of ZFP36L1 which can explain the strong vascular 
phenotype of ZFP36L1 knockout (Desroches-castan et al. 2011). Given that the ANLN 
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3’UTR contains ARE elements (figure 1.7), there may be a regulatory mechanism of 
post transcriptional regulation of ANLN by ZFP36 RBPs in angiogenesis.  
1.10 Zebrafish in medical research:  
It was decided to use zebrafish as our model organism for the investigation of ANLN 
in angiogenesis. Zebrafish have become a valuable tool in the investigation of gene 
function in development, organogenesis and regeneration. This is owing to their 
small size, high fertility and their translucent embryos; these features were first 
utilised by George Streisinger thirty years ago (Grunwald & Streisinger 1992). Large 
scale screening studies in zebrafish embryos and mapping of their genome has 
identified multiple zebrafish homologues and orthologues of mammalian genes 
(Howe et al. 2013; Haffter & Nusslein-Volhard 2003). The zebrafish genome has at 
some point  duplicated, some of these duplications have been lost and some have 
drifted from the original function (Postlethwait et al. 1998). Despite the duplication 
of the zebrafish genome the number of chromosomes remains similar to humans 
(Postlethwait et al. 2000). The rapid achievement of embryonic landmarks and the 
ease of imaging has led to a near requirement for the use of zebrafish in some areas 
of biology.  
The relative ease of genetic modification of the zebrafish embryo and the volume of 
viable single cell stage embryos created allows for the generation of multiple 
different transgenic lines using a number of different techniques. Microinjection of 
morpholinos is a readily used technique to mediate transient interference of genes 
in vivo (Timme-Laragy et al. 2012). Morpholinos are small DNA oligos which can bind 
to the kozac sequence or splice sites in the mRNA transcript, this interferes with 
protein expression. Morpholinos however can produce a wide array of off target 
effects which can cause misleading phenotypes (Timme-Laragy et al. 2012). Using 
CRISPR-Cas9 to replace all previous forms of genetic interference is increasingly 
common. CRISPR-Cas9 originated as a bacterial immune response against viral 
infection. It was first identified to function in S.thermopilus, where resistance to 
bacteriophages had been acquired through integration of viral DNA with the Cas9 
45 
 
enzyme and excision of viral DNA from the host genome (Barrangou et al. 2007).  Of 
the three CRISPR-Cas9 mechanisms present in bacteria, type 2 is the method 
currently most used for genome editing. It requires three components, (i) a 
complementary RNA (crRNA) which is reciprocal to the target gene locus, (ii) a trans-
activating crRNA (tracrRNA), which is complementary to the crRNA and (iii) the Cas9 
enzyme. Cas9 associates with the crRNA and tracrRNA and facilitates association of 
nucleases which initiate a doublestrand break of the target locus. For genome editing 
purposes, the crRNA and tracrRNA can be combined into a short guide RNA (sgRNA); 
when paired with a recombinant Cas9 enzyme this can be injected into single cell 
embryos to direct targeted double stranded breaks of loci of interest in the genome 
(Jinek et al. 2012). The only requirement of target sites is the presence of a 2-5 
nucleotide protospacer adjacent motif (PAM) sequence. PAMs are specific to 
different recombinant Cas9 enzymes wand must directly follow the sgRNA sequence 
to allow recognition of the site (Swarts et al. 2012). The similarity between multiple 
zebrafish genes make zebrafish an ideal model for investigating mammalian gene 
function. However a caveat of zebrafish research is the lack of available antibodies 
for zebrafish proteins. This makes traditional methods such as Western blot and 












1.11 Zebrafish in Cardiovascular research:  
In cardiovascular research the zebrafish has become increasingly popular. Within the 
first 24 hours of its life, the zebrafish embryo develops a contracting heart tube and 
the beginnings of the early vascular system and blood flow (Isogai et al. 2001). These 
features, along with the ability of the early embryo to receive oxygen by diffusion, 
means that the use of severe cardiovascular injuries or knockout lines have ethical 
advantages in zebrafish embryos over adult mice.  
1.12 Zebrafish Vasculogenesis: 
Angiogenesis as previously described in section 1.4 refers to the development of 
blood vessels from existing vascular networks. In early embryonic development the 
initial vascular cords form through vasculogenesis, this process is the de novo 
creation of blood vessel by the coalescence of endothelial cell progenitors (Lawson & 
Weinstein 2002).  
This process is well described in the zebrafish embryo, as shown in figure 1.10. 
Vasculogenesis occurs after the formation of the neural tube and somites from the 
initial embryonic layers. The developing neural tube and notochord release the 
soluble factor sonic the hedgehog (shh). SHH stimulates the release of VEGF from the 
somites encouraging the migration of VEGFR2+ve angioblasts from the lateral plate 
mesoderm to the trunk of the embryo, these cells form the intermediate cell mass 
(ICM) (Lawson & Weinstein 2002; Lawson et al. 2002). The angioblasts stimulated by 
VEGF from the somites and notch signalling from the notochord begin to generate 
early vascular structures. These structures become the developing dorsal aorta (DA) 
and pericardinal vein (PCV) through changes in gene expression controlling arterial 
venous designation. ECs of the early DA are stimulated by VEGF activation of VEGFR2 
activation of notch, Ephrin B2 (EPHB2) expression drives arterial 
designation.(Ellertsdóttir et al. 2010) The development of the PCV from the early 
vascular cords is caused by expression of the EPHB2 receptor Ephrin B4 (EPHB4), 
ephrin signalling between the arterial and venous side assists in early venous 
designation (Ellertsdóttir et al. 2010). The formation of the main trunk vasculature is 
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completed by ~1dpf and is capable of carrying blood flow, further developmental 
angiogenesis follows to create the microvasculature.  
Figure 1.10: Arterial/venous definition in vasculogenesis in the zebrafish trunk: 
Axial slice schematic of the 14-28 hpf zebrafish embryo. Showing the generation of the dorsal 
aorta and pericardinal vein (PCV) by signalling events from the notochord (N) located inferior 
to the neural tube (NT), and the somites (S). Angioblasts migrate from the lateral plate 
mesoderm (LPM) to produce the initial vascular cords before undergoing arterial venous 




The general architecture of the zebrafish embryo arteriovenous system is similar to 
mammalian embryos, with the embryo forming distinct arteries and veins early in 
development (Isogai et al. 2001). The complexity of the vasculature increases rapidly 
between 1-5dpf as shown in figure 1.11. Between the somites of the embryo, the 
intersegmental vessels (ISV) form in two waves of angiogenesis (Isogai et al. 2003). 
The first wave occurs at ~22-28hpf where sprouting angiogenesis from the DA 
produces vessels along the somite boundaries creating the segmental arteries. At the 
dorsal roof of the embryo the sprouting ECs merge to form the dorsal longitudinal 
anastomotic vessel (DLAV) (Kamei et al. 2006). The second wave of sprouting occurs 
between 28-32 hpf where sprouting angiogenesis from the PCV produces the 
segmental veins. Increasing EC density and mural cell attachment continue to 
develop the ISVs into mature vessels (Isogai et al. 2003). The development of the CNS, 
gill and gastro intestinal vessels also rapidly develop between 1-5 dpf as shown in 
figure 1.11 (Isogai et al. 2001). 
1.13 Investigating zebrafish vasculature: 
Multiple transgenic lines have been generated that permit the in-depth investigation 
of the developing zebrafish vasculature. Key to this are lines which express 
fluorescent reporters like mCherry or GFP under the control of EC specific reporters, 
such as fli-1 or flk-1 (VEGFR2), to fluorescently mark vascular structures throughout 
development and adulthood (Y. Wang et al. 2010; Lawson & Weinstein 2002). In 
addition, certain transgenic lines and knockouts have been shown to affect EC 
function in vivo. These include the cloche mutant, which results in the failure of EC 
development and a complete absence of vasculature (Stainier et al. 1995). The 
mindbomb mutant, a mutant of an E3 ubiquitin ligase required for efficient 
Dll4/Notch signalling, produces strong haematopoietic and EC lineage phenotypes 
(Itoh et al. 2003; Yoo et al. 2006; Bingham et al. 2003). These (and other) lines have 
been used successfully to image the developing vasculature in a manner which is not 
possible with traditional rodent based models (Kamei & Weinstein 2005).  
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Investigation of inflammatory cell involvement in cardiovascular development and 
injury is another key facet of zebrafish research. Zebrafish embryos generate innate 
immune cells (macrophages and neutrophils) by 2 dpf, whereas adaptive immunity 
develops later (Le Guyader et al. 2008). Several lines utilising fluorescent proteins to 
mark macrophages with the mpeg promoter and neutrophils with the mpx promoter 
have been developed (Renshaw et al. 2006; Ellett et al. 2011). These lines have been 





Figure 1.11: The vascular anatomy of the zebrafish embryo between 1-5 dpf:  
From 2-4 dpf there is rapid maturation and expansion of the vascular network. 
Maturation is particularly noted in the trunk and caudal artery/vascular plexus 
and increasing network density in the CNS, GI tract and gill between 2 and 5 dpf. 
taken from (Isogai et al. 2001)
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1.14 Models of cardiovascular injury in zebrafish: 
Several experimental injury models have been developed to study the cardiovascular 
response and model myocardial infarction and tissue regeneration in the zebrafish 
embryo. Such techniques have also been used to investigate the regenerative 
capacity of the heart. For example, cryoinjury in adult zebrafish demonstrated the 
remarkable capacity for heart regeneration. These studies used super chilled metal 
probes applied to the exposed heart in conjunction with fluorescent reporters to 
successfully demonstrate myocardial regeneration and neovascularisation 
(González-Rosa et al. 2011; Marín-Juez et al. 2016). In the embryo, cryoinjuries of the 
heart have been overtaken by laser injury models. Laser injury of the embryonic heart 
were shown to produce a reproducible trauma that induces cardiomyocyte 
apoptosis, reduced cardiac outflow and stimulates regenerative processes (Matrone 
et al. 2014; Matrone et al. 2013; Matrone et al. 2015).  
Exploration of vascular injury or the vascular response in regeneration has been 
carried out successfully to investigate the revascularisation of the adult zebrafish tail 
fin (Hlushchuk et al. 2016). However applying this to the developing embryo is more 
difficult because the vascular network is less developed than in the adult fish. Still, 
laser injuries of embryonic vessels have been used to study different aspects of 
vascular development, and to investigate thrombus formation and resolution in the 
embryonic fish (Watson et al. 2013). Laser induced thrombus formation identified the 
flow dependent maturation of the intersegmental vessels, identifying the role of 
blood flow in zebrafish vascular development and patterning (Watson et al. 2013; 
Gray et al. 2007). Laser injuries can moreover successfully ablate single vessels in the 
cerebrovascular system of the developing embryo. Ablation of single vessels has 
identified macrophage mediated blood vessel anastomosis (Liu et al. 2016). 
Mechanical injury models of larger vessels of the embryonic fish have also been 
developed and were instrumental in identifying the EC response in wound healing 




1.15 The anln:anln-eGFP zebrafish and asymmetric cell division in embryonic 
development: 
To investigate Anln expression in the developing zebrafish vasculature we imported 
a fluorescent reporter of Anln expression. Dr Lucia Poggi of the University of Trento 
developed this BAC based fluorescent reporter zebrafish expressing full length eGFP 
tagged Anln under the zebrafish anln promoter (zebrafish lines designated by the 
nomenclature (promoter:coding sequence)) (Paolini et al. 2015). This zebrafish was 
used extensively for investigating the asymmetric cell divisions in retinal progenitor 
cell development and differentiation. This model suggested that anln is highly 
expressed in the early neuroepithelium, marking asymmetric cell divisions of retinal 
ganglion cells (figure 1.12). Anln expression was found to decline throughout retinal 
development, simultaneously the expression of Ath5 (a marker of retinal ganglion cell 
maturity) was seen to increase. In Ath5-/- embryos Anln expression does not decrease 
during development and retinal ganglions cells do not develop (Paolini et al. 2015). 
Anln was observed to control asymmetric cell division in retinal ganglion cell 
progenitor differentiation, supporting this, interference of Anln expression with 
morpholinos reduced the number of Ath5+ve retinal ganglion cells (Paolini et al. 2015). 
Furthermore, anln-eGFP marked the mitotic potential of retinal cell and progenitor 
cell populations within the cell layers of the pre-juvenile zebrafish retina (Malo et al. 
2017). This anln:anln-eGFP reporter fish was proposed to be useful for investigating 
the asymmetric cell divisions and the progression of  the cell cycle in regeneration 
















Figure 1.12: The anln:anln-eGFP zebrafish marks asymmetric cell division in retinal 
development 
(A) The anln:anln-eGFP fluorescent reporter marks matches an anln mRNA in situ 
hybridisation showing high Anln expression in the retina . (B) Confocal imaging of the 
retinal cell layers identified Anln association with asymmetric cell divisions of retinal 
ganglion cells (Paolini et al. 2015). 
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Asymmetric cell division is a key process in eukaryotic invertebrate development 
where smaller daughter cells are produced by a larger parent cell (Knoblich 2008). 
This process is observed in budding yeast reproduction, where budding of the 
daughter cells from the mother cell is controlled by asymmetric gene expression, 
driving asymmetric placement of the cleavage furrow. This process is less common in 
vertebrates, particularly in embryogenesis, where cell divisions are typically 
symmetrical. Important regulators of asymmetric cell division observed across 
species include NUMB, PROSPERO and BRAT (Knoblich 2008). In vertebrate tissues, 
asymmetric cell division is rather associated with the differentiation of two individual 
daughter cells of separate lineages from progenitor cell types as investigated by 
Paolini and Malo et (Paolini et al. 2015; Malo et al. 2017). Outside of neuronal cell 
development, asymmetric cell division is also associated with the generation of 
multiple cell lineages in development, and in disease, by regulating self-renewal and 
tissue regeneration (Berika et al. 2014). Asymmetric cell division in haematopoiesis 
(controlled by Notch) regulates the self-renewal and differentiation of 
haematopoietic progenitors. Loss of Notch expression is associated with asymmetric 
haematopoietic cell differentiation, whereas increased Notch expression is 
associated with symmetric self-renewal of progenitor populations (Duncan et al. 
2005; Schroeder 2007). Different inheritance of NUMB is thought to be associatewith 
altered levels of Notch signalling in daughters cells; NUMB was shown to act as a 
tissue specific repressor of NOTCH signalling in other cell types (Knoblich 2008). 
In C.elegans, asymmetric cell division is key to early embryonic development, where 
embryonic cell lineages are generated from initial asymmetric cell divisions after 
fertilisation of the egg. ANLN has been associated with the establishment of cell 
polarity in early C.Elegans embryogenesis and cytokinesis. Here, the C.elegans 
orthologue of LKB1 (PAR4) has been shown to regulate the placement and activity of 
the ANLN orthologue ani-2 (Chartier et al. 2011). Loss of PAR4 results in inappropriate 
ani-2 localisation and dysfunctional acto-myosin contractility in asymmetric cell 
division (Chartier et al. 2011). 
54 
 
The relevance of asymmetric cell division to EC development and blood vessel 
formation has not been fully explored, however, recent investigations in zebrafish by 
Costa et al has shown asymmetric cell division in angiogenesis (Costa et al. 2016). The 
control of collective EC migration in angiogenesis in the mouse is influenced by baso-
lateral inhibition between tip and stalk cell ECs (Phng & Gerhardt 2009). This is heavily 
influenced by asymmetric cell division and the differential inheritance of cell products 
to produce these two separate cell types (Costa et al. 2016). Imaging of zebrafish 
intersegmental vessels at 22-28hpf have identified fundamental differences in cell 
size between tip and stalk cells during angiogenesis (Costa et al. 2017; Costa et al. 
2016). Asymmetric placement of the centriole allows for different post-mitotic 
inheritance of VEGFR machinery. This is a requirement of tip/stalk cell designation, 
allowing for efficient collective cell migration in angiogenesis (Costa et al. 2017; Costa 
et al. 2016).  
Investigation of ANLNs expression in early vascular development or injury of the 

















1.16 Hypothesis:  
ANLN is a new important target in ECs in cardiovascular disease. This thesis therefore 
examined the hypothesis that “ANLN is an important mediator of angiogenesis in vivo 
and in vitro”. 
 
1.17 Aims: 
I sought to identify whether ANLN could affect EC function in angiogenesis in vivo and 
in vitro by addressing three separate questions. Hence my three aims were: 
1. Investigate the effects of ANLN in post ischaemic angiogenesis. 
2. Identify a potential post transcriptional mechanism for the regulation of ANLN 
in vitro and in vivo RBP. 
3. Investigate the expression and role of ANLN in ECs in vivo using a zebrafish 






































2.1 techniques for in vitro studies 
2.1.1 Cell culture: 
All cell culture was carried out at 37 ᵒC with 20% and 5% CO2 in a humidified 
incubator, cell lines used and media are listed in table 1. For simulation of 
inflammation conditions, HUVECs had media supplemented with the addition of 
10ng/ml IL-1β (Peprotech, 200-01B).  
Table 1: cell lines used in in vitro studies: 
Cells  media 
Human vein umbilical ECs (HUVEC) 
(Lonza, C2517A 
EGM-2 (EBM2+EGM bullet kit) (Lonza, 
CC-3162) 
HEK293T (ATCC®, CRL-11268) DMEM  (10% FBS+1% Pen-Strep+2.5 
mM glutamine) (Lonza) 
1.1.2 SiRNA transfection: 
Transfections were carried out using RNAimax lipofectamine transfection reagent 
(Thermofischer, 13778075). 1x105 HUVEC were added to a 6 well dish and transfected 
with RNAimax according to the manufacturer’s protocol with Optimem low serum 
media (Thermofisher, 3195062) using the siRNA and concentrations listed in table 2. 
The media was changed ~16 hours post transfection and transfections left for 48 
hours before use in experiments.  
Table 2: siRNA used in in vitro experiments  




All stars negative control Quiagen (SI03650318) 10nm 
ANLN  Quiagen (SI00122710) 10nm 
ZFP36L1 1 Ambion (SI2089) 10nm 
ZFP36L1 2 Ambion (SI2091) 10nm 
ZFP36 1 Ambion (SI2026) 20nm 
ZFP36 2 Ambion (SI2027) 20nm 
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2.1.3 Lentivirus production and transfection: 
Lentivirus particles containing ZFP36 and EGFP coding sequences in the  pRRL vector 
were obtained from Luccia Montorsi produced as described in Montorsi et al. 2016. 
Two lentiviral vectors were purchased from CyagenTM, an ANLN-EGFP and control 
EGFP plasmid [(pLV[Exp]-Neo-CMV>ClaI/EGFP(ns)/XbaI:hANLNSbfI)+(pLV[Exp]Puro 
CMV>EcoRV/ORF_91bp/XmaI/XbaI:IRES:EGFP/ClaI)]. After lentiviral plasmid DNA 
production and purification (see section 2.1.21), plasmid preparations were given to 
Pamela Brown of Edinburgh University Core facilities for packaging as per established 
methods (Collins et al. 2009).  
1x105 HUVECs were plated in each well of a 6 well dish and transfected by incubation 
with 10 M.O.I. of lentiviral particles in EGM-2 containing 8μg/ml polybrene (Sigma, 
TR-1003) overnight. Media was replaced with fresh EGM-2 and the cells used in 
downstream assays.  
2.1.4 Cell sorting: 
ANLN-EGFP and EGFP control HUVECS were detached using trypsin (Thermofisher, 
25200056) and resuspended in EGM-2 media in sterile FACS tubes (BD Biosciences, 
352008). Cells were sorted on a FACS ARIA 2 (100μm nozzle) cell sorter, the live 
populations were gated from cell debris using BD FACS DIVA software and EGFP+ve 
cells collected in a FACS tube containing EGM-2 media. Post sorting cells were 
centrifuged at 300g at R.T and the FACS buffer and media aspirated away, the cell 
pellet was washed two times with PBS at R.T. The cell pellet was resuspended in EGM-
2 and added to a T75 for further culture at standard cell culture conditions.  
2.1.5 Matrigel assay: 
In vitro angiogenesis assays were performed via the matrigel tubulogenesis assay. 
Matrigel was thawed on ice overnight and pipetted to the bottom of a 96 well plate 
(Corning, CLS3595) and solidified for half an hour at 37ᵒC. 1x104 HUVEC were added 
to each well and incubated at 37ᵒC for 5-6 hours before being fixed with R.T 4% PFA 
for 10 minutes, PFA was replaced with PBS and images taken on a Leica inverted 
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microscope. Images were analysed with FIJI with the angiogenesis analyser plugin 
(NIH, Image J).  
For live imaging matrigel was plated in a μ-angiogenesis slide (Ibidi). Live imaging data 
was acquired using a Zeiss wide field observer inverted microscope. Images were 
taken every 15 minutes, images were exported as high quality tiff format and 
compiled in FIJI. 
2.1.6 Barrier function and wound healing assay: 
Using the electric cell impedance (ECIS) based assay system (Applied Biophysics) the 
barrier function and migration capacity of HUVEC were measured. 8W10PET+ 
chambers (Applied Biophysics) for barrier function or 8W2LE chambers (Applied 
Biophysics) were coated with 1.5mM homo-cysteine and 10 µg/ml fibronectin and 
0.2% gelatine. 6x104 HUVECS were added to each well of the ECIS assay chambers. 
For barrier function experiments, assay chambers were left to equilibrate for 24 
hours before the acquisition of data; following a further 24 hours post data collection 
the peak resistance for each chamber was taken and used for analysis. For wound 
healing assays the assay chambers were left to equilibrate for 24 hours before the 
application of an electrical wound at the parameters 20000mV for 30 seconds. 
Measurements were acquired up to 24 hours post injury and used to calculate the 
rate of wound closure post injury. 
2.1.7 Cell cycle staining: 
First, sub-confluent HUVECs were detached using Trypsin/EDTA, pelleted at 300G and 
washed three times with PBS. 10mls of ice cold 70% Ethanol v/v  was then added to 
the pellet dropwise with gentle vortexing to disrupt the cell pellet into a homogenous 
solution, this was then stored at -20ᵒC. For propidium Iodide (PI) staining. The fixed 
cells were allowed to gently equilibrate to R.T for 15 minutes before being 
centrifuged at 1500 g for 5 minutes then washed once in PBS followed by 
centrifugation at 1500 g for 5 minutes. PBS was aspirated and the cells were stained 
by addition of 200 µls per 3x105 cells of staining solution containing 25 µg/ml PI and 
30 µg/ml RNAse A (Sigma, 10109134001) in PBS, this was incubated at 37ᵒC shielded 
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from light for 30 minutes. Samples were transferred to FACS tubes and analysed on 
a 5LSR Fortessa flow cytometer (BD biosciences). The cells were gated to generate 
cell cycle histograms by identification of the cells and exclusion of doublet cells, 
histograms were generated showing the relative intensity of PI stain. The individual 
peaks were gated to obtain counts of cells in the G0/G1, S and G2M phases. 
 
2.1.8 Cell proliferation assay: 
Cellular proliferation assays was analysed by measuring via Edu (Thermofisher, 
E11087) incorporation. 1x104 HUVECs per well were plated into a 96 well plate 
(Corning), after 24 hours the media were replaced with EGM-2 containing 10μM of 
EdU. This was incubated overnight before being fixed in 4% PFA for 15 minutes, cells 
were washed 3 times with PBS before being permeabilized with 0.5% Triton X-100 in 
PBS for 5 minutes. Staining for Edu incorporation was carried out using the Click-iT 
EdU alexa fluor 594 imaging kit (Thermofisher, C10339) according to the 
manufacturer’s instructions.  Images of each well were taken and on an inverted 
digital microscope the percentage of EdU+ve nuclei against total nuclei were 
quantified using ImageJ. 
 
2.1.9 Transwell filter migration assay: 
 6.5 mm transwell filter inserts (Corning, 3422) were coated with 10 µg/ml fibronectin 
and 0.2% gelatin (both manufacturers) and left to dry. HUVECs were starved in 
supplement free  EGM-2 media for 6 hours and then detached with trypsin/EDTA and 
resuspended in migration media (EGM-2 without addition of growth factors  
supplemented with 0.5% BSA). EGM-2 supplemented with 20 ng/ml VEGF-A 
(Peprotech, 100-20) or its vehicle (PBS) was added to the wells of a 24 well plate 
(Corning, 3422), and 5x104 HUVECs were added into each insert. Inserts were 
incubated for 3 hours in a humidified tissue culture incubator.  Then, cells on the 
upper layer were scraped off using a cottons swab before fixing the transwells in ice-
cold methanol for 10 minutes. HUVEC nuclei were stained using 1:5000 DAPI (sigma, 
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D5942) in PBS and then washed 3 times with PBS. The filter was cut from the insert 
and mounted on a glass slide using fluoromount (Sigma, F4680) and a coverslip. 
Images were taken on a Leica inverted microscope and images quantified with the 
ImageJ cell counter plugin. 
1.10 Immunocytochemistry: 
HUVECs were cultured on sterile 25 mm glass coverslips coated with 10 μg/ml 
fibronectin and 0.2% gelatin at a density of 5x104 cells per well. Coverslips were fixed 
with 4% PFA (Fischer, 28908) at RT for 15 minutes. Coverslips were washed 3 times 
with PBS and permeabilized in PBS with 0.5% Triton X-100 (Sigma, T8787) for 15 
minutes. Coverslips were blocked for one hour in 3% BSA in PBS. Following blocking, 
primary antibody (see table 3) was added to each coverslip in 1% BSA in PBS at 4ᵒC 
overnight. Following primary antibody incubation staining solution was removed and 
coverslips washed 3 times with PBS. Secondary antibody incubations (see table 3) 
were carried out in 1% BSA in PBS for one hour at RT. Secondary antibody solution 
was removed and the coverslips were washed 3 times with PBS, this was followed by 
staining with DAPI and Phalloidin (see table 3) in PBS at RT for 5 minutes. Coverslips 
were mounted with Fluoromount™ (Sigma, F4680) on glass slides (Surgipath, 08001E) 
and left to set in the dark overnight at 4ᵒC. Images were taken using a Zeiss LSM 780 
confocal microscope. 
Table 3: antibodies used in immunocytochemistry 
Antibody and supplier Clone  dilution 
Anti-ANLN (Abcam, ab154337) Polyclonal 1:125 
Anti-EGFP (Abcam, ab6556) Polyclonal  1:2000 
Phalloidin conjugated to Alexa-Fluor 
594nm (life technologies, A12381) 
- 1:200 
DAPI (Sigma, D9542) - 1:1000 
Anti-rabbit conjugated Alexa-Fluor 
488nm (Life Technologies, A11072) 
Polyclonal  1:500 
2.1.11 Western blot sample preparation: 
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Protein sample concentration was assayed by BCA assay as per manufacturer’s 
protocol (Thermofischer, 23225) in a 96 well plate (Corning). Samples were prepared 
in loading buffer (0.5% bromophenol blue, 2% β-mercaptoethanol, 10% glycerol (w/v) 
and 2% SDS) and heated to 95ᵒC for 2 minutes.  
2.1.12 SDS page and western blot: 
Reduced samples and corresponding molecular weight markers (Thermofischer, 
26616) were separated on 8/10% acrylamide gels; resolving gel (30% v/v Protogel 
(30% acrylamide w/v 0.8 % Bis-acrylamide w/v) (National diagnostics, EC-890) + 
0.375M Tris-HCl pH 8.8+0.1% SDS +0.33% ammonium persulfate (10% w/v) + 0.1% 
TEMED), stacking (13% protogel v/v, 0.1M Tris-HCl pH 6.8, 0.1%SDS + 0.5% 
ammonium persulfate (10% w/v) + 0.1% TEMED). Gels were poured using a mini-
protean stacking system (Bio-Rad, 1653303) and ran in an electrophoresis chamber 
in tris-glycine-SDS buffer (25mM Tris, 200mM glycine, 0.1% SDS) for 40 minutes at 65 
volts followed by 1.5 hours at 95 volts. Proteins were transferred onto PVDF 
membranes in tris-glycine-methanol buffer (25mM Tris, 200mM Glycine and 10% 
Methanol) at 60mA overnight at 4ᵒC.  
After transfer membranes were stained with Ponceau S stain (Sigma, P7170) to 
confirm transfer, followed by washing in 0.03% w/v trichloroacetic acid in ddH2O 
(Sigma, T6399). Membranes were then blocked in TBST (Tris-buffered saline pH 7.4 
supplemented with 0.1% tween) and 5% non-fat milk for one hour at RT. The 
membrane was then incubated overnight in primary antibody (see table 4) at 4ᵒC in 
TBST with 4% milk.  
The primary antibody solution was removed and retained for future use and the 
membranes washed 3 times in TBST. Membranes were then incubated in the 
corresponding HRP linked secondary antibody in TBST with 4% milk for 1 hour at RT. 
Membranes were washed 3 times in TBST before being developed with ImmobilonTM 
Western Chemiluminescent HRP Substrate (EMD Millipore, WBKLS0500) for 5 
minutes. Excess development solution was removed by capillary action and the 
membrane was sealed in a development cassette with cling film. Signal was captured 
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by exposing CL-Xposure film (Thermofischer; 34089) to the membrane in a dark 
room. Film was developed using an automated processor (Konica, SRX-101A). 
Molecular weights were marked on the film after exposure and films scanned using 
an office scanner (Xerox). 
Table 4: Antibodies used in Western blot:  
Antibody and supplier Clone Concentration 
Rabbit anti-ZFP36L1 (CST, 
2119s) 
Polyclonal 1:1000 
Rabbit anti-ZFP36 CST (CST, 
14030) 
monoclonal   1:1000 
Rabbit anti-EGFP  (Abcam, 
ab6556) 
Polyclonal 1:1000 
Goat anti-ANLN (Abcam, 
ab5910) 
Polyclonal  1:1000 
Mouse anti-beta actin  (Sigma, 
A3516) 
Monoclonal 1:50000 
Sheep anti-mouse HRP (Sigma 
A5906)  
Polyclonal 1:5000 





RNA extraction was carried out using the MiRneasy kit (Qiagen: 217084). RNA was 
extracted by addition of Qiazol (Quiagen: 79306) to cultured cells. Homogenates 
were incubated for 5 minutes and vortexed before the addition of 140µls of 
chloroform. Samples were vortexed and then centrifuged for 15 mins at 12000g at 
4ᵒC, the supernatant was removed leaving protein residue and phenol. The upper 
aqueous phase was transferred into a new tube (~600µl by volume) and 1.5 volume 
of 70% ethanol was added and mixed thoroughly. The sample was added to an 
RNeasy® Mini Spin Column and all on column steps were performed as per the 





2.1.14 DNA/RNA quantification: 
DNA and RNA samples were thawed on ice and 1.5μls added to a nanodrop. The 
RNA/DNA concentration was quantified in the sample for downstream application in 
cDNA generation or Biochemical assays. 
2.1.15 Reverse transcription polymerase chain reaction (RT-PCR) by genomic DNA 
wipeout: 
The QuantiTect Reverse Transcription Kit (QIAGEN, Cat. # 205311) kit and protocol 
were used for this process. 500 ng of RNA extract was added to RNAse free water to 
a volume of 12μl in PCR tubes and placed on ice. Then, 2μl of 7xgDNA wipeout buffer 
was added to each sample and mixed thoroughly by pipetting. The RT-PCR master 
mix per sample was made as; 1μl Quantiscript RT enzyme, 1 μl Quantiscript RT primer 
mix, 4µl of Quantiscript RT buffer 5x.  
Each PCR tube was added to the thermocycler using the following protocol; 2 minutes 
42ᵒC, 4 minutes hold at 4ᵒC (addition of 6μls of master mix followed by thorough 
mixing by pipetting), 30 minutes at 42ᵒC, incubation for 3 minutes at 95ᵒC, cDNA was 
stored frozen at -20ᵒC. 
2.1.16 qPCR protocol: 
Power SYBR® Green PCR Master Mix (Applied Biosystems, Cat. # 4367659) was used 
for the following qPCR protocol. Primers were supplied by Life Technologies and 
sequences are listed in table 5. Sample mixes consisted of 5μls Power SYBR green PCR 
master mix, 3µls of RNase-free water and 1 μl of 10µM primer mix.  
The lightcycler™ protocol used is as follows; melting 95ᵒC, 15 seconds, annealing 
65ᵒC, 30 seconds; extension 72ᵒC for 30 seconds. Quantification was performed using 






Table 5: qPCR primers: 
Primer name sequence 
ZFP36 Forward: CAAGTAATCCCCTTTTCCAG 
Reverse: CACCATCATGAATACTAGC 
ZFP36L1 Forward: TTATGGAAGGGTAACAAGC 
Reverse: TGGTTCTGGTGGAACTTG 
ANLN Forward: ATAGCAGCAGTGTTAAGCAGG 
Reverse: AACCAAAGACCCATCACAGC 
VEGF Forward: ATCTGCATGGTGATGTTGGA 
Reverse GGGCAGAATCATCACGAAGT 
18s Forward: CCAGTAAGTGCGGCTCATAT 
Reverse: CCGAGGGCCTCACTAACC 
2.1.17 Cloning: 
The sequences were selected from the UCSC genome browser 
(https://genome.ucsc.edu/) and primers designed on Primer3 primers and 
manufactured by Sigma Custom oligos, see table 6.  PCR reactions were carried out 
using 1x Q5 reaction buffer (NEB: B90275), Q5 High Fidelity polymerase 0.02U/μl, 
200μM dNTPs (NEB: B90275), 0.5μM forward, 0.5μM reverse primer and 1μl 
template cDNA. Reactions were ran on a thermocycler with the following protocol, 
Denaturation at 98ᵒC for 30 seconds, 25-30 cycles of 98ᵒC for ten seconds then 63ᵒC 
for 30 seconds then 72ᵒC for 30 seconds followed by a final extension at 72ᵒC for 2 
minutes and a final hold at 4ᵒC.  
Table 6: primers for insert preparation 















2.1.18 DNA gel electrophoresis: 
PCR products were mixed with 10X loading buffer (100mg orange G, 15 ml glycerol 
and 35 ml H2O) and DNAse free water, then ran on a 1.2% ultrapure agarose 
(Thermofishers) gel incorporating  Gel Red (Biotium) in TAE buffer (0.04M Tris-
acetate and 0.001M EDTA) at 95V at 4ᵒC. The gel was imaged using a trans illuminator 
and the corresponding molecular weight bands cut from the gel using a scalpel, 
transferred to a DNAse free tube for processing and stored frozen at -20ᵒC.  
2.1.19 Restriction digests: 
PCR products and plasmids [pMIR or pCDNA3.1 (Thermofisher, AM5795+V79020)] 
were digested to produce sticky ends using Spe1 (NEB: R01335), HindIII (NEB: 
R70025) or XbaI (NEB: R0145S), using NEB2 buffer (NEB: R90275) at 37ᵒC for 2 hours 
as per the manufacturers protocol. The digestion products were purified by 
chloroform phenol extraction; products were made up to 300 µls with H2O, 150µls of 
Phenol and chloroform were added and the solution vortexed. This was incubated at 
room temperature for 2 minutes then on ice for 2 minutes. This was then centrifuged 
at 13000 g at 4ᵒC and the upper aqueous layer removed and added to 3x volumes of 
100% ethanol and 1:10 v/v 3M sodium acetate. This was vortexed and frozen at -
80ᵒC. Samples were thawed on ice and centrifuged at 13000g for 30 minutes and the 
supernatant discarded. The pellet was washed in 70% ethanol, allowed to dry and 
then resuspended in DNAse free H2O.  
2.1.20 DNA gel extraction: 
DNA gel extractions were performed using the QIAquick Gel Extraction Kit (Qiagen, 
28704). First, excised DNA bands were suspended in 3 times the gel weight of QG 
buffer and heated at 50ᵒC until the agarose gel had dissolved. Following this, one 
volume of isopropanol was added to the sample and mixed thoroughly by pipetting. 
Then the entire sample was added to a QIAquick column and centrifuged for 1 minute 
at 13000 g. Following this all on column steps were carried out as per manufacturer’s 
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instructions. DNA was eluted by addition of 30μls of DNase free water to the column 
and centrifugation at 13000 g. 
2.1.21 DNA ligation and bacterial transformation: 
Ligations were performed using a rapid ligation kit (Roche: 11635379001) using 3-10x 
molar insert-to-plasmid ratio, as described in the manufacturers protocol. 2µls of 
ligation mixture were mixed gently with 50 µls of NEB-5α Bacteria (NEB; P/N: C2988J) 
on ice and the mixture was left on ice for 30 minutes before being heat shocked at 
42oC for 45 secs and placed on ice for 2 minutes. Bacteria were added to 1 ml of LB 
broth (1% w/v Tryptone, 0.5% w/v bacto-yeast extract 170 mM NaCl2 PH 7.0 NaOH) 
and placed on a shaker for one hour at 37ᵒC. The bacteria were spread onto plates 
(Corning) containing LB agar with 100µg/ml ampicillin (manufacturer). Colonies were 
selected and grown in 10 ml LB broth with 100 µg/ml ampicillin. Miniprep (Quiagen: 
27104) extractions were performed as per manufacturers protocol and selected 
colonies were sequenced by Reliance Biosciences. One selected colony was grown in 
300 ml of LB broth with 100µg/ml ampicillin overnight, bacteria were pelleted and 
maxi prep extractions (Thermofisher, K210006) were performed as per the 
manufacturer’s instructions. 
2.1.23 Calcium phosphate transfection: 
300μM CaCl2 containing ANLN-LUC plasmid, ZFP36/ZFP36L1/control plasmid and 
CMV-β-galactosidase plasmid (Clontech, 631712) was left at room temperature for 
15 minutes. This solution was then diluted 1:1 v/v by dropwise addition to 37ᵒC HEPES 
buffer (270mM NaCl, 10mM KCl, 12 mM D-Glucose, 25 mM HEPES, 1.5mM Na2PO4 
pH 7.06) while being vortexed. DNA solution containing 20ng of ANLN-Luc plasmid, 
20ng ZFP36/ZFP36/PcDNA3.1 and 100 ng β-galactosidase was added to 4x105 HEK293 
with fresh DMEM in a 24 well plate (corning). The media was replaced after 24 hours 





2.1.22 Luciferase assay: 
The cell lysates were centrifuged at 12000 g at 4ᵒC and a BCA assay performed as per 
manufacturer’s instructions (Thermofisher, 23225). 2µg of each lysate was added per 
well of a 96 well plate (Corning,3610) and 100µl of luciferase substrate 
(Promega:E151A) was added to each well simultaneously using a multipipette. The 
plate was read in luminescent plate reader (Tecan, infinite). To normalise the 
transfection, a β-galactosidase enzyme assay (Promega, E2000) was carried out in 
parallel in a 96 well plate (Corning, 3610) according to the manufacturer’s protocol. 
The optical density (420 nm) was read in a plate reader (molecular devices, 
Spectramax) and the values obtained used to normalise the results of the luciferase 
assay. 
2.1.23 RNA immunoprecipitation (RIP):  
The Magna RIP kit (Millipore, 17:700) was used to extract RNA bound to 
ZFP36L1/ZFP36 from HUVEC cell lysates as per the manufacturer’s protocol. 6x106 
HUVEC were used per RIP with 5µg anti-ZFP36L1/ZFP36 antibody (Santa Cruz, 
79151/14030). 10% of the input lysate was retained for downstream analysis. The 
beads and input lysate had bound RNA extracted by phenol:chloroform extraction as 
previously described in section 2.1.19 and RNA samples were stored at -80ᵒC. cDNA 
was produced as described in section 2.2.15 and  analysed by qPCR, CT values were 










2.2 techniques for in vivo studies: 
2.2.1 Immunohistochemical DAB stain: 
Hind limb ischaemic adductor muscles were harvested at day 7 and fixed in 10% 
buffered formalin (Sigma, HT501128) for 16h at 4°C before embedding in paraffin 
blocks. 4μm paraffin embedded skeletal muscle tissue sections were cut and baked 
onto glass slides.  
Tissue sections were rehydrated gradually by incubation of slides in the following 
solvent gradient, 2 times 5 minute incubations in Xylene, 5 minutes in 100% ethanol, 
5 minutes in 85% ethanol, 5 minutes in 50% ethanol. The slides incubated in 3% 
Hydrogen peroxide (sigma, H1009) in distilled water for 20 minutes followed by two 
5 minute washes in phosphate buffered saline-tween (0.05% Tween) to block 
endogenous peroxidases. Antigen retrieval was carried out in 10mm sodium citrate 
buffer, samples were boiled for 5 minutes in a microwave on the fast cook setting, 
followed by another 10 minutes of heating on low. Samples were allowed to cool to 
RT before being blocked with 10% goat Serum for 30 minutes at RT. Slides were 
incubated overnight in primary rabbit anti-ANLN diluted (Abcam, Ab154337) to 1:125 
in 5% goat serum. Primary antibody solution was removed and the slides washed in 
three 5 minute washes in PBST. After washing slides were incubated in biotinylated 
secondary goat anti rabbit antibody (DAKO, BA1000) diluted to 1:200 in 5% goat 
serum for 45 minutes at RT. Secondary antibody solution was removed and the slides 
were washed in three 5 minute washes in PBS-Tween. The section was covered in 
Elite ABC all in one reagent (Vector, Vector PK7100) and incubated for 30 minutes in 
the dark. ABC solution was removed and the slides washed in three 5 minute washes 
in PBST. The section was covered in peroxidase substrate DAB kit solution (Vector, 
SK4100), the brown stain was allowed to develop and the reaction stopped at the 
first sign of positive signal by washing the slides for 5 minutes in ddH2O.  After DAB 
stain development samples were counterstained with 0.5% light green counterstain 
(Genetex, GTX73306). Samples were dehydrated in a reverse solvent gradient and 
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mounted with cover glass using DPX mounting media (Sigma, 06522) and left 
overnight at RT.  
Slides were imaged using a Nanozoom XR with NDP viewer 3.1 (Hamamatsu). Images 
were exported at 20x digital zoom Tiffs and the average number of ANLN+ve ECs 
counted per vessel.  
 
2.3 zebrafish production: 
2.3.1 Zebrafish maintenance and husbandry: 
All zebrafish maintenance and experimentation were carried out in accordance to 
home office guidelines under the project licence: and personal licence: Zebrafish 
were maintained in system water at 28.5ᵒC and were fed three times daily a mixture 
of either dry food or brine shrimp as in accordance with the University of Edinburgh 
husbandry policies. Zebrafish used are listed in table 7  
Table 7: Zebrafish lines utilised: 
Zebrafish line Phenotype description  Source 
WIK Wild type Dr Carl Tucker  (CBS 
aquatics university of 
Edinburgh) 
flk:mcherry Flk:mcherry express 
mcherry in ECs. 
Professor John Mullins 
(CVS University of 
Edinburgh) 
fli1:eGFP Fli1:eGFP express eGFP in 
ECs.  
Dr Martin Denvir (CVS 
University of Edinburgh 
fli1:eGFP x mpx:mcherry   fli1:eGFP: mpx:mcherry 
express eGFP in ECs and 
mcherry in neutrophils. 
Dr Martin Denvir (CVS 
University of Edinburgh) 
anln:anln-eGFP  anln:anln-eGFP fish 
express Anln-eGFP fusion 
protein under the anln 
promoter globally. 
Dr Luccia Poggi 




2.3.2 Zebrafish embryo production: 
Transgenic embryos were produced by pair mating in breeding tanks, WIK embryos 
were produced using a mass embryo production system (MBK installations ltd). 
Zebrafish were maintained in E3 media (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4, 10-5 % Methylene Blue) in 90mm dishes in a 28.5ᵒC incubator with 
daily water changes and maintenance.  
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2.4 Zebrafish experimental techniques: 
2.4.1 Anaesthesia protocol: 
Zebrafish were anaesthetised by suspension of embryos in system water containing 
0.02% tricaine until fully unresponsive.  
2.3.4 Morpholino mediated gene expression interference: 
Morpholinos were used to modulate the expression of anln as described in Paolini et 
al. 2015. Lyophilised morpholinos were reconstituted to 1 nM concentration with 300 
μls of DNAse free dH20 and gentle mixing via pipetting. 
Table 8: Morpholinos used in injections: 
Morpholino  manufacturer Sequence  Target 
Control Gene tools CCTCTTACCTCAGTTACAATTTATA No genomic 
target 












Micropipettes (WPI, IB100F-4) were pulled on a micropipette puller (Sutter’s, 
instruments) with settings; heat 580, pull 250, velocity 50, time 125ms. 
Microinjection needles were loaded with injections solutions containing 8ng/µl 
morpholino (see table 8) and 0.01% phenol red (Sigma,143-74-8). 1nl of each 
morpholino solution was injected in zebrafish embryos at the one cell stage, damaged 
embryos were removed after ~4 hours and the viable embryos had E3 media changed 
daily prior to being imaged.  
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2.4.4 Zebrafish mRNA extractions 
Zebrafish mRNA extractions were carried out essentially as detailed in section 2.1.13, 
except that an additional initial homogenisation step was carried out. 30 embryos 
were anaesthetised and media was removed before the addition of 700μls QIAzol 
followed by storage at -80ᵒC. Samples were defrosted on ice and added to an RNase 
free 2ml tube containing 2 metal beads (fisher, 15505809) samples were 
homogenised with a benchtop homogeniser (Retsch, mm301) for 2 minutes at 30 Hz. 
The homogenate was then processed using the standard miRNAeasy kit protocol 
(Qiagen, 217084).  
2.4.5 Zebrafish QPCR: 
This was carried out essentially as described in section 2.1.16, using the primers listed 
in table 9. 
Table 9: Zebrafish QPCR primers  
Primer  sequence 
Beta actin F: GATCTTCACTCCCCTTGTTCA 
R: GGCAGCGATTTCCTCATC 
elf1α F: CCTTCGTCCCAATTTCAGG 
R: CCTTGAACCAGCCCATGTT 
ANLN  F: CGTGGCGAGTGTGTGTATGT 
R: CTCTCCGCCATCTTCTTCTG 
 
2.4.6 Laser Injury induction: 
Embryos were anaesthetised with tricaine by established methods and then mounted 
on a glass coverslip; excess water was wicked away with tissue paper. Fish were 
orientated on a glass cover slide using the brightfield of an inverted microscope 
(Nikon, TE62000), using the 40x objective lens the caudal artery was brought into 
focus. The eye piece shutter was closed and the embryos were treated with pulses of 
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unattenuated 455nm micropoint laser (Andor). Fish were rehydrated by addition of 
E3 media with Tricaine before being imaged. 
2.4.7 Tail fin injury: 
Embryos were anaesthetised using the established tricaine method. Fish were 
orientated using forceps and a small transection of the tail fin of the zebrafish embryo 
cut using a size 11 scalpel (Swann Morton, W260). The anatomical end of the 
notochord was identified visually and by pigment location; with the help of these 
markers, the same degree of injury was induced in all fish. Fish were then imaged 
using Spinning disk microscopy at 4 and 24 hours post injury time points post injury. 
Images were exported and analysed using FIJI (ImageJ, NCBI). 
2.4.8 SgRNA production for CRISPR/CAS9: 
The sgRNA core sequence was taken from CHOPCHOP using the experimental design 
parameters of Xu et al. 2015. The T7/SP6 sequence and universal primer sequence 
were added onto the ~20 nucleotide core sequence, these are listed in table 10.  
Table 10: sgRNA sequences for CRISPR/CAS9 generation yet: 





























2.4.8 sgRNA annealing and in vitro transcription: 
The sgRNA templates were produced by annealing of a sgRNA oligo (see table 10) to 
the universal tracRNAoligo: 5’AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAA-
CGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC 3’ by Q5 polymerase. 
Reactions were carried out using Q5 reaction buffer 1x (NEB: B90275), Q5 high fidelity 
polymerase 0.02U/μl, 200μM dNTPs (NEB: B90275), 0.5μM oligo and 0.5μM TRACR 
oligo. Annealing reactions were ran on a thermocycler (Techne, Thermal personal) 
with the following protocol; denaturing 98oC 2 mins, annealing 50oC 10 mins, 
extension 72oC 10 mins. Annealed templates were quality checked by agarose gel 
electrophoresis as previously described in section 2.1.18.  
The sgRNA was transcribed from templates by addition of 3μls gRNA template to a 
T7/SP6 mMessage machine in vitro transcription reaction according to the 
manufacturer’s protocol (AMBION, AM1340/AM144). 1μl of completed reactions 
were suspended in RNase free water and orange G buffer to a volume of 10 µls. 
Samples were then ran in a 1.2 % agarose gel as previously described in section 
2.1.18. 
2.5 Zebrafish Microscopy techniques: 
2.5.1 Epifluorescent microscopy: 
Zebrafish anaesthetised by established tricaine method were aligned on a glass cover 
slide in a drop of E3 media in 0.5% w/v methylcellulose (Sigma, M7140). Images were 
acquired on a Leica M205FCA epifluorescent microscope with a 1x planpo objective 
lens using filter sets ET GFP2 and ET mcherry (Leica, 232FL349303, 232FL349306). 
Images were acquired with LASX software and exported in Tiff format; quantification 





2.5.2 Andor Spinning disk confocal microscopy: 
First, a 35 mm round cover glass was attached to a custom mounting dish with 
vacuum grease (Thorlabs, SG10). Zebrafish were anaesthetised via established 
method and added in system water to the glass cover slip, excess system water was 
removed and molten 0.5% agar was added to the coverslip and individual fish were 
manipulated with forceps to the desired position.  
After mounting fish on the microscope stage images were taken using 10x and 20x 
air objective lenses (Zeiss, UPLFLN10X2/UPLSAPO20X) with Channel 488 (300 ms 
exposure) and 561 (100ms exposure). Images were acquired with IQ3 software 
(Andor) and exported as the TIFF image format; images were compiled in FIJI (NIH, 
ImageJ). For live imaging, E3 media containing tricaine was added on top of mounted 
fish in a heated and humidified stage (Oko-lab) utilised to maintain the temperature 
at 28ᵒC. 
2.5.3 Confocal microscopy: 
First, a 35 mm round cover glass was attached to a custom mounting dish with 
vacuum grease; anaesthetised fish were mounted in 0.5% Agar. For this, zebrafish 
were anaesthetised via established method and added in system water to the glass 
cover slip, excess system water was removed and molten 0.5% agar was added to the 
coverslip and individual embryos were manipulated with forceps to the desired 
position. To obtain serial Z-stacks and tile scanned images of zebrafish embryos, a 
Leica SP8 confocal microscope was used. Images were acquired with a HC PLAAPO 
10X CS2 (Leica) and HC PLAPO 20X CS2 (Leica) objective lenses. The following detector 
sets were used HYD1 (498-550nm) HYD2 (571nm-650nm) with lasers used 488nm 
(8%) laser 561 nm (2%) laser. 
Images were acquired using LAS X software (Leica) and images saved as .LIF files 
before being exporter to TIFF format with ImageJ. Tile scanning was performed by 
scanning through the entire Z-stack and setting the highest and lowest points, 
followed by gating of the entire embryo for stack acquisition through spiralisation.  
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2.5.4 Selective plane illumination microscopy (SPIM): 
Zebrafish embryos were anaesthetised by established tricaine method and placed in 
molten 0.5% Agar in E3 media (no methylene blue). Embryos were mounted in 
custom syringe mounts by pulling on the plunger to orientate the embryo in 
fluorinated ethylene propylene tubing (Adtech, TW01), the agar was left to solidify.  
Embryos in syringe mounts were placed in the SPIM microscope stage and images 
acquired using a 16x NIKON CFI plan fluor objective (N16LWD-PF) with a Vortran 
Versalase multiple wavelength system as the light source, using 2 lasers 488 nm and 
561 nm. Data was collected through two QI-Click Mono CCD cameras (Q-Imaging 
Inc.). Lasers were set to pulse and scan, the acquisition of each wavelength was 
acquired independently (40ms exposure and 100 ms exposure). Z-stack projections 
were produced and recorded through a custom SPIM control software written in the 
C programming language (Johnathan Taylor, University of Glasgow). Images were 
exported as multi-layer tiffs and concatenated and compiled using ImageJ. 
2.6 Statistics: 
All statistical analyses were carried out using Prism 5 (Graph pad) and are detailed in 



























Chapter 3:                                                    














As stated in chapter 1 cardiovascular disease is one of the leading causes of death 
world-wide, in western countries an increasing elderly population and poor diets 
have created a health crisis. Critical limb ischaemia and coronary artery are the 
leading causes of ischaemic injury, disability, and death in cardiology patients. In 
these conditions chronic ischaemia and inflammation leads to EC dysfunction, 
disrupting natural regeneration and angiogenesis, resulting in poor prognoses and 
eventual death. 
Identification of new potential therapeutic targets in the natural angiogenic response 
to injury or ischaemia is essential for future drug discovery. In the Caporali lab initial 
studies have identified numerous potential angiogenic targets of interest in 
improving the vascular response to injury (Caporali & Emanueli 2011; Caporali et al. 
2011). Comparison of microarray datasets from sorted mouse hind limb ischaemic 
ECs and HUVEC overexpressing the P75 NTR (a negative regulator of angiogenesis) 
has identified numerous genes in cell motility, the cell cycle and actin remodelling as 
key potential mediators of angiogenesis (Caporali et al. 2012; Caporali et al. 2015). 
Investigating genes controlling these processes is essential to understanding early 
angiogenesis (Silvestre et al. 2013). ANLN was a robust gene identified in these in vivo 
and in vitro datasets as a gene of interest in the EC angiogenic response to ischaemia 
(Caporali et al. 2012; Caporali et al. 2011). 
ANLN is an F-actin binding protein which is associated with the cleavage furrow 
formation during cytokinesis in all cell types as laid out in chapter 1. Here ANLN acts 
as a structural component of the cytoskeleton to allowing the association of F-actin 
with RhoA to regulate the ingression of the cleavage furrow and the orderly 
completion of the cell cycle (Piekny & Maddox 2010). Outside of these key roles ANLN 
has been a gene of interest in other aspects of cell function in numerous cell types 
(Piekny & Maddox 2010; Dorn et al. 2010). ANLN expression has been associated with 
pro migratory and invasiveness phenotypes in lung, breast and prostate cancers, 
ANLN+ve tumour biopsies result in a poor prognostic survival of clinical patients 
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(Suzuki et al. 2005; Zhou et al. 2015).  In embryonic development of the CNS ANLN is 
associated with migrating neuroblasts, where, ANLN localises toward the leading 
filopodia of neurite outgrowth helping to stabilise the interaction between F-actin 
and RhoG (Tian et al. 2015; Fotopoulos et al. 2013).  ANLN has been identified as a 
potential regulator of cell to cell junction integrity in epithelial cells (Reyes et al. 2014; 
Wang et al. 2015). Here ANLN was suggested to have interactions with multiple 
signalling pathways by acting as a structural component for the interaction of the 
cytoskeleton with cell to cell junction proteins (Reyes et al. 2014; Wang et al. 2015).  
ANLN has been identified as a highly upregulated in both tail fin and myocardial 
regeneration in zebrafish and its expression is of interest in marking mitotic cells or 
the regenerative response in these injuries (Kang et al. 2016; Malo et al. 2017). ANLN 
has never been investigated in ECs in angiogenesis and it would be of advantage to 
identify its potential effect on EC phenotypes and behaviours particularly the EC 
response to ischaemia. 
3.2.1 Hypothesis: 
Experiments were carried out with the hypothesis that ANLN is required for normal 
EC function and that ANLN is required for the response to ischaemia in vivo, to be 
investigated with the following aims.  
3.2.2 Aims: 
1. Investigate the expression of ANLN in ischaemic angiogenesis using in vivo 
hind limb ischaemia 
2. Investigate a possible role for ANLN in ischaemic angiogenesis using in vitro 








3.3.1 There is an association between ANLN expression and Ischaemia in ECs: 
To investigate the expression of ANLN in the endothelial response to ischaemic insult 
a hind limb ischaemia surgery was performed in mouse.  ANLN expression was 
assayed by QPCR in CD31+ CD45- ECs sorted from ischaemic hind limb muscle. This 
demonstrated an increase of ANLN expression from 3-15 days post ischaemia 
compared to the mRNA from whole muscle as shown in figure 3.3.1B+C (***= 
P<0.001 *=P<0.05 Two-way Anova with post-hoc Bonferroni). As detailed in figure 
3.3.1A the response of the tissue and blood vessels in the skeletal muscle changes 
over the time course of the experiment, with the peak proliferation of ECs occurring 
at ~7 days post-ischaemia. Therefore, at 7 days post ischaemia we stained for ANLN 
in sectioned hind limb ischaemic muscle to identify ANLN expression in the vessels. 
DAB staining of Ischaemic muscle tissue 7 days post ischaemia seen in figure 3.3.1D+E 
showed an increased expression of ANLN in the vessels compared to non-ischaemic 
muscle tissue (*= P<0.01 t-test). These experiments suggested an association 
















Figure 3.3.1: ANLN expression is increased in the ECs of mouse hind limb ischaemia muscle:  
(A) Timeline of the response of the skeletal muscle and blood vessels to femoral artery 
transection induced ischaemia over 3, 7 and 15 days (adapted from Jia et al. 2011 and 
Mohiuddin et al. 2019). (B) ANLN mRNA  expression is significantly increased between 3, 7 and 
15 days post ischaemia in CD31+CD45- ECs sorted from hind limb ischaemia (n=4 ***=P<0.001, 
**=P<0.01 by 2 way ). (C) Shows a trend for an increase of ANLN mRNA expression in whole 
ischaemic muscle tissue compared to control non-ischaemic muscle 7 days post ischaemia (n=4, 
ns=P>0.05 by t-test) (D) Quantification of the average ANLN positive ECs per vessel in non-
ischaemic and ischaemic muscle tissue (n=3, *= P<0.05 by t-test). ) (E) 20x and 40x objective 
representative images of control and ischaemic muscle tissue DAB stained for ANLN expression 




3.3.2 ANLN-EGFP can be successfully overexpressed and WT localisation is conserved 
in ECs  
HUVECS were transfected with control or ANLN siRNA resulting in a reduction of 
ANLN mRNA expression as shown in figure 3.3.2A-B. A loss of ANLN mRNA expression 
results in a loss of WT ANLN signal in the nucleus of transfected HUVECs (figure 
3.3.2C). 
To identify the effect of ANLN overexpression on EC function and ANLN localisation 
in ECs an ANLN-EGFP lentivirus was produced. Inverted microscope images of HUVEC 
after treatment with ANLN-EGFP or control GFP lentivirus showed that ANLN-EGFP 
has a nuclear localisation compared to dispersed cytosolic control EGFP expression. 
Transduction with 10 M.O.I. of ANLN-EGFP lentivirus gives a visibly lower 
transduction efficiency than an equivalent control EGFP lentivirus. Flow analysis of 
HUVEC after treatment with the lentivirus showed was 50% less ANLN-EGFP+ve ECs 
than the equivalent EGFP control (**=P<0.01, t-test). To obtain pure ANLN-EGFP 
overexpressing populations, cells were sorted using FACS, the gating strategy is 
shown in figure 3.3.3B. 
Confocal microscopy of ANLN-EGFP transduced HUVEC shown in figure 3.3.4A after 
staining for EGFP, DAPI and phalloidin confirms the nuclear localisation of ANLN-
EGFP, furthermore, cortical and mid-body localisation can be seen in mitotic cells 
confirming ANLN-EGFP functionality. Western blot of lysates from sorted ANLN-EGFP 
and control EGFP transduced HUVEC showed a band of ~160kda in size after staining 
with both anti-GFP and anti-ANLN antibody (figure 3.3.4B). These experiments 
suggest that functional ANLN can be overexpressed successfully and visibly retain WT 














Figure 3.3.2 WT ANLN expression is nuclear in ECs in vitro:  
(A) Brightfield images of HUVECS 48 hours after transfection with 10 nm ANLN or control siRNA. 
(B) QPCR of HUVEC mRNA 48 hours after transfection with 10nm siANLN shows a concurrent 
decrease in ANLN mRNA (n=3 *=P<0.05 t-test). (C) Immunocytochemistry of HUVECS after 
transfection with 10nm Control/siANLN showing staining for DAPI, ANLN and phalloidin 
demonstrating a reduction of ANLN expression in the nuclei of siANLN transfected cells (scale 






Figure 3.3.3 Cell sorting is required to obtain a pure population of ANLN-EGFP overexpressing ECs:  
(A) Lentiviral overexpression of ANLN-EGFP in HUVEC produces a low efficiency of ANLN-EGFP+ve 
nuclei in ECs compared to EGFP control detected by brightfield and epifluorescence (scale 
bar=50μm). (B) Flow analysis of ANLN-EGFP/EGFP expressing ECs identified a significantly lower 









Figure 3.3.4: Overexpression of ANLN-EGFP in ECs produces functional full length ANLN:  
(A) Localisation of ANLN-EGFP fusion protein in HUVEC showing (indicated by arrows) a nuclear 
localisation of the ANLN-EGFP (20x and 40x objective) and with cortical (grey arrow) and cleavage furrow 
(white arrow) localisation during cell division (scale bars=100μm). (B) Western blot of HUVEC lysates after 
ANLN-EGFP overexpression showing the molecular weight of ANLN-EGFP after detection with an anti-




3.3.3 ANLN expression affects tubulogenesis in HUVECS: 
To investigate the effect of ANLN expression on an in vitro model of angiogenesis, 
tubulogenesis assays were carried out on HUVEC after treatment with ANLN siRNA 
or ANLN-EGFP lentivirus as shown in figure 3.3.6A-D. These showed that ANLN 
silencing significantly reduced the total length of the tubule network formed by the 
ECs, however, ANLN-EGFP overexpression significantly increased the total length of 
the tubule network. After completion of tubule formation ANLN-EGFP expression 
appeared to remain distributed mainly to the nucleus as seen in figure 3.3.6B.  
Given the effect of ANLN-EGFP overexpression on tubulogenesis live imaging was 
used to determine the localisation of ANLN-EGFP during tubulogenesis. However, the 
weak ANLN-EGFP signal and drift of the microscope focus after one hour causes 
difficulty in observation of localisation as shown in figure 3.3.6. These experiments 


























Figure 3.3.5: ANLN silencing and overexpression affect in vitro matrigel tubulogenesis assay 
performance:  
(A) Brightfield images of matrigel tubule networks of HUVEC after treatment of HUVEC with 10nm 
control or ANLN siRNA. (B) Brightfield and fluorescent images of matrigel tubule networks of HUVEC 
after treatment with ANLN-EGFP or EGFP lentivirus. (C-D) Quantification of matrigel tubule networks 
showing a significant decrease of total network length after silencing and a significant increase in total 































Figure 3.3.6 It was not possible to determine ANLN localisation in in vitro matrigel 
tubulogenesis assays of HUVEC after ANLN-EGFP overexpression: 
Brightfield and fluorescent live imaging of tubulogenesis assays of EGFP and ANLN-EGFP 
transduced HUVEC plated on matrigel in a μ-angigogenesis slide. Time points show the drift 
of the focus during time-course experiment making tracking of individual cells difficult 
(Representative scale bar = 100μm) 
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3.3.4 Silencing of ANLN expression has a significant effect on EC cell to cell junctions 
and migration: 
ANLNs effect on other aspects of EC function were determined by trans-well filter 
migration assay and impedance based ECIS chamber assays as shown in figures 3.3.7-
3.3.8.  
ECIS chamber assays were used to determine the effect of ANLN on the wound 
healing capacity and cell to cell junctional integrity of HUVECS (figures3.3.7 A-D). 
ANLN silencing   significantly reduced the integrity of EC cell to cell junctions and 
wound healing capacity of HUVECS (*=P<0.05 t-test). Transwell migration assays 
showed that ANLN silencing in HUVECS treated with siRNA compared to control 
significantly reduced the ability of ECs to migrate towards VEGF without affecting 
basal migration (figure 3.3.8 A). Figures 3.3.7A+B and 3.3.8B show that there was no 
difference in EC performance after ANLN-EGFP overexpression in either transwell or 
ECIS assays (t-test= P>0.05). 
These assays suggested that ANLN silencing has a greater effect on EC migration, 






















Figure 3.3.7 ANLN silencing reduces wound healing and cell to cell junction integrity but 
overexpression has no effect: 
(A-B) The wound healing velocity of cultured HUVEC by ECIS electric wound application after 
silencing of ANLN or ANLN-EGFP overexpression, showing a significant decrease in wound 
healing speed after ANLN silencing. (C-D) The resistance of a cultured monolayer of HUVEC 
indicative of cell to cell junctional integrity after treatment with ANLN siRNA or ANLN-EGFP 
overexpression, showing a significant decrease in barrier integrity after ANLN silencing. (Error 






















Figure 3.3.8: ANLN silencing reduces EC migration towards VEGF but overexpression has no effect:  
(A) Shows the number of migrated HUVEC through transwell filter towards 25ng/ml VEGFA or PBS 
vehicle after treatment with control siRNA or ANLN siRNA. (B) Shows the number of migrated HUVEC 
through transwell filter towards 25ng/ml VEGFA or PBS vehicle after EGFP or ANLN-EGFP 





3.3.5 ANLN expression modulation does not affect proliferation or cell cycle 
progression in ECs: 
EDU incorporation and propidium iodide (PI) staining was used to investigate the 
effect of ANLN on the cell cycle dynamics and proliferative capacity of HUVECs shown 
in figures 3.3.9-3.3.10. Figure 3.3.9 A+B shows the incorporation of EDU into HUVEC 
after treatment with ANLN siRNA or ANLN-EGFP overexpression, neither conditions 
significantly affected the overnight proliferation of HUVECS (ns=P>0.05 t-test).  
Similarly, there was no difference in the distribution of the cells in each cell cycle 
stage, as assayed by PI staining in either HUVECS treated with ANLN siRNA or ANLN-
EGFP overexpression as shown in figure 3.3.10 A+B (ns=P>0.05 t-test). This data 



























Figure 3.3.9: ANLN silencing or overexpression has no effect on EC proliferation:  
(A) Merged images of DAPI stained and EDU positive nuclei (pink nuclei) showing the number 
of proliferating HUVECS after ANLN silencing or ANLN-EGFP overexpression. (B) 
Quantification of the percentage of EDU positive nuclei showed no difference in proliferation 
between control and either silencing or overexpression. (Silencing n=2 and overexpression 















Figure 3.3.10: ANLN silencing or overexpression has no effect on EC cell cycle progression:  
(A) Flow diagrams of cell count in G0/G1, S and G2/M phase after flow cytometry of ANLN 
silenced and ANLN-EGFP overexpressed HUVEC stained with PI. (B) Quantification of cell 
number in each stage of the cell cycle showing no difference between control and either 
ANLN silenced or ANLN_EGFP overexpressed HUVEC showing no difference between 





In this chapter, a role of ANLN in EC function in post ischaemic angiogenesis was 
investigated for the first time.  
ANLN expression was increased in the ECs of skeletal muscle from a mouse model of 
hind limb ischaemia. This suggested an involvement of ANLN in the EC response to 
ischaemic injury as has been observed in mouse and zebrafish cardiomyocytes after 
myocardial cryoinjury  (Kang et al. 2016; Hesse et al. 2012).   
3.4.1 ANLN silencing has a more severe effect on EC performance than 
overexpression in vitro: 
To identify the effect of ANLN expression on EC phenotypes in vitro siRNA and an 
ANLN-EGFP lentivirus were used to modulate ANLN expression. After transduction 
with ANLN-EGFP lentivirus cell sorting was required to enrich the ANLN-EGFP positive 
cells for use in functional assays. The distribution of overexpressed ANLN-EGFP was 
mainly nuclear which matched our own observations of endogenous ANLN and those 
made in most cell types (Wang et al. 2015; Zhou et al. 2015). ANLN-EGFP localisation 
was conserved and observed in the nucleus during interphase and associated with 
the cell cortex and  cleavage furrow during cytokinesis (Piekny & Maddox 2010). This 
localisation helped confirm the functionality of the EGFP fusion ANLN as observed in 
other studies (Liu, Gregory D. Fairn, et al. 2012; Paolini et al. 2015).  
The effect of ANLN expression on basic assays of EC function were polarised between 
the overexpression and silencing of ANLN. Wound healing and EC barrier function 
assays were inhibited by ANLN silencing confirming observations of the effect of 
ANLN on cell to cell junctions and cell motility in epithelial cells (Reyes et al. 2014; 
Wang et al. 2015). Migration towards a chemoattractant (in this case VEGF) was 
impaired by ANLN silencing, however, the basal migration was not affected. This 
observation may suggest an involvement of ANLN with stimulated migration that is 
not observed in basal migration. However, ANLN-EGFP overexpression had no effect 
on these assayss. It is possible that ANLN-EGFP overexpression may affect cell 
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junctions after EC treatment with a growth factor like VEGF which could be 
investigated using ECIS capacitance based assays. Further investigation of expression 
of the ANLN-EGFP reporter at the cell to cell junction of ECs would also identify a 
possible role of ANLN in the structural machinery of EC junctions. It is possible that 
very little ANLN is required to fulfil many of its cellular functions, in our western blot 
there was no endogenous ANLN found at the exposure that detected the 
overexpressed ANLN-EGFP. Thus, ANLN-EGFP overexpression may have no effect on 
certain aspects of EC function. It should be noted that proliferation was not blocked 
pharmacologically during migration or wound healings assays. As there is a 
proliferative component to wound healing and migration this may have contributed 
to the result. However, the cells were starved before the migration assays to reduce 
proliferation, and the time course for both the migration and wound healing assays 
were short (<6hours), therefore, the proliferation of ECs in this time frame should be 
minimal. 
Interestingly, cell cycle progression and proliferation were not affected by 
modulating ANLN expression. This has been observed in podocytes where 
overexpression of WT ANLN does not affect proliferation (Gbadegesin et al. 2014). 
However multiple studies have observed binucleation and G2/M accumulation in cell 
lines after the silencing of ANLN (Zhang et al. 2018). However, this phenotype has 
only been observed in immortalised or cancer derived cell lines after ANLN silencing 
(Gbadegesin et al. 2014; Hall et al. 2018; Zhang et al. 2018).  It is possible that ANLN 
silencing with our siRNA is not strong enough to induce this phenotype but may cause 
other effects on cell function. This phenotype may be more likely in immortalised 
cells that already have a dysregulation of the cell cycle than in primary cells like 
HUVECs. It is also possible that there is a degree of cell cycle dysfunction that is not 
detectable by EDU incorporation or PI stain after ANLN silencing. Therefore this 
should be investigated by qPCR for different cell cycle or cytoskeletal markers in both 
ANLN silenced and overexpressing HUVECs.  
The low efficiency of ANLN-EGFP expression after lentiviral transduction could be a 
result of post translational regulation of ANLN-EGFP protein by APCcdh1. This complex 
98 
 
is responsible for the ubiquitination and subsequent degradation of ANLN after the 
completion of the cell cycle (Zhao & Fang 2005). This has effect has been noted in a 
flt1/ANLN-EGFP mouse model where ANLN-EGFP was only detected in proliferative 
endothelial cells (Herz et al. 2018). Treatment of unsorted ANLN-EGFP HUVECS with 
a proteasome inhibitor like MG132 would determine this possibility. If the number of 
ANLN-EGFP positive cells increases after proteasome inhibition then ANLN-EGFP 
overexpression is being suppressed by APCcdh1 after mitotic exit.  
It was not known what type of phenotype ANLN-EGFP overexpression in ECs would 
exhibit as ANLN expression is tightly controlled in terms of localisation and protein 
expression during the cell cycle (Piekny & Maddox 2010). The ANLN-EGFP protein 
produced had a very high atomic mass of 180Kda and the size of the plasmid is much 
larger than the control EGFP lentivirus. It would be easier to utilise a smaller tag such 
as a flag tag or his tag to reduce the size of the expressed protein and improve 
efficiency. However using another non-fluorescent tag would impair the ability to do 
live imaging of ANLN localisation in vitro. A fragment of ANLN tagged with GFP has 
been used by Liu et al where ANLN localisation was identified with an EGFP fusion to 
just the PH domain of ANLN (Liu, et al. 2012). Using this strategy may improve the 
expression of the fusion reporter. However, a fluorescent reporter of just the PH 
domain or the Actin myosin binding domain may reduce the relevance of the 
observed localisations compared to overexpression of endogenous ANLN. 
It should be noted that a difference between our EC phenotype observed between 
silencing and overexpression may be partly caused by the usage of cell sorting to 
enrich ANLN-EGFP positive cells. There was a noticeable difference in baseline results 
for the cell cycle staining, proliferation, migration and wound healing between 
control siRNA and EGFP overexpression. HUVECS are not a homogenous population 
of cells, they are primary cells obtained from trypsin digest of umbilical cords (Davis 
et al. 2007). Cell sorting could have selected different populations of cells with slightly 
different phenotypes. In addition to this, the continued quality of the cultured 
HUVECs could also have been impaired due to the time spent in room temperature 
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flow buffer during cell sorting. Including an unsorted population of HUVECS in future 
in vitro assays would act as a control for this possibility. 
3.4.3 ANLN may affect sprouting angiogenesis:  
There was a correlation between tubulogenesis assay performance and ANLN 
expression modulation. Performance was improved in ANLN-EGFP overexpression 
and reduced in ANLN silencing experiments. Interestingly fluorescent images of the 
completed EC network showed that ANLN-EGFP remained nuclear after the tubule 
network formation. It was hoped that ANLN expression would be visible at sites of 
cell to cell contact or at the leading edge of the cell as has been observed in neurite 
outgrowth (Tian et al. 2015). Live imaging of tubulogenesis in ANLN-EGFP 
overexpressing HUVEC was attempted to determine changes in ANLN localisation. 
This has been observed in neuronal outgrowth where ANLN-EGFP associates with the 
leading edge of the cell (Tian et al. 2015). Normal 96 well cell culture plates did not 
produce high quality images for live imaging due to the menisci formation of matrigel 
and the plastic thickness. Another approach used µ-angiogenesis slides, this is a glass 
bottomed 15-well imaging slide. This used less matrigel to reduce menisci formation 
and create a thickness of 0.8 mm of matrigel to allow a smaller working distance 
between the objective lens and the cell layer. Imaging of tubulogenesis assays with 
this method were still insufficient due to drift of the microscopes focus caused by 
changing thickness of the matrigel layer. Using cell tracker dyes or lifeact-RFP 
lentivirus to pre-stain cells before the assay would give a stronger secondary signal 
to maintain focus on the imaged cells. These imaging issues could be addressed by 
performing tubulogenesis assays without matrigel, this would involve a co-culture of 
HUVECs and fibroblasts (Staton et al. 2009). The fibroblasts secrete a matrix which 
acts as a structural scaffold for tubule formation, these assays more closely resemble 
capillary beds than the more common matrigel based assay. This assay would be less 




 However, in retinal angiogenesis assays from an flt1/ANLN-EGFP reporter mouse, 
ANLN expression was seen to be entirely nuclear in ECs (Herz et al. 2018). This study 
supports our observed localisation of ANLN in in vitro tubulogenesis, but still doesn’t 
capture a dynamic change in ANLN localisation during EC sprouting. 
Tubulogenesis is regarded as a sprouting angiogenesis like assay, being a potential 
predictor of EC cell function, however, it doesn’t exactly model angiogenesis and 
multiple cell types can form tubules (Weavers & Skaer 2014; Pollack et al. 1998). To 
fully investigate sprouting angiogenesis in vitro it would be required to use spheroid 
cell culture to generate EC spheroids for embedding in 3D matrices. For this HUVECs 
or an equivalent EC cell type could be cultured in a low adhesion coated round 
bottom plate to allow spheroid formation (Heiss et al. 2015). EC spheroids would then 
be plated in a 3D matrix (collagen or matrigel), EC spheroids cultured in this manner 
form tip and stalk cells more similar to the process of angiogenesis than 
tubulogenesis. This would allow investigation of the effect of ANLN on dorsal lateral 
inhibition and tip cell formation in vitro (Heiss et al. 2015). Here ANLN-EGFP lentivirus 
can be used to investigate the formation of sprouting after ANLN-EGFP 
overexpression. Using siRNA to investigate the opposite effect may be problematic 
as HUVECS may not form spheroids after ANLN silencing. For this, a tamoxifen 
inducible shRNA lentivirus system may be more suitable for the investigation of 
sprouting after ANLN silencing. Validated sequences of ANLN shRNA are available, 
here, shRNA expression can be induced during sprouting to observe the effect of 
ANLN silencing on sprouting angiogenesis (Suzuki et al. 2005).  
ANLN has been associated with asymmetric cell division in the differentiation of cell 
types in the zebrafish CNS and retina (Malo et al. 2017; Paolini et al. 2015; Fotopoulos 
et al. 2013). In zebrafish, asymmetric cell division of ECs is required for tip/stalk cell 
designation, this helps generate the different sprouting EC daughter cells (Costa et al. 
2016). Even if ANLN expression is not associated with the leading edges of sprouting 
ECs its distribution at the cleavage furrow may affect EC sprouting (Fotopoulos et al. 
2013; Dorn et al. 2010). Therefore, future experiments should also include 
identification of ANLN localisation in asymmetric cell division of ECs in sprouting 
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angiogenesis. An anln:anln-eGFP reporter zebrafish was imported for this purpose 
from Dr Lucia Poggi of the university of Trento.  
3.4.3 Future investigations of ANLN signalling pathways: 
Investigations of the signalling mechanisms of ANLN could be carried out using the 
ANLN-EGFP lentivirus. Using ANLN-EGFP HUVECs would produce a relatable result to 
ECs as ANLN has been shown to interact differently with binding partners in individual 
cell types (Gbadegesin et al. 2014; Haglund et al. 2010; Hall et al. 2018). These studies 
initially identified ANLN interactions with signalling pathways through unique 
localisations with the cytoskeleton outside of cytokinesis. These include interactions 
with CD2AP in podocyte foot process like structures in HEK293/podocytes, and, 
association of C.elegans homologue ani-1 with RhoG in the leading edge of migrating 
neurites in C.elegans (Tian et al. 2015; Gbadegesin et al. 2014; Hall et al. 2018). 
We observed a nuclear localisation of ANLN, this has never been thoroughly 
investigated despite ANLN’s expression in HUVECS being mainly nuclear in interphase 
(Piekny & Maddox 2010; Zhao & Fang 2005). High nuclear ANLN expression has been 
suggested to have an effect on cell size and metastatic potential in cancer 
(Magnusson et al. 2016; Suzuki et al. 2005). When localised to the nucleus ANLN could 
be interacting with short lived actin structures. The role of actin in the nucleus is a 
contentious issue, monomeric and filamentous actin is detected within the nucleus, 
however the function of these structures is still being determined (Misu et al. 2017). 
Nuclear actin polymerisation is regulated by multiple factors with 30 actin binding 
proteins being found within the nucleus which can prevent or facilitate actin 
polymerisation (Misu et al. 2017). A key effect of nuclear actin is its association with 
nuclear programming and transcriptional regulation where actin has been associated 
with the initiation of RNA polymerase 2  (Hofmann et al. 2004). High levels of 
monomeric actin shuttled into the nucleus by importin 9 and removed by exportin 6 
has been shown to support active transcription (Stüven et al. 2003).  
The cell response to serum response factor (SRF) has been shown to be induced partly 
by alterations to nuclear actin dynamics (Sotiropoulos et al. 1999). The formin mDIA2 
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(a binding partner of ANLN) has been shown to be involved in the polymerisation of 
nuclear actin in NIH3T3 cells stimulated by SRF (Watanabe et al. 2008; Watanabe et 
al. 2010; Baarlink et al. 2013).  Here mDIA2 was seen to localise to the nucleus from 
the cytoplasm after SRF activation and was associated with polymerised nuclear F-
actin structures (Baarlink et al. 2013). MDia2 stimulates the formation of short actin 
filaments promoting their stability and allowing the formation of the centromere by 
the association of CENP-A during the G1 phase (Liu et al. 2018). No studies have 
investigated the association of ANLN with its binding partners separately in the 
nucleus and the cytoplasm despite its mostly nuclear localisation out with cytokinesis 
(Piekny & Glotzer 2008). This could be investigated by using a nuclear fractionation 
in HUVECs overexpressing ANLN-EGFP or ANLN-flag and retaining the cytoplasmic 
fraction. Using a pulldown for the tagged ANLN in each fraction and SDS-page with 
western blotting of common ANLN binding partners would identify an association 
between ANLN and nuclear F-actin. Liquid chromatography with Mass spectrometry 
could be used with the products of the pull down to identify all enriched ANLN 
binding partners from both nuclear and cytoplasmic fractions. This approach would 
identify all novel interactors of ANLN in ECs, the nucleus and the cytoplasm. 
3.5 Conclusions: 
To conclude, we have identified a potential role of ANLN in ECs in the response to 
ischaemic injury. Comparison of ANLN overexpression and silencing phenotypes 
identified tubulogenesis as an assay affected by both ANLN silencing and 
overexpression. As this is a predictor of EC function in angiogenesis future studies 
should focus on identifying a role for ANLN in sprouting angiogenesis in a suitable in 
vitro or in vivo model. If a strong association between ANLN and EC sprouting is found 
then investigation of potential binding partners within this process is justified. This 
could be investigated by immunoprecipitation and mass spectrometry or western 









 Chapter 4:                                             
Does the ZFP36 RNA binding 












Identifying a potential regulatory mechanism for ANLN in ischaemia is essential for 
understanding its role in the angiogenic response of ECs. The ANLN 3’UTR contains 
multiple adenylate-uridylate rich elements (ARE) in its 3’UTR that are targetable by 









Figure 4.1.1: The ANLN mRNA transcript contains putative RBP binding sites: 
Bioinformatic analysis data from AREsite showing that the ANLN mRNA transcript contains in 
its 3’UTR 6 AUUUA RBP binding sites. (A+B) shows the location of the ATTTA binding sites on 
the 3’UTR (C) Table of the exact base location of the RBP binding sites within the ANLN mRNA 




ZFP36 family RBPS are key regulators of mRNA expression in inflammation and cell 
growth, and they may target the ATTTA ARE sites in ANLNs the 3’UTR.  The ZFP36 
family RBPs consist of ZFP36, ZFP36L1 and ZFP36L2 with each protein having 
individual and overlapping targets (Blackshear et al. 2005; Hacker, Valchanova, 
Adams & Munz 2010).  
ZFP36 RBPs knockout studies in mice have shown a significant effect on mouse 
development and the response to inflammation. ZFP36 knockout mice have a severe 
phenotype with very low body weights, increased inflammation, vascular 
dysfunction, arthritis, and defects in myelopoesis and haematopoiesis (Taylor et al. 
1996). Endothelial cell dysfunction in ZFP36 knockout mice was attributed to an 
increase in inflammation and reactive oxygen species (Bollmann et al. 2014). ZFP36L1 
knockout mice show embryonic lethality due to placental defects early in 
development, however, embryos have significant vascular disorganisation and 
cardiac out flow abnormalities. ZFP36L1 tissue specific knockouts in B-cells causes 
increases in B-cell precursor cells, whereas, knockout in T-cells results in thymus 
atrophy and T-cell based tumour formation (Hodson et al. 2010; Vogel et al. 2016). 
These different in vivo phenotypes point towards each RBP having independent 
targets in different cell types. The binding efficiency and stability of ZFP36 RBPs is 
controlled by their phosphorylation. Phosphorylation of ZFP36 RBPs is controlled by 
the ERK and PI3K pathway, controlling ZFP36 RBPs mediated mRNA degradation 
(Rataj et al. 2016; Benjamin et al. 2006). 
In the EC response to ischaemia and hypoxia the expression of ZFP36 family RBPs 
have been shown to be amongst the most affected genes in in vivo and in vitro 
conditions (Kamphuis et al. 2007; Chamboredon et al. 2007; Desroches-castan et al. 
2011). ZFP36 and ZFP36L1 regulate the key angiogenic genes HIF-1α, VEGF and Dll4 
in ECs and may contribute to the control of angiogenic signalling in vivo (Desroches-
castan et al. 2011; Chamboredon et al. 2007). In skeletal muscle regeneration ZFP36 
RBPs have been shown to regulate satellite cell muscle quiescence and maturation 
into skeletal muscle myofibers (Busse et al. 2008; Hausburg, Doles, Clement, 
Cadwallader, Hall, Blackshear, Lykke-andersen, et al. 2015; Bye-A-Jee et al. 2018). 
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Therefore, there is a potentially important role of ZFP36 RBPs in the regenerative 
response of ECs in ischaemia.  
There is an inverse correlation between ANLN expression and ZFP36 RBPs expression 
in the regeneration of zebrafish tail fin and myocardial injury, this suggests a potential 
regulatory mechanism (Kang et al. 2016b). Due to the presence of ARE regions in the 
3’UTR of ANLN it was decided to investigate ANLN regulation by RNA binding protein 
in ECs.  
4.2.1 Hypothesis 
These experiments were performed under the hypothesis that ANLN had a post 
transcriptional regulatory mechanism by ZFP36 family RBPs in the EC response to 
Ischaemia.  
4.2.2 Aims: 
In this chapter I aimed to identify ZFP36 RBP regulation of ANLN by: 
1. Identifying a potential regulatory mechanism between ANLN and ZFP36 RBPs 
in in vivo hind limb ischaemia and in vitro assays performed in ECs 














4.3.1 There is an association between ANLN mRNA expression and RBP expression: 
Using the online toolset AREsite (University of Vienna) the ANLN mRNA sequence was 
screened for putative RNA binding sites as shown in figure 4.1.1. This showed that 
the ANLN mRNA transcript contains 6 ATTTA sites in 3’UTR which can be the targeted 
by RNA binding proteins of the ZFP36 RBPs family, these sites had not been validated 
experimentally for RNA binding protein regulation before (Fallmann et al. 2016). In 
ECs sorted from hind-limb ischaemia there is an association between a down 
regulation of ZFP36 mRNA and ZFP36L1 mRNA (figure 4.3.1A+B) (*=P<0.05 
**=P<0.01, Two way ANOVA with post hoc Bonferroni) matching a concurrent 
increase in ANLN mRNA (as detailed in chapter 3.1.1A+B). Moreover, in vitro 
simulation of vascular inflammation using IL-1β stimulation of HUVEC demonstrated 
a down regulation of ANLN mRNA rapidly at 4 hours post stimulation and continued 
down regulation at 16 and 24 hour time points (***=P<0.001, Two way ANOVA with 
post hoc Bonferroni). This matches an increase in ZFP36L1 mRNA in HUVEC 4 hours 
post stimulation with IL-1β (figure4.3.2A+B) (**=P<0.01, T way ANOVA with post hoc 
Bonferroni). Western blot of lysates from HUVEC demonstrated that ZFP36L1 protein 
is induced at 4 hours post treatment after IL-1β stimulation (figure4.2.2C).  
This data suggests that there is potential for ANLN regulation by ZFP36 RBPs, because 
of the presence of binding sites in its 3’UTR, and a regulatory association in hind limb 


























 Figure 4.3.1 The expression of ZFP36 RBPs in ECs is altered during ischaemic injury:   
 
Expression of (A) ZFP36L1 and (B) ZFP36 in endothelial cells (CD31+CD45-) sorted from 
adductor muscles after femoral artery ligation at the indicated time points. (n=4 










4.3.2 Association between ANLN with ZFP36 RBPs expression in vitro: 
HUVEC were stimulated with IL-1 β (10 ng/ml) at indicate time points. The charts are showing:  A) 
ANLN; and B) ZFP36L1 expression.  (n=3 **=P<0.01,***=P<0.001 by Two-way ANOVA with post-
hoc Bonferroni test). C) Western blot of HUVEC after IL-1β stimulation (10ng/ml) showing an 
induction of ZFP36l1 protein at 4 hours post stimulation. (A+B QPCR by Lorraine Rose) 
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4.3.2 ZFP36 RBP family expression modulation in endothelial cells: 
To determine If ANLN mRNA stability was affected by ZFP36L1 expression, two anti-
ZFP36L1 were used to silence ZFP36L1 in HUVEC. Western blot for ZFP36L1 in HUVEC 
protein lysates after transfection with ZFP36L1 siRNAs showed that only siZFP36L1 
#1 successfully knocked down ZFP36L1 as shown in figure 4.3.3A. Q-PCR of HUVEC 
mRNA after transfection with siZFP36l1 #1 (figure 4.3.3B) showed a significant 
decrease of ZFP36L1 mRNA but no significant increase of ANLN mRNA (*= P<0.05 ns= 
P>0.05 t-test). This experiment was repeated with two anti-ZFP36 siRNA as shown in 
figure 4.3.4A, but again this did not significantly increase ANLN mRNA expression. To 
compensate for a potential redundant increase in one of either ZFP36 or ZFP36L1 
after silencing transfections of HUVECs with both siRNAs were used, however, these 
did not cause an increase in ANLN mRNA (figure 4.3.4B). 













Figure 4.3.3: The ANLN mRNA transcript is not increased after ZFP36l1 silencing 
 (A)Western blot of lysates from siRNA transfected HUVEC:  ZFP36L1 1# and #2 or both at 10nm 
or 20nm concentration. (B) qPCR showing ZFP36L1, ANLN and ZFP36 expression in HUVEC 48 










Figure 4.3.4: The ANLN expression is not effected by ZFP36 knock-down or ZFP36 RBPs 
family silencing  
(A) qPCR showing the expression of ZFP36, ANLN and ZFP36L1 in HUVEC 48 hours after 
transfection with ZFP36 siRNAs (10nM); (B) qPCR showing the expression of ZFP36, ZFP36L1 
and ANLN in HUVEC after transfection with both ZFP36 and ZFP36L1 siRNAs (error 




4.3.3 Plasmid production for the validation of ANLN 3’UTR regulation by RBPs: 
To confirm the direct binding of RBPs to the ANLN 3’UTR, a luciferase target validation 
had to be performed. This required the cloning of a plasmid containing the ANLN 
3’UTR fused to a luciferase reporter. The insert was generated via RT-PCR producing 
a band of ~1.2kb  in length (figure 4.3.5A); this insert was ligated into the p-MIR 
luciferase plasmid, and restriction digest of the produced clones identified insert 
carrying clones as shown in figure 4.3.5A. Protein lysates of HEK293 transfected with  
the ANLN 3’UTR luciferase plasmid  produce a luciferase signal after addition of 
luciferin, this showed that the plasmid is functional as shown in figure 4.3.5C. A 
plasmid for ZFP36 overexpression had already been received from Dr Lucia Montorsi 
so a corresponding plasmid for the overexpression of ZFP36L1 was generated 
(Montorsi et al. 2016). The insert for ZFP36L1 overexpression was generated via RT-
PCR, producing a ~1 kb insert containing the coding sequence including the Kozac 
sequence. The insert was ligated into the pcDNA3.1 plasmid as shown in figure 
4.3.6A-B and restriction digest of the plasmid identified multiple clones carrying the 
insert. Western blot for ZFP36L1 in protein lysates from HEK293 transfected with the 
ZFP36L1 plasmid produces a strong band at ~37kda confirming overexpression of 
ZFP36L1 protein as shown in figure 4.3.6C. The plasmids generated here were to be 










Figure 4.3.5: Generation of ANLN 3’UTR plasmid 
for luciferase target validation of ANLN 3’UTR by 
RBPS 
(A) Agarose gel of the ANLN 3’UTR insert 
containing HindIII and SpeI restriction sites 
(band of ~1.2kb). (B) Selection of colonies after 
ligation of ANLN 3’UTR insert into pMIR plasmid. 
(C) Luciferase assay after calcium phosphate 
transfection of 20ng of ANLN-3’UTR luciferase 















Figure 4.3.6: Generation of ZFP36L1 PcDNA3.1 
construct for plasmid for luciferase target 
validation of ANLN 3’UTR by RBPs  
(A) Agarose gel showing the generation of a 
ZFP36L1 coding sequence ~1kb insert 
containing XbaI and HindIII restriction sites; (B) 
Constructs produced after ligation of insert 
into cut pcDNA3.1 (C) Western blot of HEK293 
lysates after calcium phosphate transfection of 






4.3.4 The ANLN 3’UTR is regulated by ZFP36 family RBPs 
The biochemical interaction between ZFP36 family RBPs was confirmed by a 3’UTR 
luciferase assay. The ANLN 3’UTR-luciferase signal was regulated by RNA binding 
proteins when assayed with luciferin after co-transfection of the ANLN luciferin 
reporter plasmid with ZFP36 or ZFP36L1 plasmid in HEK293 (figure 4.3.7A). 
Overexpression of ZFP36 or ZFP36L1 significantly reduced the luciferase activity 
compared to a transfection with a control plasmid, pCDNA3.1 (***=P<0.01, one way 
ANOVA with post-hoc Bonferroni).  
To demonstrate the binding of ANLN mRNA to ZFP36L1 and ZFP36, an RNA 
immunoprecipitation (RIP) for ZFP36L1 was performed on HUVEC protein lysates. 
QPCR of the mRNA products of the RIP showed that there was significant enrichment 
of the positive control mRNA VEGF in the ZFP36L1 pulldown compared to IgG, there 
was no significant enrichment of ANLN mRNA (**=P<0.01, ns=P>0.05, t-test) (figure 
4.3.7B). However, there was a significant enrichment of both VEGF and ANLN mRNA 
on the ZFP36 RIP (**=P<0.01, *=P>0.05, t-test).  
Finally, to confirm the post-transcriptional regulation of ANLN by ZFP36, ZFP36 was 
overexpressed in HUVECs. Overexpression of ZFP36 by lentivirus in HUVEC produced 
~50KDa protein detectable by Western blot (figure 4.3.8A). QPCR analysis of mRNA 
from HUVEC transduced with ZFP36 lentivirus showed a trend for a reduction in ANLN 
mRNA expression (P>0.05=ns, t-test) as shown in figure 4.3.8B. 
These experiments suggest that the reporter luciferase assay identified the ANLN 
3’UTR as a potential target of ZFP36 and ZFP36L1. However the transcript was only 














Figure 4.3.7: Validation of ZFP36 family RBP 
binding to the ANLN 3’ UTR  
(A) Luciferase assay of HEK293 lysates after 
calcium phosphate transfection of either 
ANLN 3’UTR construct with empty control 
pcDNA3.1 and ZFP36 or ZFP36l1 plasmid, 
and β-Gal plasmid (error bars = S.E.M,  n=3 
***=P<0.01 one way ANOVA with post-hoc 
Bonferroni). (B) Expression of VEGF and 
ANLN in mRNA isolated from a ZFP36L1 pull 
down (IgG used as control) (error 
bars=S.E.M n=3 **=P<0.01  t-test). (C) 
Expression of VEGF and ANLN in mRNA 
isolated from ZFP36 pull down (IgG used as 



















Figure 4.3.8: There is a trend for a reduction of ANLN mRNA after ZFP36 overexpression:  
(A) Western blot for ZFP36 in HUVEC lysates after transduction with EGFP and ZFP36 lentivirus. 





In this chapter, for the first time, the post transcriptional regulation of ANLN in ECs 
by the ZFP36 RNA binding protein family was investigated.  
4.4.1 There is a potential regulatory mechanism of ANLN by ZFP36 RBPS: 
An increase of ANLN expression and a reduction in ZFP36/ZFP36l1 expression was 
shown in CD31+/CD45- ECs sorted from mouse hind limb ischaemia at the 3 and 7 day 
time points. This suggested a regulatory association between ANLN mRNA levels and 
ZFP36 RBPs in proliferating or migrating ECs as expected at this experimental time 
point in ischaemia. As ZFP36 RBP expression is in part regulated by inflammatory 
stimuli it would be required to check the expression of the RBPs in ischaemic muscle. 
Confirmation of ZFP36 protein down regulation in vivo would be difficult, it is not 
feasible to collect enough protein from CD31+/CD45- sorted ECs for western blot. 
Staining for ZFP36 RBPs in 7 day ischaemic muscle would identify ZFP36 RBP down 
regulation in ischaemic ECs, and could identify ZFP36 RBP expression in satellite 
muscle cell differentiation in post ischaemic skeletal muscle regeneration (Hausburg 
et al. 2015; Bye-A-Jee et al. 2018). 
The mouse model of hind limb ischaemia induces tissue hypoxia and the activation 
of angiogenic and inflammatory response. To simulate vascular injury and 
inflammation in vitro, IL-1β stimulation of ECs has been used, as in other studies to 
model this condition (Merhi-Soussi et al. 2005). IL-1 beta stimulation of epithelial cells 
has been shown to induce ZFP36 RBP expression in a p38MAPK dependant 
mechanism (King et al. 2009). The observations match a regulatory mechanism 
whereby there was an observable increase of ZFP36L1 matching a concurrent drop in 
ANLN mRNA during IL-1 beta stimulation. The change in expression of ZFP36 RBPs 
could be controlled as in other cell types by phosphorylation and induction of protein 
expression through p38MAPK (King et al. 2009). In addition to ZFP36L1 protein 
induction at 4 hours, increased streaking of the protein band suggested an increase 
in phosphorylation of ZFP36L1. This could be investigated by western blotting of IL-
1β stimulated HUVEC lysates with an anti phospho-ZFP36L1 antibody. This would 
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determine if ZFP36l1 is activated/de-activated by phosphorylation in IL-1β 
stimulation. Furthermore, modelling ischaemia in vitro using a hypoxia chamber (1% 
O2) may better simulate the ischaemic expression of ZFP36 RBPs. 
To understand the potential regulatory mechanism, ZFP36 RBPs were knocked down 
in vitro with siRNA, however, Silencing of ZFP36 RBPs with siRNA did not significantly 
increased ANLN expression in HUVECS. This was counter to observations of other 
targets of ZFP36 RBPs in the literature where HIF-1α and dll4 mRNA were significantly 
increased after ZFP36L1 or ZFP36 silencing  (Chamboredon et al. 2007; Desroches-
castan et al. 2011). There appeared to be a trend for the increase of ZFP36 expression 
after silencing of ZFP36L1. This could be a redundancy mechanism by which ZFP36 
expression is increased to compensate for a loss of ZFP36L1. This has been observed 
in T cells where loss of ZFP36L1 leads to perturbed mouse thymus development, 
however, loss of ZFP36 was recovered by a redundant increase of ZFP36L1 expression 
to maintain normal gene expression (Hodson et al. 2010). Transfections with siRNA 
of both ZFP36 and ZFP36L1 did not produce the up-regulation of ANLN mRNA which 
was expected. Confirmation of a redundant increase of expression of either ZFP36 or 
ZFP36l1 could be confirmed by western blot in HUVEC lysates after silencing. 
Moreover, it should be recognised that a post translational regulatory mechanism of 
ANLN expression exists through APCcdh1 mediated ubiquitination and degradation 
(Zhao & Fang 2005). This mechanism functions to degrade ANLN and other cell cycle 
associated proteins after completion of the cell cycle (Zhao & Fang 2005). In the CAG-
ANLN-EGFP mouse and flt1-ANLN-EGFP mouse, which function essentially as ANLN 
overexpression models, ANLN-EGFP is degraded rapidly by APCcdh1 in non-
proliferating cells (Hesse et al. 2012; Herz et al. 2018). This mechanism may be 
affected by any treatment which affects proliferation, including; IL-1β stimulation 
and ZFP36 RBP overexpression/silencing. IL-1β stimulations and ZFP36 RBP 
interference could be used in ANLN-EGFP transduced HUVEC to determine their 
effect on ANLN-EGFP protein stability. Flow cytometry could be used to detect shifts 
in ANLN-EGFP+ve cell numbers of sorted and unsorted ANLN-EGFP transduced cells, 
this could identify changes in post-translational regulation of ANLN-EGFP protein.  
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Plasmids for investigating the regulation of ANLN were successfully produced.  
Overexpression of ZFP36 RBPs is possible despite the presence of auto regulatory 
ATTTA sites in their 3’UTR (Mukherjee et al. 2014). The ANLN 3’UTR was confirmed 
as a target of ZFP36 and ZFP36lL1 by luciferase assay in HEK293, confirming the RBP 
binding to one or multiple of the ARE sites on the ANLN 3’UTR. This effect was not 
due to changes in transfection efficiency as all transfections included the β-
galactosidase plasmid as a control. The physical interaction of the ANLN mRNA 
transcript was confirmed by RNA immunoprecipitation. This showed that the positive 
control mRNA VEGF, was enriched compared to the control input lysate in ZFP36 and 
ZFP3L1. ANLN was only enriched compared to input in a ZFP36 but not in a ZFP36L1 
pull down. ZFP36 and ZFP36L1 are homologous (particularly the zinc finger domains), 
but they have some key differences in surrounding domains, these differences may 
affect their regulation and target recognition (Ciais et al. 2013). The individual binding 
site on the 3’UTR was not confirmed, however, we could do this by site directed 
mutagenesis or a deletion of each of the 6 binding site present on the 3’UTR luciferase 
plasmid. Additionally we could include a mutant control RBP plasmid, this would be 
ZFP36 and ZFP36L1 with mutated zinc finger domains to prevent binding to the target 
ARE elements in the 3’UTR. It is possible that ANLN mRNA does bind to the ZFP36L1 
active site, but this is undetectable in normal HUVEC lysates. We could use the 
approach of other studies, where flag tagged ZFP36 RBP plasmids were 
overexpressed in HEK293 to confirm the target transcript presence on the RIPs 
(Chamboredon et al. 2007). If this approach is used then mutated ZFP36 RBP plasmids 
could also be used as an additional negative control in ZFP36 RIPs. Although using 
HEK293 would remove some physiological relevance, the experiment would still 
demonstrate the biochemical interaction between the ANLN mRNA transcript and 
ZFP36L1. Again it would not be feasible to produce enough protein lysates from ECs 
sorted from hind limb ischaemic muscle to perform ZFP36 RBP RIPs with these cells.  
Overexpression of ZFP36 in HUVECs by lentivirus caused a trend for a concurrent drop 
in ANLN mRNA compared to control. ZFP36 overexpressed HUVEC didn’t survive 
multiple passages so this experiment may not accurately portray the true expression 
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of ANLN. This could be caused by ZFP36 overexpression down-regulating proliferative 
gene expression. This may lead to cell cycle suppression and cell death as has been 
reported in other cell types  overexpressed with ZFP36 RBPs (Wegmüller et al. 2007; 
Suk et al. 2018). This may be a result of enhanced mRNA target repression seen in 
ZFP36 RBP overexpression, where, overexpression results in direct shuttling of ZFP36 
bound mRNA from the nucleus to P-bodies.  Although this is a normal mechanism of 
ZFP36 mediated RNA degradation, it is increased during overexpression of ZFP36 
RBPs. The effect of ZFP36 RBP expression on the could be confirmed by staining for 
apoptotic markers via TUNEL staining or through staining of PCNA or Ki67 to 
determine if the cell cycle is being suppressed (Bologna-Molina et al. 2013). We only 
had a limited volume of ZFP36 lentivirus which restricted the amount of experiments 
we could perform at this point. 
4.4.2 Future investigations of ZFP36 RBPs in angiogenesis:  
The initial aim with the RBP protein hypothesis was to use an animal model for 
investigating the effects of RBP knockout on vascular regeneration after ischaemia. 
This was to be done by using an inducible endothelial specific Cre-lox knockout of 
either ZFP36 or ZFP36L1 in mice (Newman et al. 2017). However, this model wasn’t 
obtainable due to time constraints in organising the importation and establishment 
of this mouse line.  
Several studies showed that in vitro functional assays after ZFP36 RBP expression 
modulation are not necessarily representative of an in vivo phenotype. Some of the 
phenotypes induced in vivo by global RBP knockout may be a paracrine effect caused 
by increased growth factor release from surrounding cells. This effect has been 
hypothesised as a contributing factor to vascular disorganisation seen in ZFP36L1 
knock outs (Bell et al. 2006). Cultured myeloid cells from ZFP36 knockout mice do not 
have a hyper proliferative phenotype as observed in vivo. Moreover, the endothelial 
dysfunction observed in ZFP36 knockout mice is attributed to a paracrine effect of 
increased overall inflammation and not a direct effect on ECs (Bollmann et al. 2014). 
The same effect is observed in fibroblasts obtained from ZFP36L1 knockout mice, 
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where there is no difference in cell proliferation or apoptosis compared to controls 
(Hacker, Valchanova, Adams, Munz, et al. 2010). Therefore for these experiments to 
be accurate, a vascular specific knockout of ZFP36 RBPs is required. This would 
eliminate a paracrine effect of cytokine or growth factor secretion from surrounding 
cells and demonstrate a true vascular phenotype.  
Finally, the tools generated and utilised in this study can be used to identify ZFP36 
RBP gene targets, particularly those of ZFP36L1. The ZFP36L1 RIP and siRNA could be 
used in HUVEC to generate samples for RNA sequencing to identify targets of 
ZFP36L1. This would allow for further investigation of RNA binding protein post 
transcriptional control of gene expression in angiogenesis (Vogel et al. 2016). 
Multiple potential targets expressed in tip stalk cell designation including, Apelin, Dll4 
and Notch contain ZFP36 ARE elements. Identifying a regulatory mechanism of these 
genes by ZFP36L1 could explain the vascular defects associated with ZFP36L1 
knockout mice (Fallmann et al. 2016). 
4.5 Conclusions: 
To conclude, the ANLN 3’UTR was a potential target of ZFP36 RBPs and there was a 
regulatory association in vivo and in vitro between ANLN and ZFP36 family RBPs in 
ECs. However ANLNs expression was not affected by the silencing of ZFP36 and 
ZFP36L1 RBPS and the transcript was not present on the binding site of ZFP36L1. The 
ANLN mRNA transcript was present on the ZFP36 binding site, however, because we 
couldn’t obtain a ZFP36 RBP vascular specific knockout mouse model to carry out 
suitable in vivo experiments we decided to stop. Instead it was decided to focus the 
last part of the thesis on investigating the ANLN expression and function in vascular 
injury in vivo. If this RBP regulatory mechanism was to be continued in future, ZFP36 








Chapter 5:                                             
Does Anln expression localise with 
endothelial cells during 
development or vascular injury in 












ANLN has been shown to profoundly affect the cleavage furrow, where its association 
with the contractile ring is  required for successful cytokinesis to take place (Straight 
et al. 2005; Field & Alberts 1995). Importantly, ANLN is required for the correct 
placement of the mitotic centriole during cytokinesis (van Oostende Triplet et al. 
2014). ANLN silencing in invertebrates has been shown to produce asymmetric cell 
division phenotypes resulting in a loss of asymmetry in embryogenesis (Piekny & 
Glotzer 2008). In mammalian cell lines, loss of  ANLN is also associated with 
asymmetric cell division phenotypes (Liu, Gregory D. Fairn, et al. 2012). 
Zebrafish are a powerful and versatile tool for investigating embryogenesis, 
angiogenesis, wound healing, and gene function as laid out in chapter 1. We 
investigated and acquired the anln:anln-eGFP zebrafish line which was generated by 
Dr Lucia Poggi of the University of Heidelberg, Germany, to allow us to conduct 
investigations of anln in zebrafish. This zebrafish line was generated by injection of a 
BAC plasmid containing the full zebrafish anln promoter with the coding sequence of 
anln fused to eGFP (Paolini et al. 2015). This generated a zebrafish that expresses a 
fluorescent reporter of Anln expression and cellular localisation. This line was used 
extensively for the investigation of Anln in the asymmetric cell division of zebrafish 
retina progenitor cells (Paolini et al. 2015; Malo et al. 2017). Asymmetric cell division 
is a well described cellular process whereby asymmetric placement of the centriole 
allows for polarised inheritance of cell products and changes in cell size (Berika, 
Marwa E Elgayyar, et al. 2014). This process is important in budding yeast 
reproduction where daughter cells bud from the parent cell (McFaline-Figueroa et al. 
2011). In non-vertebrate organisms like C. elegans asymmetric cell division is 
associated with early embryonic development. The first division of the zygote is 
asymmetric to produce daughter cells that will produce embryonic layers through 
further asymmetric cell division (Berika, Marwa E Elgayyar, et al. 2014).  
Although essential in invertebrates, it is less important in vertebrates where there is 
some evidence for this process in stem cell renewal and tissue maturation (Ettinger 
126 
 
et al. 2011; Dubreuil et al. 2007; Berika, Marwa E. Elgayyar, et al. 2014). Asymmetric 
cell division has been observed to mediate tip stalk cell designation in 
neoangiogenesis (Costa et al. 2016; Costa et al. 2017). During tip/stalk cell 
designation the leading EC or tip cell has a different migratory phenotype to the stalk 
cells that make up the rest of the developing vessel (Costa et al. 2016). In zebrafish, 
tip cells were found to be 1.8 to 1.9 times larger than stalk cells in volumetric analysis 
of 26-32hpf flk:mcherry intersegmental vessels (ISV)  (Costa et al. 2016). Asymmetric 
placement of the centriole in ECs predicts the motility of produced daughter ECs 
(Costa et al. 2016). In this way asymmetric division was shown to affect the 
distribution of VEGF signalling components, with polarised localisation of VEGFR2 
receptor in the leading tip daughter cell (Costa et al. 2017; Costa et al. 2016).  
The in vitro data in chapter 3 showed that ANLN overexpression and silencing both 
affect EC tubulogenesis. Tubulogenesis was employed as a model of early sprouting 
angiogenesis, therefore it was decided to investigate Anln in the early vascular 
development of the zebrafish embryo. Furthermore, due to an association of ANLN 
expression with hind limb ischaemia in the mouse, a vascular injury model in 














The underlying hypothesis for this chapter was, that Anln localises to ECs during 
vascular development/injury and that interference with anln expression impairs the 
morphology of zebrafish blood vessels by impairing asymmetric cell division 
associated with tip/stalk cell designation.  
This hypothesis was to be addressed by using the anln:anln-eGFP zebrafish provided 




In this chapter I aimed to;  
1. Investigate anln expression in the zebrafish vasculature using the anln:anln-
eGFP and flk:mcherry zebrafish lines  
2. Develop a method for vascular injury of the zebrafish to observe if anln:anln-
eGFP is expressed at the site of injury localised within ECS 
3. Determine the effect of anln knock-down on the vascular morphology of 













5.3.1 The anln:anln-eGFP transgene is weakly expressed from 24hpf 
To investigate the expression of Anln in angiogenesis and vascular development in 
the zebrafish embryo, reporter zebrafish expressing anln:anln-eGFP were imported 
and raised to breeding age. The live anln:anln-eGFP embryos were screened by 
epifluorescence at the early stages of development after fertilisation. Representative 
images of the whole fish are shown in figure 5.3.1A-B anln:anln-eGFP fluorescence is 
visible in the cell mass of the early 32-cell and shield stage embryo (figure 5.3.1A). 
Later time points of the embryos between 24-72hpf exhibited no detectable 
expression of the anln:anln-eGFP transgene except for the yolk sack. This suggested 
that from ~24 hpf onwards the expression of anln:anln-eGFP required a more 




















Figure 5.3.1: The anln:anln-eGFP transgene is not detectable with epifluorescence from 24 
hpf:  
(A) Weak anln:anln-eGFP fluorescence is visible via epifluoresence of the early cell mass 
embryonic stages up until the shield stage of embryonic development. (B) At later time 
points (24-72hpf)  no detectable Anln-eGFP expression could be detected with 
epifluorescence, with only yolk sack auto fluorescence visible as indicated by grey arrow 
(scale bar=1mm).  
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5.3.2 The anln:anln-eGFP transgene expression is reduced with age of the fish embryo 
Using a more sensitive detection method, 24-48 hpf anln:anln-eGFP embryos were 
screened  by single plane illumination microscopy (SPIM) to determine anln:anln-
eGFP expression throughout embryonic development of the zebrafish. In figure 5.3.2 
the expression of the anln:anln-eGFP transgene in the head eye and trunk of the 
embryonic fish is shown. This reveals anln:anln-eGFP transgene expression at 24 hpf 
is widespread in the dermis, head, eyes, and CNS of the developing embryo. In the 
trunk of the 24hpf fish  two strong bands of GFP positive cells were found adjacent 
to the cloaca, that align anatomically with the notochord and developing vessels 
(figure 5.3.3). At 48hpf, anln:anln-eGFP expression is more restricted in these areas, 
with expression retained in the dermis and eye but lost in the CNS and trunk of the 
fish. This showed that between 24 hour and 48 hpf the anln:anln-eGFP transgene can 
be detected by SPIM imaging. During the 24-48hpf time points there is a concurrent 
significant decrease of anln mRNA as indicated by QPCR analysis of the whole fish 
embryo (**=P<0.01, t-test) (figure5.3.3B). This matched a reduction in expression of 
the transgene in the head, eye and trunk over these time points. For reference 

















Figure 5.3.2: The anln:anln-eGFP fluorescence in the developing zebrafish embryo 
declines at 24-48hpf in the embryonic CNS and eye: 
SPIM imaging of the 24-48 hpf anln:anln-eGFP embryos showing the head and eye of 
embryos. The anln:anln-eGFP transgene is widely expressed at 24hpf throughout the eye 











Figure 5.3.3: The expression of anln:anln-
eGFP in the trunk declines between 24-48 
hpf: 
SPIM imaging of the 24-48 hpf anln:anln-
eGFP embryos showing the trunk of the 
embryo. Indicating arrows mark the 
cloaca (C) of the developing fish. (A) Anln-
eGFP is expressed in the  trunk of the 
24hpf zebrafish marking cells of 
developing embryonic tissues which is 
lost at 48hpf (scale bar= 100μms) (B) 
qPCR analysis of whole zebrafish embryos 
between 24-48 hpf  detects a significant 
reduction in expression of ANLN mRNA 
between 24-48 hpf n=5 (groups of 30 




5.3.3 anln:anln-eGFP signal does not co-localise with blood vessels at 24hpf  
To determine whether expression of the anln:anln-eGFP transgene was associated 
with the developing blood vessels, anln:anln-eGFP fish were crossed with the 
flk:mcherry expressing zebrafish and offspring were analysed at regions of interest. 
SPIM microscopy was used to investigate the trunk, tail, and CNS of the resulting 
24hpf anln:anln-eGFPxflk:mcherry  zebrafish. Representative images are shown in 
figure 5.3.4-5.3.6. In the head, eyes, and CNS, the cerebrovascular system was 
developed and there appeared to be an association of the anln:anln-eGFP transgene 
with some cells of the vessels of the CNS in figure 5.3.4A. However, investigation of 
these cells in smaller Z-stacks and by manipulation of a 3D image showed that these 
cells were not associated with the vessels (figure3.3.4B-C). In the trunk and tail, 
vascular structures of the caudal artery plexus (CAP) and dorsal aorta (DA) were 
observed; an association, but no actual co-localisation of the anln:anln-eGFP 
transgene with these vascular structures was detected. A band of Anln-eGFP+ve 
positive cells is positioned inferior and adjacent to the dorsal aorta but does not co-
localise with the vessel; in the CAP there was an association of Anln-eGFP+ve positive 
cells interspersed with the developing vessel, but again there was no co-localisation. 
These data identified that in the developing 24-48hpf fish at least in these regions of 
interest there is no co-localisation of the anln:anln-eGFP transgene expression with 












Figure 5.3.4: anln:anln-eGFP does not co-localise with the vessels in the 24hpf CNS: 
 SPIM imaging identified no association of Anln-eGFP+ve cells with the blood vessels of 
the developing CNS of the 24 hpf anln:anln-eGFP x flk:mcherry zebrafish embryo. (A) 
Maximum intensity projection of a Z-stack of the CNS (showing potential co-
localisation with arrows)  (B) Individual z projections from the top of the z-stack 
(showing potential co-localisation with arrows)  C. Rotation of a 3D MIP at 0, 40 and 
100 degrees identified that potential co-localisations were in a different plane to the 










Figure 5.3.5: There is an association but no co-localisation of anln:anln-eGFP with the 
vessels in 24 hpf zebrafish embryo trunk and tail:  
SPIM imaging showed an association but not co-localisation of Anln-eGFP+ve cells with 
the vessels of the trunk and tail of 24 hpf anln:anln-eGFP x flk:mcherry zebrafish 













Figure 5.3.6 anln:anln-eGFP associates but does not co-localise with blood vessels in 
the 24 hpf zebrafish embryo:  
Imaging with confocal microscopy identified Anln-eGFP localisation in the vasculature 
of the whole embryo. Individual sprouting ECs at the cloaca showed no co-localisation 
with anln:anln-eGFP.  Tile scan of whole fish are shown. Arrows indicate the retina (R) 
dorsal Aorta (DA) and the caudal artery/vein plexus (CAP). Cloaca showing the 
developing caudal artery (CA) and cardinal vein (CV) with individual sprouting ECs (S) 




5.3.4 Micro point laser injury produces non-lethal injuries of the caudal artery 
To investigate Anln expression in the EC response to injury, a protocol for vascular 
injury of the caudal artery in larval zebrafish was developed using a micro point laser 
system. Figure 5.3.7A shows representative images of the laser injury induced after 
3 and 6 pulses of unattenuated laser power demonstrating a single clot at the site of 
injury. The clotting time of the blood after injury was dependent upon injury 
intensity, with a significant reduction in time for clot formation seen between 
embryos receiving 1, 3 or 6 pulses of the micro point laser (P<0.001=*** one way 
ANOVA with post hoc Bonferroni) as shown in figure 5.3.7B.  Survival was observed 
overnight as shown in figure 5.8 where there was no significant difference between 
uninjured and injured groups in overnight survival or blood flow recovery. These 
experiments demonstrated that laser injury of the caudal artery is possible in 
embryonic fish and that this type of injury is not final, with regeneration observed 
within 24 hours.  These three intensities of laser injury were classified as either weak, 
moderate or severe based on the clotting times. To assess the impact of this type of 
laser injury on the vessel, time-lapse SPIM imaging was used to capture the recovery 
of the caudal artery in 48-72hpf and 72-96hpf flk:gfp larval fish after injury with 3 
pulses of unattenuated laser (figure 5.3.9+5.3.10). The representative images shown 
demonstrate a temporary loss of fluorescence at the site of laser injury which fully 
recovered over a period of ~ 12 hours. I also employed flk:gfp x mpx:mcherry fish, in 
which ECs are marked by green and neutrophils by red fluorescence, a line commonly 
used to assess regeneration and neutrophilic inflammation in response to wound 
healing, to determine if neutrophils associate with the caudal artery at the site of 
laser injury (figure 5.3.11). These experiments identified an association of neutrophils 
with the laser injury site in 2-3 dpf zebrafish. Interestingly, from 1 hpi injury 
neutrophils associated with the injury site leaving the injury site by 24 hpi, identifying 
immune cell localisation with the injury. To exclude the possibility that photo 
bleaching might be a component of these injuries, laser injury experiments were 
repeated using the flk:mcherry zebrafish (figure 5.3.12). The injuries observed were 
different in the flk:mcherry zebrafish with a gradual  recovery of fluorescence and 
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visible EC motility in close proximity to the injury site. These experiments showed 
that the laser injuries did induce a loss of fluorescence in the flk-eGFP, but not the 
flk:mcherry line and that damage to the vessel causes localisation of inflammatory 








Figure 5.3.7: laser injury of the caudal artery induces a thrombus at the site of injury: 
(A) 3-6 pulses of un-attenuated micro point laser focused on the caudal artery of 48hpf 
zebrafish induces a thrombus at the site of injury. (B)  In 48-72hpf embryos the time for 
thrombus formation of the caudal artery after laser injury was measured, indicating a 
faster thrombus formation with increased laser pulse number (n=30) (Error bars=SEM 











Figure 5.3.8 – Embryonic zebrafish are highly resistant to laser injuries at 48-96 hpf:  
(A) There is a complete recovery of blood flow in 48-96 hpf WIK zebrafish after 
application of one, three and six pulses of un-attenuated micro point laser to the 
caudal artery. (B) There is a high rate of survival in 48-96 hpf WIK zebrafish embyros 
after application of one, three and six pulses of un-attenuated micro point laser to 












Figure 5.3.9: Green fluorescence recovers after laser injury of the caudal artery: 
SPIM images of injured 48hpf flk:GFP zebrafish embryos after moderate micro point 
laser injury (3 pulses). Images show a gradual closing of the wound and recovery of 
fluorescence at the injury site injury   0, 5, 10, and 15 (A,B,C and D) hpi with arrows 













Figure 5.3.10 There is a recovery of fluorescence after laser injury of the caudal artery 
SPIM images of injured 72hpf flk:GFP zebrafish embryos after moderate micro point 
laser injury (3 pulses). Images show a showing gradual closing and recovery of 
fluorescence at the injury site injury 0, 5, 10, and 15 (A,B,C and D) hpi with arrows 










Figure 5.3.11: Neutrophils associate with laser induced injury of the caudal artery:  
Epifluorescence images showing the lateral view of the 48hpf flk:eGFP x mpx;mcherry 
zebrafish embryo caudal artery after injury with moderate (3 pulses) and severe (6 pulses) 
micro point laser injury. Arrows indicate the injury site (IS), neutrophil association is 






Figure 5.3.12: Moderate laser wounds of the caudal artery of flk:mcherry zebrafish 
heal within 10 hrs without loss of fluorescence  
Time-lapse spinning disk microscopy of 48 hpf flk:mcherry embryos after moderate 
micro point laser injury (3 pulses) of the caudal artery. Images show recovery of the 
injury site (IS) with a minimal loss of fluorescence 0, 5 and 10 hpi in injured fish  
compared to uninjured fish  (representative scale bars=100 μm). 
144 
 
5.3.5 Anln-eGFP expression is not induced by laser injury of the 48hf caudal artery: 
Using the vascular injury model developed, the caudal artery of the 2-3 dpf anln:anln-
eGFPxflk:mcherry zebrafish was injured with moderate laser injury and observed at 0 
and 10 hours post injury. Representative images of these injuries are shown in figure 
5.3.13. This identified no association of anln:anln-eGFP signal with the site of injury 
at either time point.  
Next, a mechanical injury of the tail fin was used to stimulate a more severe injury 
response (figure 5.3.14A-D).  Severing the tail fin of the developing 3-4 dpf zebrafish 
produced a significant increase of anln positive cells at the injury site (**=P<0.01). 
Dividing Anln+ve cells were observed in the tail of both injured and uninjured 
zebrafish. We concluded that although there was no association of anln:anln-eGFP 
with laser injury sites of the vessel there may be an association of Anln-eGFP+ve cells 






















Figure 5.3.13: Anln-eGFP expression is not associated with Injury of the caudal artery 
with moderate laser injury of 48-72 hpf zebrafish embryo: 
SPIM images of 48hpf flk:mcherry x anln:anln-eGFP after application of moderate 
micro point laser injury (3 pulses) 0 and 10 hpi. (A) Injured flk:mcherry x anln:anln-
eGFP fish with injury site indicated with arrow showing no association of  (IS). (B) 










Figure 5.3.14 There is increased anln:anln-eGFP expression after tail fin injury:  
(A) Spinning disk confocal images of 72-96hpf anln:anln-eGFP zebrafish embryo after 
mechanical tail fin injury (representative scale bars=100 μm). (B) Quantification of anln-
EGFP positive cells on a 1500μm boundary site of 4 and 24 hours post tail injury (hpi) (n=10 
error bars=SEM significance **=P<0.01 t-test). (C) Anln-eGFP+ve indicated by grey arrows 




5.3.6 Partial silencing of anln does not affect vascular development: 
To further investigate the effect of anln expression on vascular development and 
regeneration, morpholinos were used that had already been shown to partially 
silence anln expression (Paolini et al. 2015). Partial silencing had to be used to 
prevent the generation of lethal phenotypes observed with global Anln knock out 
(Gbadegesin et al. 2014).  
Injection with either control, splice or ATG targeting morpholinos did not cause any 
visible differences in overall vascular structure and no changes in ISV number at 48 
or 72 hours post injection (figure 5.3.15-5.3.17). The structure of the trunk 
vasculature including the DLAV, ISVs, caudal artery and caudal vein displayed no 
visible differences between groups and there were no differences in the length of the 
ISVs or caudal artery width between groups. Injection of the splice mRNA showed a 
trend for a ~30% reduction in anln mRNA 24hpi (n=2) as shown in figure 5.3.15C 
.These experiments showed that partially silencing anln with morpholino did not 
















Figure 5.3.15: Partial silencing of anln with morpholinos does not affect ISV number:  
(A) Images taken by epifluorescence show the lateral view of whole flk:eGFP zebrafish 
embryos after microinjection at the one cell stage with either control, splice or ATG 
blocking morpholinos (representative scale bars=1mm). (B) Quantification of ISV number 
along the zebrafish, morpholino treated groups showing no significant difference 
between groups (n=20, P>0.05 one way ANOVA with post-hoc Bonferroni) (C) qPCR 
analysis of whole zebrafish embryo mRNA 24 hpi detects a trend for a reduction in 








Figure 5.3.16: Partial silencing of anln with morpholino has no effect on the overall 
zebrafish vascular morphology: 
Images taken by epifluorescence show the lateral view of flk:eGFP zebrafish ISVs after 
microinjection 24 and 48 hours post injection with 8pg of control, splice or ATG blocking 
morpholino. Arrows indicate the intersegmental vessels (ISV), dorsal longitudinal 
anastomotic vessel (DLAV), caudal vein (CV), and caudal artery (CA). No differences in 














Figure 5.3.17: Morpholino-induced knockdown of Anln does not induce any obvious 
vascular abnormalities: 
(A) The lengths of ISVs and (B) width of caudal artery of 48-72 hpf flk:eGFP zebrafish 
after morpholino injections between 48 and 72 hpf were not different between 
treatment groups. (n=20 error bars=SEM, ns= no significance by one way ANOVA 
with post hoc Bonferroni). 
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5.3.7 Generation of sgRNA guides for tissue specific anln CRISPR/CAS9 deletion: 
There are difficulties associated with morpholino mediated Anln knockdown, these 
include severe overall embryonic phenotypes induced by complete knock out. I 
aimed to develop a tissue specific Anln knock-out fish to once more address the 
possibility that Anln might regulate angiogenesis/vascular development in the 
zebrafish. Unfortunately I failed to produce a CRISPR/Cas9 mediated knockout due to 
technical reasons that are laid out in the following.  
The custom web tool CHOPCHOP was used to identify suitable sites for CRISPR CAS9 
interference. This identified 201 potential sites with the NGG PAM motif in the 
zebrafish anln coding sequence, that would be suitable for sgRNA mediated 
CRISPR/CAS9 gene editing by injection into the one cell stage embryo as shown in 
figure 5.3.18A-B. The in vitro transcription of sgRNA guides was not producing 
detectable capped mRNA, therefore, the process had to be optimised to produce 
suitable capped sgRNA.  
To confirm that sgRNA guides were being annealed successfully, a positive control 
annealed and non-annealed sgRNA guide template was received from Panna Tandon 
(Minchin group CVS, UoE). This positive control sgRNA template was annealed to the 
standard oligo alongside 3 sgRNA templates targeting the anln genomic sequence; 
the products of this reaction and the annealed positive control were ran on an 
agarose gel shown in figure 5.3.19A. This confirmed successful annealing of the 
sgRNA templates to the standard oligo. The annealed templates were used in an 
overnight T7 or SP6 reaction to produce capped sgRNA for CRISPR/CAS9 injection and 
the products were ran on an agarose gel as shown in figure 5.3.19B. No capped sgRNA 
was produced from the anln sgRNA templates via the T7 reaction whereas capped 
sgRNA was produced from both the preannealed positive control and the positive 
control template annealed in the same annealing reaction. This demonstrated that 
the failed capped sgRNA production was not related to the annealing reaction. 
To investigate whether the in vitro transcription reaction was affected by the quality 
of the sgRNA oligonucleotide templates or the type of T7 reaction, two sgRNA were 
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produced using standard desalting and HPLC purification methods. They were 
annealed successfully and the products ran on an agarose gel as shown in figure 
5.3.20A; the annealed product was then used in an overnight T7 reaction which again 
produced no capped sgRNA from either standard desalted or HPLC purified annealed 
template as shown in figure 5.3.20B. This showed that the failure to produce capped 
sgRNA was not due to the method used to purify the sgRNA oligonucleotides. 
Finally to investigate whether the reaction was due to the wrong concentration of 
sgRNA oligo template or by RNase contamination, the volume of annealed gRNA 
guides added to the T7 reactions were titrated with 1, 3 and 6 uls of gRNA template 
being added to reactions, and RNase inhibitor was added to duplicate reactions to 
inhibit potential RNase contamination within the T7 kit. The products of these 
reactions were ran on an agarose gel as shown in figure 5.3.20C. However this again 



















Figure 5.3.18; Bioinformatic analysis identifies multiple CRISPR/CAS9 target sites in the 
zebrafish anln gene. 
(A) Shows the anln coding sequence containing the different sites targetable by CRISPR 
CAS9 whilst indicating the quality of each target site. Image taken from 
(CHOPCHOP.cbu.uib.no). (B) A selection of gRNA templates used during gRNA 
production optimisation showing the score of each template and target sequence 










Figure 5.3.19: Low yield of Cas9 sgRNA is not due to faulty annealing reaction for T7 in 
vitro transcription: 
 (A) An agarose gel of gRNA guide oligos after being annealed to the universal TRACR 
oligo by Q5 polymerase. Guides target the N-terminal (N1-N2) region of ANLN and one 
of the PH domain (PH) for use in the T7 machine assay and a positive control gRNA guide 
annealed by myself and one preannealed are included. (B) Agarose gel of the products 
of an overnight T7 and SP6 reaction show that only the SP6 guide (PC) and pre-annealed 









Figure 5.3.20: Low yield of Cas9 sgRNA is not due to poor oligo template quality, reaction 
mix or RNase contamination.  
(A) Annealing of gRNA standard (S) and HPLC (H) templates show successful annealing of 
both gRNA templates. (B) Overnight T7 reaction of standard and HPLC purified annealed 
templates. (C) An agarose gel of products of T7 transcription reactions with increasing 
concentration of 1, 3 and 9 μls of annealed template, the positive control plasmid (STD) 
and a reaction containing RNAse inhibitor (RI) show no production of capped sgRNA 




In this chapter, I investigated the expression of anln in the vascular development of 
the zebrafish embryo.  Furthermore, I developed a novel method of vascular injury in 
the zebrafish embryo to address a potential association of anln with regenerating 
vasculature.  
5.4.1 Anln is not associated with vascular development  
The expression of Anln in early vascular development was investigated with the 
anln:anln-eGFP transgenic zebrafish line. Initial imaging of zebrafish embryos showed 
that the anln:anln-eGFP transgene was weakly expressed in early development and 
was detectable at the 32 cell, and shield stage of embryonic development by 
epifluorescence. There is a requirement for high Anln expression for the organisation 
of membrane contraction and cellularisation in non-vertebrate embryos like 
drosophila melanogaster (Straight et al. 2005). Anln is highly expressed in 
gametogenesis and is required for oogenesis so maternal inheritance of Anln to the 
zygote is expected (Dorn et al. 2010). By 24hpf, detection of signal in anln:anln-eGFP 
zebrafish however required light sheet or confocal level of microscopy. Therefore, a 
form of light sheet microscopy, “SPIM”, was employed for further screening. 
Screening of 24 hpf to 48hpf embryos revealed anln:anln-eGFP signal in the head 
region, and particularly in the eye where, fluorescence was retained from 24-48hpf; 
this was previously characterised by Paolini et al (Paolini et al. 2015).  In the trunk 
and tail, expression was visible in the dermis of both the 24-48hpf fish, with two 
strong bands of Anln-eGFP+ve cells observed ventrally and toward the midline of the 
trunk lost by 48 hpf. The mid line band appears to align anatomically with the 
developing notochord and CNS; these cell types in particular are highly proliferative 
at this time point (Stemple 2005). The notochord in particular has key roles in 
embryonic patterning by establishing the arterial venous border, assisting in early 
neurogenesis and allowing for rapid elongation of the trunk during embryonic 
development (Stemple 2005).  
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The ventral band of Anln positive cells observed at 24 hpf aligned with the developing 
trunk vasculature of the embryonic zebrafish (Isogai et al. 2001). The dorsal aorta and 
caudal artery/vein plexus undergo rapid maturation and development at this time 
point. These regions in particular were screened in the anln:anln-eGFP x flk:mcherry 
embryos (Isogai et al. 2001). I had hypothesised that Anln would co-localise with ECs 
and identify Anln distribution typical of either asymmetric cell division or,  localising 
to the leading edge of migrating or sprouting ECs (Costa et al. 2016; Tian et al. 2015). 
Although there appeared to be an association of these anln:anln-eGFP positive cells 
with the developing vasculature at 24 hpf there was no evidence for Anln expression 
in ECs as judged by co-localisation of red and green fluorescence in these fish.  
The identity of  Anln-eGFP+ve positive cells in close proximity to the vessels at 24 hpf 
is ambiguous; they are likely to be erythroid cells of the intermediate cell mass (ICM) 
which is surrounded by endothelium at this time-point (Willett et al. 1999). The 24 
hpf ICM is located ventrally and superior to the yolk sac and is the source of primitive 
haematopoiesis. These cells form early erythrocytes that express gata1 stimulated 
by tissue secreted erythropoietin (Galloway et al. 2005). By crossing the anln:anln-
eGFP line with fluorescent lines that mark primitive erythoid/myeloid markers such 
as the gata1;dsRED/gata2;dsRED/scl-α;ds;RED lines the association of anln with 
these cell lineages could be investigated (Zhen et al. 2013; Butko et al. 2015; Galloway 
et al. 2005). The early haematopoietic and EC precursors share a common lineage 
with haemangioblasts (Xiong 2008). It is therefore possible that populations of Anln+ve 
cells in the ICM may be EC precursor cells (Stainier et al. 1995). Flow cytometry on 
cell suspensions of collagenase digested pooled groups of anln:anln-eGFP x 
flk:mcherry 24hpf embryos could be used to detect Anln association with ECs and EC 
progenitors. If such an approach were successful, these cells could be enriched by 
FACS sorting for further analysis (Manoli & Driever 2012). Furthermore, we could fix 
and section 24-32 hpf embryos and stain them for anln-eGFP using an anti-eGFP 
antibody; this would allow for the detection of the localisation of Anln  in vivo.  
Signal intensity might be improved by injecting the anln:anln-eGFP BAC plasmid onto 
the flk:mcherry background to obtain a double reporter zebrafish line. However the 
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weak fluorescent intensity of the anln:anln-eGFP signal may be due to limitations of 
the transgene. Paolini et al demonstrated that the expression of the fluorescent 
anln:anln-eGFP transgene overlaps with an in situ hybridisation of endogenous anln 
mRNA in 28 hpf zebrafish embryos (Paolini et al. 2015). However the integration site 
or exact copy number of the BAC plasmid in the anln:anln-eGFP line genome was not 
investigated (Paolini et al. 2015). It is possible that several BACs integrated initially 
into distinct locations. If so, expression may have become diluted in subsequent 
generations due to copy number dilution in meiosis. The endogenous anln gene was 
not knocked out in this zebrafish line. It is conceivable that due to gene dosage effects 
endogenous Anln might reduce the expression of the anln:anln-eGFP transgene. Such 
factors would customarily be investigated in mice but with zebrafish it is less common 
to perform these validation steps (Chandler et al. 2007). Alternatively, weak 
expression of Anln-eGFP could be caused by the weakness of the anln promoter itself. 
Recently a mouse model expressing ANLN-eGFP under the flt1 promoter was 
described (Herz et al. 2018), where ANLN-eGFP expression was identified only in 
proliferating ECs of the mid gestation embryo (Herz et al. 2018). ANLN-eGFP+ve cells 
are rare in adult tissues and only visible in mitotic cells; Anln-eGFP was found to be 
completely degraded through ubiquitination by APCcdh1 after the cell cycle (Herz et al. 
2018; Zhao & Fang 2005). Anln-eGFP when expressed with the weaker anln promoter 
could accumulate slower than when expressed under the stronger flt1 promoter in 
ECs. Subsequent degradation by the APCcdh1 complex could further reduce the limit 
of detection of the anln:anln-eGFP transgene (Zhao & Fang 2005).  
 
5.4.2 Anln is not associated with a laser induced vascular injury 
To facilitate the investigation of Anln expression in injury of the zebrafish vasculature, 
a method of vascular injury had to be developed. Several methods are described in 
the literature for causing an insult to the vessels using an array of techniques. Physical 
injury has been used as a tool in both the adult and embryonic zebrafish to investigate 
angiogenesis, wound healing and immune cell migration and recruitment as laid out 
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in chapter 1 (Chassot et al. 2016). Two methods were of particular interest to injure 
an embryonic vessel. First, to tear of the caudal vein with a minutia pin to create an 
immediate vascular injury (Clay & Coughlin 2015), and second to use of a high energy 
laser system to induce a lesion or ablation of an area of a large vessel within the 
developing embryo (Matrone et al. 2014). Laser injury was chosen here, as it was 
considered to generate more reliable and reproducible injuries. Moreover, laser 
induced injuries were previously used to investigate vessel collateralisation, blood 
clot resolution and vessel repair in the zebrafish embryo (Matrone et al. 2013; Gray 
et al. 2007). Our data demonstrated that visible, yet not terminal injuries can be 
introduced in the zebrafish embryo using the 450nm wavelength micropoint laser 
system. The lack of lethality in laser injuries is likely due to the embryonic fish meeting 
their oxygen requirements through passive diffusion at these time points. 
Interestingly, the injuries induced in the two transgenic lines were not identical. The 
injury site appeared larger in the flk:eGFP line, likely due to a loss of fluorescence at 
the site of laser injury compared to injuries induced in the flk:mcherry zebrafish. It is 
possible that photo-bleaching contributes to the appearance of the injury; this is a 
known effect of laser injury and the 450 nm laser lies within the excitation spectra of 
eGFP (Saha et al. 2013). The excitation spectra of flk:mcherry does, however, not 
overlap with the laser wavelength. In line with this, I observed less loss of 
fluorescence at laser the injury sites with fish expressing the flk:mcherry than  the 
flk:eGFP transgene. The loss of fluorescence may not necessarily be due only to the 
overlap of the laser and excitation spectra. Heat or reactive oxygen species generated 
by the laser can also cause denaturation and quenching of fluorescent proteins.  
When the laser injury model was performed in anln:anln-eGFP x flk:mcherry 
zebrafish, no fluorescence was observed  at the site of injury 1 or 10 hours post injury. 
There are multiple explanations why we may not have observed expression of 
anln:anln-eGFP at the wound site. Whether the vascular laser injury causes a severe 
enough injury to cause apoptosis and cell death to induce meaningful cell migration 
and proliferation is an issue that should be explored. Although it was shown that 
neutrophils associate with the site of the injury using the mpx:mcherry line, 
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macrophages were not analysed.  An experiment with the mpeg:eGFP line would 
allow visualisation of macrophages in vascular injury. The migration and presence of 
these immune cells could be better explored via time-lapse microscopy or by simply 
adding more time-points and repeats to existing experiments. However such 
experiments would not necessarily show specifically why immune cell migration has 
occurred, as neutrophil migration could be initiated by alternative events such as 
thrombus formation or response to the injury of nearby tissues (Pfeiler et al. 2017). 
Therefore, to investigate the damage to the vessels itself, more specific techniques 
would be required. Electron microscopy can be used to further investigate the 
damage to the vessel ultrastructure caused by laser injury. This technique has been 
used widely to identify different cell types during myelopoesis and blood vessel 
formation (Armer et al. 2009; Lieschke et al. 2008). This would require fixation and 
resin mounting of zebrafish embryos, sectioning through the fish to the injury area 
and scanning electron microscopy used to investigate the morphology of the injured 
area. Investigation of the cellular response to damage can be investigated by either 
EDU of TUNEL staining and associated microscopy. EDU incorporation by treating 
laser injured embryos with EDU would identify if there are proliferating ECs as a 
regenerative response to the laser injury. Furthermore TUNEL staining would be able 
to identify the apoptotic cells in the laser injury site to measure the intensity of injury 
by quantification of cell death. 
Contrasting with the results obtained in the laser injury model, tail fin injuries of anln; 
anln-eGFP embryonic zebrafish induced by scalpel identified an increase in Anln 
positive cells in the dermis at 4hpi. This suggested that the anln:anln-egfp transgene 
is expressed during the regenerative process of a mechanically induced injury model. 
Ideally, this experiment would be repeated with additional time points to identify the 
exact number of cycling mitotic cells over a 24 hour period post injury. Live imaging 
would require all fish to be embedded in agar over a 12 hour period which may impair 
the tail fin wound repair response. Given that the mechanical injury appeared to 
increase Anln expression, an equivalent mechanical vessel injury such as the minutia 
pin vessel tear injury described by Clay & Coughlin et al may generate a superior 
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regenerative response (Clay & Coughlin 2015). Mechanical injury of the somites of 
the developing embryo via a syringe has been shown to induce sprouting and 
anastomosis of ISVs that was mediated by macrophages (Gurevich et al. 2018). This 
model could also be used as analyse potential Anln expression in EC tip cell formation 
in regenerative angiogenesis. Furthermore introducing a known positive control line 
such as the nfkb;eGFP zebrafish might help with identifying a positive signal of injury 
response to validate both physical and laser injury models (Ogryzko et al. 2014).  
5.4.4 Anln interference did not induce a strong vascular phenotype: 
Knock-down of anln expression with morpholinos had no effect on the vascular 
morphology of 2-4 dpf zebrafish embryos. Modulating the expression of anln in the  
developing embryo requires a partial knockdown to prevent a severe general 
phenotype as was observed in other zebrafish morpholino studies (Gbadegesin et al. 
2014). The partial knock down morpholino used in this study has been shown to 
produce cytokinetic defects by inhibiting asymmetric cell division in retinal cell 
division (Paolini et al. 2015). Therefore I hypothesized that the same partial anln 
knock down might affect asymmetric cell division during the development of the ISVs, 
thus leading to vascular defects. However at the selected time points of 48hpf-72hpf 
there was no impairment of ISVs vessel number or morphology. As there was no 
retardation of vessel development at the time points selected, it is possible that there 
is a recoverable phenotype at an earlier time-point. Investigating at 24-32 hpf as per 
Costa et al  and investigating sprouting with live imaging would identify actual 
asymmetric cell division defects (Costa et al. 2016). It would also be useful to include 
the EC nuclear reporter (flk:NLS-eGFP)  line to identify the nuclear midbody location 
of ECs after anln partial silencing. 
The limitations of morpholino mediated interference may be a factor in our lack of 
an observed phenotype. Our morpholino injection at the dose specified by paolini et 
al produced a trend for a ~30% knockdown of anln mRNA 24 hpi; these injections 
should be repeated at a higher dose and over a longer time course (i.e. including 
48hpi and 72hpi timepoints) to further optimise this experiment. A western blot using 
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the human anti-ANLN antibody did not work in zebrafish protein samples, therefore, 
I was unable to determine an efficiency of knockdown for the ATG morpholino. 
However, increasing the dose may cause an overall severe phenotype that may mask 
a cardiovascular phenotype. In addition to this, injected morpholinos are not 
consistently inherited equally during cell division and smaller doses can be diluted, 
this inheritance could be observed if our morpholinos were fluorescently tagged. 
CRISPR/Cas9 can be used to induce germ-line mutation at the single stage embryo. I 
aimed to use CRISPR/Cas9 mediated anln deletion, but struggled with the production 
of sgRNA guides despite extensive trouble shooting. Recently the interaction with 
cd2ap and anln was investigated as a mechanism of familial renal dysfunction 
(Gbadegesin et al. 2014). This study initially utilised morpholino interference of anln 
which produced severe phenotypes in zebrafish, whilst in a later follow-up study 
CRISPR/Cas9 interference was used to mutate the predicted cd2ap/anln interaction 
site(Hall et al. 2018; Gbadegesin et al. 2014). Hence, a point mutation could be 
incorporated to specifically mutate this site of anln to investigate the effect on the 
vascular phenotype of transgenic embryos. Any C.Pyogenes CAS9 mediated gene 
deletion would still result in a global knockout rather than a vascular specific 
mutation and so any phenotype observed could be caused by multiple different 
factors. Therefore, if CRISPR/Cas9 based interference of anln expression was used, 
one of two methods could be used. Either, the generation of a vascular specific CAS9 
plasmid or, use of a vascular specific dCas9 flk:gfp zebrafish. The first option can be 
carried out as detailed by Ablain et al where plasmids were generated using gateway 
cloning containing a tissue specific promoter driven Cas9 and a sgRNA guide driven 
by the U6 promoter (Ablain et al. 2015). This generates a tissue specific CAS9 
knockout that would express the sgRNA globally, producing a tissue specific mutation 
of your gene of interest. The second option utilises dCAS9, a mutant form of CAS9 
which contains no active site for DNA cleavage (Ma et al. 2016). Therefore, when used 
in conjunction with a suitable gRNA guide, this would cause translational blocking of 
anln expression. Even with these methods generation of an ANLN knock out model 
may still be problematic. The mitotic requirement of ANLN would likely cause lethal 
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cytokinetic defects in knockout tissues (Piekny & Maddox 2010). A recent study in 
mice investigating a post mitotic role of ANLN in the septin organisation of 
oligodendrocytes successfully produced an ANLN conditional knockout mouse (Erwig 
et al. 2019). This used a Cre-Lox system where Cre recombinase was driven by the 
CNP promoter. CNP is only expressed in post-mitotic oligodendrocytes therefore 
removing a possible lethal ANLN knock out phenotype (Lappe-Siefke et al. 2003; 
Erwig et al. 2019).  
In addition to improving modulation of anln expression, the quantification of vascular 
differences might also be improved. Using epifluorescence images to investigate and 
quantify vascular phenotypes can be achieved successfully (Watson et al. 2013). This 
technique can have more variation due to the orientation and mounting of individual 
fish in methyl-cellulose. Using confocal microscopy or light sheet microscopy to 
create 3D reconstructions of vascular networks can be employed to detect smaller 
differences by measuring branching or volumes of vessels. This was attempted using 
SPIM microscopy and IMARIS but limitations of the ability to obtain full 3D 
reconstructions reproducibly between samples was challenging. This could be 
improved by using the vertebrate automated screening technology (VAST) system for 
image acquisition, this uses spinning disk microscopy and an automated sample 
collection system to align and rapidly collect images of 2-7dpf embryos (Pulak 2016). 
Using the VAST system might remove variation in images as the fish are automatically 
aligned in the same orientation and then collected in at a 96 well plate for future 










To conclude, the anln:anln-eGFP is a valid tool for investigating anln expression in 
zebrafish development and appears to mark different developing cell types, including 
potential developing haematopoietic cells. However, at the time points investigated 
anln was not visibly co-localised with the developing ECs. In response to laser-induced 
vascular injuries, anln was not expressed during repair of the injury. This may be due 
to insufficiencies with the method of injury, as suggested by the increased Anln-
eGFP+ve cells observed with tail fish injuries in zebrafish embryos. Anln interference 
was not observed to affect vascular morphology of the 48-96hpf zebrafish. However, 
this experiment may be improved by using different methods for genetic interference 

















Chapter 6:                                             














6.1 Discussion and future directions: 
In this thesis, I aimed to identify a role of ANLN in EC function and ischaemic 
angiogenesis. A post transcriptional regulatory mechanism of ANLN by ZFP36 RBPs 
was proposed. Unfortunately it proved impossible to obtain the relevant knockout 
mouse model, putting an end to this line of investigation. Instead I made use of a 
fluorescent zebrafish reporter model. This allowed me to characterise ANLN 
expression and localisation in vivo in developmental angiogenesis and to develop a 
new vascular injury model. 
6.1.1 ANLN affects EC function in vitro: 
My third chapter identified a potential role of ANLN in post ischaemic angiogenesis, 
but fell short of uncovering the exact mechanism by which ANLN affects EC function. 
In hind limb ischaemia ANLN was found to be specifically upregulated in ECs, 
suggesting a role for ANLN in pathological (post ischaemic) angiogenesis.  
In agreement with such a function, the in vitro data demonstrated an involvement of 
ANLN in EC function. ANLN silencing experiments typically had a greater effect on the 
performance of EC in vitro than ANLN-EGFP overexpression. In particular, I observed 
a correlation between matrigel performance and ANLN expression which suggested 
an involvement of ANLN in sprouting angiogenesis. The localisation of ANLN observed 
in ECs reflected that previously described in the cell cycle, i.e. nuclear in interphase, 
and becoming associated with the cortex and cleavage furrow during cytokinesis 
(Piekny & Maddox 2010). I had hoped to observe endothelial ANLN localisation to the 
leading edge or to cell to cell contacts during tubulogenesis. Unfortunately, due to 
the high background and drift (likely due to shrinking of matrigel over time) I was 
unable to observe ANLN-EGFP localisation in tubulogenesis by live imaging. No 
changes in ANLN-EGFP localisation from the nucleus could be detected in fixed 
tubulogenesis assays. Using 2D co-cultures of ECs and fibroblasts would produce 
tubulogenesis without requiring the use of matrigel. These co-culture tubulogenesis 
assays would be easier to stain for other proteins of interest and could be imaged at 
multiple timepoints.  
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The localisation of ANLN with cytoskeletal structures may have helped with 
demonstrating a role of ANLN outside of cytokinesis. Other studies which have 
achieved this, and used these results as major justification for their entire study of 
ANLN. For example, ANLNs role in podocyte foot processes and its association with 
CD2AP-mediated PI3K signalling was identified in this way. Here overexpressed ANLN 
was seen to co-localise with CD2AP in foot process-like structures in HEK293 and 
immortalised podocytes in vitro (Gbadegesin et al. 2014; Hall et al. 2018). Altered 
ANLN distribution ameliorated concerns that increased ANLN expression in kidney 
injury was just a marker of podocyte entry into the cell cycle, because cell cycle entry 
is a marker of podocyte loss in renal disease (Gbadegesin et al. 2014). Similarly, in C. 
elegans, the ANLN homologue ani-1 was observed at the leading edges of migrating 
neurites, where it linked the cytoskeleton with RhoG (Tian et al. 2015). Importantly 
though, C. elegans ANLN homologues lack nuclear localisation sites, and are 
therefore characterised by distinct subcellular distribution to human ANLN (Maddox 
et al. 2005). The lack of altered ANLN localisation in ECs made it difficult to identify a 
specific mechanism of action in ECs outside of cytokinesis. Still, further in vitro 
experiments using EC spheroid cultures and fluorescent microscopy may more 
accurately identify ANLN distribution in EC sprouting.  
It may be appropriate now to look at a role of ANLN in the regulation of nuclear actin 
as we only observed a typical nuclear distribution of ANLN in vitro. There is 
filamentous actin in the nucleus which has been shown to be able to support gene 
expression (Misu et al. 2017). This nuclear actin is supported by formins, including 
mDia2, a binding partner of ANLN (Liu et al. 2018). Therefore it may be of value to 
investigate the association of ANLN in vitro with nuclear actin being a potential 
mechanism of action in ECs. 
It is possible that my initial in vitro assays did not reveal the true function of ANLN in 
EC function. As previously discussed (section 3.4.1), ANLN silencing can have adverse 
effects on the completion of cytokinesis, which may mask other functions (Piekny & 
Maddox 2010). It is therefore possible that the endothelial phenotype observed upon 
ANLN silencing may be the result of a cytokinetic defects rather than being specific 
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for ECs. We did not observe a cell cycle phase accumulation in HUVEC that ANLN had 
been silenced or overexpressed in, binucleation associated with the failure of 
cytokinesis would be expected in these conditions (Wang et al. 2015; Zhang et al. 
2018; Zhao & Fang 2005). It is possible that there are other effects on the completion 
of cytokinesis that were not detected by these experiments, such as; asymmetric cell 
divisions or oscillation of the cleavage furrow (Zhao & Fang 2005; Piekny & Maddox 
2010). The placement of the cleavage furrow could have been altered by ANLN 
depletion, this could result in different sized daughter cells (Paolini et al. 2015). We 
could investigate cell size after ANLN silencing or overexpression, this could be done 
by staining for VE-Cadherin and measuring the area of individual cells, or capturing 
individual cell divisions with live imaging and looking at placement of the cleavage 
furrow.   
In addition, ANLN-EGFP overexpression required cell sorting, which may have caused 
ANLN-EGFP/EGFP overexpressing ECs to deteriorate. This conclusion is supported by 
the different base line of performance observed in some of the cell based functional 
experiments. To address this possibility, unsorted control groups of ECs could be 
included in future experiments aimed at identifying the reason for these differences 
in base line performance.  
6.1.2 ZFP36 RBPs regulation of ANLN: 
In my fourth chapter, a potential regulatory mechanism by ZFP36 RBPs was proposed 
due to the presence of ARE elements in the ANLN 3’UTR. These ARE elements can be 
targeted by ZFP36 RBPS. We showed a correlation between ANLN mRNA expression 
and ZFP36 RNA binding protein in an in vivo hind limb ischaemia model. In vitro we 
found an association between ZFP36L1 expression and ANLN mRNA expression in IL-
1β-stimulated ECs. However silencing of ZFP36 RBPs in ECs did not result in the 
increased ANLN expression that would be typical of RBP based regulation.  Binding of 
ZFP36 RBPs to the ANLN 3’UTR was supported by a luciferase assay. However, a RIP 
of ZFP36L1 did not show an enrichment of ANLN compared to the positive control 
VEGF. These experiments did not support the notion that ANLN is a target of ZFP36L1, 
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however, ANLN mRNA was enriched on a ZFP36 RIP. This has been observed with 
ZFP36 regulation of HIF-1α, where HIF-α mRNA is only enriched in ZFP36 silenced 
HUVEC after exposure of the ECs to hypoxia (Chamboredon et al. 2007). Therefore 
repeating the RIP and siRNA transfections with additional IL-1β stimulation to identify 
binding of the ANLN mRNA transcript to the ZFP36 RBPS under ‘inflammatory 
conditions’. 
It was initially intended to establish an inducible endothelial-specific knockout mouse 
model of either ZFP36 or ZFP36L1 in Edinburgh. This was to be used in hind limb 
ischemia experiments to determine the effect of ZFP36 knockout in post ischaemic 
angiogenesis and ANLN expression. Unfortunately, it was impossible to establish 
these lines for in vivo experiments due to difficulties with the import and time 
limitations.  This limited how well we could determine an accurate phenotype of 
ZFP36 RBP knockout in angiogenesis. We considered performing functional EC based 
experiments such as those described in chapter 3 also with ECs in which ZFP36 family 
RBPs had been silenced. This would have informed on the role of ZFP36 RBPs in EC 
function in vitro. However, given the difficulties in obtaining the relevant ZFP36 RBP 
knockout mouse, we decided to focus on identifying a functional role of ANLN in ECs.  
It is possible that the upregulation of ANLN in ECs in ischaemia is actually a marker of 
EC proliferation, this has been observed in reporter mouse models of ANLN (Herz et 
al. 2018; Hesse et al. 2012). If this is the case then the reason for ANLN expression in 
ischaemic ECs is to stabilise the contractile ring in EC cell division in proliferation to 
support angiogenesis. In this event the most likely regulatory mechanism of ANLN 
would be post translational by ubiquitination through the APCcdh1 complex rather 
than through a post transcriptional mechanism by RBPs (Zhao & Fang 2005). A caveat 
with this is that any treatment which affects the cell cycle may also affect ANLN 
expression. So, in vitro stimulation with cytokines or even the 
silencing/overexpression of RNA binding proteins may positively or negatively 
potentiate ANLN protein expression through altering APCcdh1 activity (Zhao & Fang 
2005). Further experiments with the ANLN-EGFP lentivirus could determine if post 
translational regulation of ANLN is a significant factor in its degradation in ECs. In 
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skeletal muscle regeneration, muscle satellite cell proliferation and differentiation is 
in part controlled by ZFP36 RBP control of gene expression (Hausburg, et al. 2015). 
Therefore, it may be advantageous to identify if ANLN is upregulated in satellite cells 
in ischaemia and determine if ANLN’s expression is regulated by ZFP36 RBPs in 
skeletal muscle regeneration.  ANLN expression in this cell type in ischaemia would 
reinforce an association of ANLN with asymmetric cell division given the fact that 
satellite muscle cell division in regeneration is asymmetric (Gurevich et al. 2016).  
6.1.3 There is no association of Anln-eGFP with zebrafish developmental 
angiogenesis: 
In chapter 5 I imported and established an anln:anln-eGFP zebrafish from an external 
collaborator (Dr Lucia Poggi, University of Trento). I investigated Anln expression in 
the developing zebrafish vasculature. This was based on my initial in vitro results, 
where I hoped to observe a subcellular redistribution of the Anln-eGFP reporter in 
ECs during angiogenesis. The anln:anln-eGFP zebrafish had previously been used to 
identify asymmetric cell divisions in retinal neurogenesis. Asymmetric cell division has 
been suggested as a potential mechanism of angiogenesis in tip stalk cell designation 
(Costa et al. 2017). I therefore aimed to observe an association of Anln-eGFP with 
asymmetric cell division in early angiogenesis, or localisation of Anln-eGFP to the 
leading edge in EC migration.  
Screening of initial anln:anln-eGFP embryos showed only very weak expression of the 
Anln-eGFP reporter past 24 hpf. Signal from anln:anln-eGFP was detected in the CNS, 
Retina, notochord and trunk. Outcrossing the anln:anln-eGFP fish with the 
flk:mcherry line allowed me to detect Anln expression and blood vessels 
simultaneously. Embryos were screened at 24 hpf, but, there was no association of 
Anln-eGFP with the developing vasculature. This was most likely due to a limit of 
detection or issue with the anln:anln-eGFP zebrafish. At ~24 hpf I noticed Anln-
eGFP+ve cells to be associated with the caudal artery/vein vascular plexus, these could 
be cells of the ICM. The ICM contains haematopoietic and endothelial progenitors, so 
it would be interesting to see if there is a population of Anln+ve and flk:mcherry+ve 
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cells. Furthermore, crossing the anln:anln-eGFP line with an erythrocyte marker such 
as gata1/2 would enable visualisation of Anln+ve haematopoietic progenitors. 
Haematopoietic primitive progenitors undergo asymmetric cell divisions to 
differentiate into different cell types. This would suggest why they would be Anln-
eGFP+ve as observed in retinal progenitor cells, before undergoing asymmetric cell 
division and differentiation into mature retinal ganglion cells (Paolini et al. 2015). The 
lack of Anln-eGFP association with the 24hpf blood vessels could be due to 
differences in pathological and developmental angiogenesis. 
To address the function of Anln in pathological angiogenesis, I developed a laser 
induced injury of the caudal artery. This allowed me to study Anln expression in 
vascular repair. Laser wounding produced a highly reproducible lesion of the caudal 
artery which healed rapidly, inducing immune cell association with the injury site. I 
had anticipated to observe the induction of Anln-eGFP protein in ECs at the injury 
site, but there was no such association. This may be due to the low severity of the 
injury, or, the fact that these are embryos and surpass most other models in terms of 
their regenerative capacity. This possibility could be investigated by PI and TUNEL 
stain to detect cell death in injured tissues. Interestingly, I did observe the induction 
of Anln-eGFP+ve cells at the site of tail fin injury which suggests that Anln-eGFP is 
induced upon tissue injury. This is supported by the expression of Anln at the injury 
border zone of adult zebrafish tail fin injury (Kang et al. 2016).  
It would be useful to continue working with the laser injury by injuring the 
intersegmental vessels or the somites of the developing fish. This has been done 
before with mechanical injuries but utilising my newly developed laser injury model 
may be beneficial in terms of reproducibility (Gurevich et al. 2018; Clay & Coughlin 
2015). When used in conjunction with fluorescent reporters of macrophages, the 
laser injury could be used to investigate vessel anastomoses and injury induced vessel 
sprouting (Liu et al. 2016; Gurevich et al. 2018).  
To investigate a vascular phenotype of anln knockdown, I employed a partial 
knockdown of anln in flk:eGFP zebrafish, using ATG and splice targeting morpholinos 
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(Paolini et al. 2015). Using this approach, I did not identify any strong vascular 
phenotype in the vessels of the zebrafish trunk. This may be due to limitations of the 
knockdown or to a limit of detection issue with the quantification system I employed. 
This could be improved upon by using a better microscopy technique such as VAST 
microscopy, and/or by inducing a more efficient knockdown method, e.g. 
CRISPR/Cas9.  
I began creating an anln CRISPR/Cas9 knockout zebrafish, but, due to technical issues 
and further consideration about its usefulness I stopped. A complete Anln knockout 
would not be helpful, because cytokinetic defects resulting from anln loss at the 
contractile ring are lethal. Even an inducible EC specific knockout would suffer from 
this issue. For example, if vascularisation of a tail fin injury of an adult inducible EC 
specific anln knockout was investigated, a potential phenotype may be observed. But, 
it would not be possible to determine if this was due to cytokinetic defects or a unique 
role of anln in EC migration in angiogenesis. Other studies have managed to avoid 
this by using conditional knockouts, for example there is an anln conditional knockout 
mouse in mature oligodendrocytes of the CNS (Erwig et al. 2019). The Cre employed 
(CNP) in this particular case functions only in mature oligodendrocytes, which are 
non-proliferating cells. There is therefore no mitotic element to the phenotype 
observed. However, ECs in angiogenesis, do not reach a stage at which they stop 
dividing for good. Unless it is possible to use a conditional knockout or viable 
mutation in ECs this approach may produce misleading data. Suitable viable 
mutations would  be difficult to identify, as there are only few non-fatal pathogenic 
mutations of anln (Deng et al. 2018).  
It would be interesting to use traditional ischaemic injuries such as hind limb 
ischaemia in a new ANLN reporter mouse line. The flt1-ANLN-EGFP mouse might be 
a suitable model for investigating ANLN in ischaemic angiogenesis and vascular 
development. In this mouse ANLN-EGFP is observed throughout development and 
including the vessels but is not present in the adult tissues. So if this direction was 
taken then this model should be established for future experiments in vivo. If 
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establishing this line is not possible then generating a flk:anln-eGFP zebrafish may be 
an improvement over the current anln:anln-eGFP zebrafish. 
6.2 Conclusions: 
To conclude, this thesis has highlighted the potential role of ANLN in ECs in 
angiogenesis.  
Future experiments should focus on identifying a localisation of ANLN expression in 
ECs, particularly in an in vitro model of sprouting such as EC spheroid cultures. This 
would be required to attribute the initial phenotypes observed in in vitro ANLN 
silencing and overexpression studies to a unique role of ANLN in EC function. If no 
distribution can be identified then it would be beneficial to investigate a nuclear role 
of ANLN in ECs. Failing this then it should be considered that ANLN upregulation in 
angiogenesis may just mark mitotic cells that are progressing through the cell cycle. 
The anln:anln-eGFP zebrafish did not mark asymmetric cell divisions or migrating 
angiogenic ECs, however, this line may be useful for studying early haematopoiesis. 
The vascular laser injury created in this thesis would be excellent for investigating 
angiogenesis in the zebrafish embryo at other time points and by targeting other 
vessels. However, some further optimisation of this injury would be useful to clarify 
the exact severity of these injuries. Further in vivo studies of ANLN in angiogenesis 
would benefit from the establishment of the flt1-ANLN-EGFP mouse or the 




















Negative control WIK zebrafish embryos at 24-48hpf show only weak auto fluorescence in 
the head and trunk: 
SPIM imaging of 24-48 hpf anln:anln-eGFP embryos showing the head and trunk of 24-48 
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